Differential equation models for Aujeszky's disease virus in Irish pig herds by Fingleton, Glenn
D i f f e r e n t i a l  E q u a t i o n  M o d e l s  f o r  
A u j e s z k y ’s  D i s e a s e  V i r u s  i n  I r i s h  
P i g  H e r d s
M.Sc. Thesis
G le n n  F in g le to n  B .S c. 
J a n u a ry  2002
Supervisor: Prof. Alastair Wood 
School of Mathematical Sciences 
Dublin City University
D e c l a r a t i o n
I hereby certify that this material, which I now submit for assessment on the program 
of study leading to the award of Masters of Science in Applied Mathematical Sciences, is 
entirely my own work and has not been taken from the work of others save and to the extent 
that such work has been acknowledged within the text of my work.
UvWVc»'__________ ID No.: 98970518
Date: ^lo  -  o  ^
Signed: ___________________
—^)
ii
A c k n o w l e d g e m e n t s
I would like to thank my supervisor Professor Alastair Wood for awakening my interest in 
this area and to acknowledge the help and support that he has given me throughout this 
work.
Others that I would also like to thank are Dr. Arie Van Nes and Dr. Aline De Koeijer, ID
- DLO, Netherlands for their help at the beginning of this work. I would also like to thank 
Professor Odo Diekmann for providing me with an early draft of his excellent book.
In this country, I would like to thank Dr. Noel Kavanagh, Oldcastle Laboratories, for his help 
and patience while providing us with some valuable information and statistics on Aujeszky’s 
Disease in Ireland. Thanks are also due to Mr. Michael Martin and Mr. Brendan Lynch, 
both from Teagasc, for their advice during the development of the questionnaire. I would 
also like to thank Dr. John Appleby for some interesting discussions and help regarding this 
work, and also for the painful introduction to the magical world of I^TeX.
I would also like to thank the examiner for some improvements to Theorem 3.4.5,
On a more personal note I would like to thank Donal for the many interesting office conver­
sations, none of which are repeatable here! I would also like to thank my fiancee, Carmel, 
and my parents, for all of their help and support throughout my time in DCU.
C o n t e n t s
1 In tro d u c tio n  to  M ath em atica l M odelling 1
1.1 Introduction.............................................................................................................  1
1.2 Review of Mathematical Modelling.......................................................................  2
1.2.1 Deterministic Models ................................................................................  3
1.2.2 Stochastic M o d e ls ......................................................................................  3
1.3 Explanation of term s..............................................................................................  5
1.3.1 Mathematical Intei'pretations....................................................................  5
1.4 Hethcote’s M odel....................................................................................................  6
1.5 AD M odel................................................................................................................  7
2  An Overview of Aujeszky’s Disease (AD) 9
2.1 Introduction.............................................................................................................  9
2.2 Disease characteristics and clinical s ig n s .............................................................  10
2.2.1 Pigs less than three weeks o ld ...................... ............................................. 10
2.2.2 Pigs three weeks to five m onths................................................................. 11
2.2.3 Mature p ig s ..................................................................................................  11
2.2.4 Post-mortem lesions...................................................................................  12
i v
2.2.5 Im m unity.....................................................................................................  12
2.2.6 Spread of infection......................................................................................  13
2.3 Diagnosis and control ...........................................................................................  14
2.3.1 D iagnosis..................................................................................................... 14
2.3.2 Control of infection......................................................................................  15
2.4 Aujeszky’s Disease in E u ro p e ........................................ ....................................... 17
2.4.1 Officially AD F r e e ......................................................................................  17
2.4.2 Partially free of A D ...................................................................................  18
2.4.3 Infected C ountries...................................................................................... 20
2.4.4 Eastern European Countries.......................................................................  22
2.5 Aujeszky’s Disease in I re la n d ................................................................................ 23
2.5.1 The Response to Vaccination.................................................................... 24
2.5.2 Proposed Eradication P rogram m e........................................................... 25
2.5.3 Eradication Costs /  Procedures................................................................. 26
3 D eterm in istic  M odel 28
3.1 SIR model................................................................................................................. 28
3.2 AD M odel................................................................................................................  35
3.2.1 Model A ssum ptions.............................................................. ..................... 37
3.3 Reproduction Ratio ..............................................................................................  39
3.3.1 Calculation of Rn ,R v ................................................................................  39
3.3.2 Further Rq calculations.............................................................................  42
3.3.3 Threshold D ensity ......................................................................................  44
v
3.4 Non Vaccinated M odel...........................................................................................  45
3.4.1 Introduction ..............................................................................................  45
3.4.2 Non Vaccinated Model................................................................................ 46
3.4.3 Non Vaccinated G rap h s ............................................................................. 51
3.4.4 Reduced M odel............................................................................................ 55
3.4.5 An Alternative Assumption....................................................................... 64
3.4.6 Reduced G ra p h s ......................................................................................... 65
3.5 Vaccinated Model....................................................................................................  70
3.5.1 Introduction ............................................................................................... 70
3.5.2 Vaccinated Model ...................................................................................... 71
3.5.3 Average level of protection ....................................................................... 72
3.5.4 Vaccinated G raphs...................................................................................... 82
3.5.5 Reduced M odel............................................................................................ 87
3.5.6 Further Reduced M o d el............................................................................  92
3.5.7 Reduced G ra p h s ......................................................................................... 93
3.6 Periodic Infection....................................................................................................  96
3.7 Biological Implications...........................................................................................  99
4 Stochastic  M odel 100
4.1 Introduction............................................................................................................. 100
4.2 Basic Stochastic Model........................................................................................... 100
4.3 AD Stochastic Model.............................................................................................. 106
5 F u tu re  W ork /  Conclusions 113
v i
5.1 Reduce Population R estric tio n ...........................................................................113
5.2 Environmental C apacity .......................................................................................114
5.3 Incomplete Immunity.............................................................................................116
5.4 Conclusions............................................................................................................118
A T heorem s and  S tab ility  A nalysis 119
A.l Theorems /  Definitions..........................................................................................119
A.2 Non Vaccinated m odel..........................................................................................121
A.3 Vaccinated model...................................................................................................122
B E rad ica tio n  P ro ced u res  124
C P ro g ram s 135
C.l Stability Analysis................................................................................................... 135
C.2 Graphs.....................................................................................................................136
C.3 Vaccination Level...................................................................................................138
v i i
L i s t  o f  T a b l e s
2.1 Comparison of health status: Ireland, U.K and mainland E u ro p e ...................  16
2.2 Infection rate detected in Irish h e rd s .................................................................... 23
2.3 Estimation of the proportion of animals positive within infected herds . . . .  23
2.4 The incidence of AD séropositives before vaccination........................................  24
2.5 The incidence of AD séropositives after vaccination...........................................  24
2.6 Pigmeat production in selected European countries...........................................  25
4.1 Probabilities of possible events occurring in population..................................... 106
C.l Values taken for Ay .............................................................................................. 138
v i i i
L i s t  o f  F i g u r e s
3.1 Orbits of (3.9) ....................................................................................................... 31
3.2 Epidemic curve of the d isease............................................................................... 34
3.3 Compartment model of A D .................................................................................. 36
3.4 Non vaccinated Van Nes m o d e l..........................................................................  52
3.5 Non vaccinated Van Nes model (modified)........................................................  52
3.6 Non vaccinated Smith and Grenfell model (/? > 6) ..........................................  53
3.7 Non vaccinated Smith and Grenfell model (ft = 6) ..........................................  53
3.8 Non vaccinated model (epidemic).......................................................................  54
3.9 Non vaccinated model (long epidem ic)..............................................................  54
3.10 Possible outcomes for y j(i,xo)............................................................................... 56
3.11 Direction of unstable manifold ................................................................... 62
3.12 Direction of A ( p ) .................................................................................................... 63
3.13 Local phase portrait to the D F E ......................................................................... 64
3.14 Reduced model (start of epidem ic)....................................................................  67
3.15 Reduced model (middle epidemic) .................................................................  67
3.16 Reduced model (end epidem ic)..........................................................................  68
3.17 Reduced model (end epidem ic)..........................................................................  68
i x
3.18 Average level of protection.....................................................................................  73
3.19 Full vaccination [v =  1 ) .......................................................................................  83
3.20 Full vaccination {v — 0.75)....................................................................................  83
3.21 Pull vaccination (longer, i; = 0.75) .................................................................  84
3.22 Full vaccination (u = 0.25)....................................................................................  84
3.23 Full vaccination (longer, v =  0.25) ...................................................................  85
3.24 Full vaccination (u =  0.01)....................................................................................  85
3.25 Middle Vaccination (u =  0 . 5 ) ............................................................................... 86
3.26 Beginning of Outbreak /  End of Vaccination....................................................... 94
3.27 End of Outbreak /  Beginning of Vaccination......................................................  94
3.28 Beginning of Outbreak /  End of Vaccination....................................................... 95
3.29 End of Outbreak /  Beginning of Vaccination....................................................... 95
B.l Proposed Eradication program for Breeding H e rd s .................................... 133
B.2 Proposed Eradication program for Finishing H e rd s .................................... 134
x
A b s t r a c t
Aujeszky’s Disease virus, (ADV) is a contagious viral disease that affects the central nervous 
system of all animals, but swine are its natural host. Its main symptoms include abortions 
and stillbirths in sows, nervous signs in young pigs and respiratory disease in older pigs. 
ADV is a very important economic problem in Ireland, where substantial losses are incurred 
in the farming community each year.
We consider various differential equation models of ADV with homogeneous and proportional 
mixing between seropositive and seronegative animals. We derive various expressions for 
the basic reproduction ratio R q, and the infectious contact rate, a. Using these, we perform 
equilibrium and stability analysis for both non-vaccinated and vaccinated models. Finally, 
we look at various graphs of the systems of differential equations created, where we consider 
values, both above and below one, for R q, a. We find that it may be possible that the disease 
will die out by itself when R q, a < 1.
With the possibility of future trade restrictions being brought about by EU regulations, a 
nationwide eradication programme has been proposed. Ireland currently exports over 50% of 
its pigmeat, so any trade restrictions would have a huge economic impact. If the eradication 
programme is to be implemented, it is imperative that it be run efficiently, so as to minimise 
the possibility of the loss of valuable export revenue. Implications for control /  eradication 
strategies are also considered.
C h a p t e r  1
I n t r o d u c t i o n  t o  M a t h e m a t i c a l  
M o d e l l i n g
1 .1  I n t r o d u c t i o n
The purpose of this thesis is to mathematically study Aujeszky’s Disease Virus (ADV) in 
Ireland. Aujeszky’s Disease (AD) is a contagious viral disease that occurs in all animals, 
but swine are its natural host. AD is a very important economic problem in Ireland, where 
substantial losses are incurred in the farming community each year. In the U.S, the cost of 
AD is over $30 million each year [4]. We intend to study a mathematical model of AD and 
to come up with some future projections to establish whether the disease can be eradicated 
or not.
In Chapter 1, we briefly mention the mathematical theory of infectious diseases over the 
past two centuries, show Hethcote’s model and mention the terms involved. Chapter 2 is a 
more detailed look at AD, its characteristics, economic importance and some Irish statistics 
relating to the disease. In Chapter 3 the main deterministic computations will be carried out 
and the stability will be analysed. Chapter 4 will look at the stochastic model and Chapter 
5 the conclusions and possible extensions for future work.
It has been extremely difficult to obtain accurate data on AD as the last work done on it 
was in 1992, and this was just a study of why it should be eradicated. The only data that
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we had to work with were those of [32] which is a model of human viral diseases, on which 
our model was based, and also [72] and [85]. As a result some parameters will be estimated 
using data from a recent pig report, [55]. Finally, before we begin this work, we give the 
floor to the medical doctor who, arguably, is the founding father of modern epidemic theory, 
Sir Ronald Ross, who wrote
‘ . . .  A ll epidemiology, concerned as it is w ith  the varia tion  o f disease fro m  tim e  
to tim e or from  place to place, m u st (sic) be considered m athem atica lly , how ever  
m any variables are implicated, i f  i t  is to be considered scientifically at all . . .
A n d  the m athem atica l m ethod o f trea tm en t is really no th ing  but the application  
o f careful reasoning to the problem s a t hand. ’ [22]
1 .2  R e v i e w  o f  M a t h e m a t i c a l  M o d e l l i n g
First we show how mathematical theories of the spread of infectious diseases have developed. 
Then we will discuss the more recent work of Bailey [7]. This excellent book has covered 
deterministic and stochastic models, and we look at both. Recorded accounts of epidemic 
outbreaks and speculations go back as far as the ancient Greeks (Epidemics of Hippocrates 
459 — 377 BC) [7]. However, genuine progress in epidemiology was not achieved until more 
recently in the nineteenth century.
This such progress was made is due to the research of Pasteur (1822-1895) and Koch (1843- 
1910) in bacteriological science. People like Graunt (1620-1674) and Petty (1623-1687) first 
compiled medical and vital statistics in the seventeenth century. However, it was still too 
early for any theory on epidemics. Around this time the necessary mathematical techniques 
were only in the process of development and there was no sufficiently precise hypothesis 
about the spread of diseases suitable for expression in mathematical terms.
In 1760, Bernoulli used a mathematical method to evaluate the effectiveness of the technique 
of variolation (preventive inoculation) against smallpox, with a view to influencing public 
health policy. Evans (1875) used some curve-fitting methods on the smallpox outbreak of 
1871-2, but this met with little success.
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1 . 2 . 1  D e t e r m i n i s t i c  M o d e l s
By the end of the nineteenth century the general mechanism of epidemic spread revealed by 
bacteriological research made some new developments possible. Hamer (1906) considered 
that the course of an epidemic must depend on the number of susceptibles and the contact 
rate between susceptibles and infectious individuals. These simple mathematical assump­
tions are basic to all subsequent deterministic theories. Hamer, by using these simple ideas, 
deduced the existence of periodic recurrences, an idea which was later taken up by Soper 
(1929).
Meanwhile Ross (1911) was working on a more structured mathematical model taking into 
account a set of basic parameters. From this model we can deduce the future state of the 
epidemic given the initial number of susceptibles, infectives and the attack, recovery, birth 
and death rates. For the first time it was possible to use a well-organised mathematical 
theory as a research tool in epidemiology.
In the 1920’s Kermack and McKendrick, [45], [46], [47] considered the problem of endemic 
diseases and later developed more detailed and elaborate mathematical studies of the same 
type. Their most outstanding result was the celebrated Threshold Theorem [46], according 
to which, the introduction of cases into a community of susceptibles would not give rise to 
an epidemic outbreak, if the density of the susceptibles were below a certain critical value, 
the threshold density, N t - If, on the other hand, the critical values were exceeded, then 
there would be an epidemic of magnitude sufficient to reduce the density of susceptibles as 
far below the threshold as it was originally above.
1.2.2 S to c h a s tic  M o d e ls
As epidemiological studies became more extensive and occasionally dealt with much smaller 
groups, the element of chance and variation became more prominent. The need for a prob­
ability model was becoming increasingly necessary. McKendrick (1926) was the first to 
publish a genuine stochastic treatment of an epidemic process. He assumed the probability 
of one new case in a short interval of time was proportional to the same quantity.
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This is known as a ‘continuous - infection’ model which describes an individual to be in­
fectious from the time that they becomes infective until they die, or recover. This did not 
attract much attention, but in 1928, Frost and Reed were doing similar work. Their model 
assumed that the period of infectiousness was short and that the latent and incubation 
periods could be regarded as constant. Greenwood (1931) also studied the same problem.
After World War II, deterministic treatments were carried further and stochastic develop­
ments increased following advances made in the mathematical handling of stochastic pro­
cesses. Whittle (1955) developed a stochastic threshold theorem, in which a set of probability 
statements replaced the original Kermack and McKendrick model. The continuous - infec­
tion model introduced by McKendrick was reconsidered and it was shown that it could be 
used for analyzing household data as well as large - scale phenomena.
The treatment of simple stochastic epidemics continued and more detailed statistical analysis 
came to the fore. Improvements in obtaining the distribution of total epidemic size were 
given by Gani (1967) and Ohlsen (1964) extended the theory of parameter estimation and 
Weiss (1965) looked at the area of models involving carriers. The area of host - vector and 
venereal disease models was looked at by Bartlett (1964,1966).
Considerable effort has been devoted in more recent years to the elaboration of deterministic 
multistate models, which attempt to be more realistic than the models so far investigated. 
The modern approach tends to regard deterministic treatment to be approximately valid in 
certain circumstances, and in some cases may even generate the same results as the stochastic 
model. When the numbers of susceptibles and infectives are large and mixing is reasonably 
homogeneous, a deterministic model is likely to be sufficient.
Some of the more recent work on stochastic modelling has been done in [8], [53], [66], [83]. 
Even where stochastic modelling is preferred, it is always wise to start with a deterministic 
model as they may generate the same results.
4
1 . 3  E x p l a n a t i o n  o f  t e r m s
The mathematical theory of infectious diseases has been extensively studied on human popu­
lations. Diseases such as AIDS, malaria and measles have all been studied previously. These 
diseases are known as S I R  diseases where:
S — the number of susceptibles in the population (i.e, individuals
who are capable of being infected with the disease)
I  = the number of infectives in the population (i.e, the individuals 
who are infective and are capable of infecting the susceptibles)
R  = the number of removed individuals in the population through
either death, isolation or recovery (which means immunity).
1.3.1 M a th e m a tic a l  I n te r p r e ta t io n s
Usually, S, I  and R  are referred to as compartments in the overall population, which is 
usually N. Hence we can say
S  + I  + R  =  N  (1.1)
In general, populations show demographic turnover: individuals die for various reasons and
new individuals appear by birth, immigration, etc. Such a demographic process has its 
characteristic time scale (for humans of the order 1-10 years). The time scale at which an 
infectious disease goes through a population is much shorter (e.g. for influenza it is of the 
order of weeks). For this reason we choose to ignore the demographic turnover and consider 
the population as closed [22]. With regards to AD modelling, more specific reasons related 
to pig farming must also be considered (these are discussed in more detail later).
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1 . 4  H e t h c o t e ’ s  M o d e l
Hethcote [30], [31], [32], [33] developed various models for S I R  diseases where recovery gives 
temporary immunity. The model we base our work on is from [32] and is as follows:
^ S ( t )  = - X I ( t ) S ( t )  + (51 + a 1) - { S 1 + a 1) S ( t ) - a 1I ( t )  (1.2a)
j t I { t )  = X I ( t ) S ( t ) - ' y 1I ( t ) - 6 1I ( t )  (1.2b)
j t R { t)  = 1 - S ( t ) - I ( t )  (1 .2c)
5(0) =  So >  0, 1(0) =  J0 >  0, R { 0) =  R 0 >  0.
where,
A = the daily contact rate between individuals,
Si = the proportionality constant ( the average lifetime is l/¿ i),
«i = daily loss of immunity rate (permanent immunity occurs when ai =  0 ),
71 =  daily recovery removal rate (the average period of infectivity is I / 7 1).
The number of contacts between I  and S  depends directly on the product of I  and S,  so 
this increases the number of infectives at a rate A I S ,  and therefore reducing the number 
of susceptibles by a corresponding rate. The number of infectives is then further reduced 
by the loss of immunity, ai, and the recovery removal rate, 7 1 . All parameters in (1.2) are 
nonnegative and only nonnegative solutions are considered as negative solutions have no 
epidemiological significance. Hence, there will always be a flow between the compartments 
in the model.
Another important aspect of the model in (1.2) is the fact that the population is consider 
to be closed, hence we can say, as we did in (1 .1), that
where N  is the size of the population, and is constant.
S +  I  +  R =  N  ( 1 .3 )
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1 . 5  A D  M o d e l
The theory of infectious diseases in animals is very similar to the equations used above. 
The main difference is that an additional parameter, the harvesting parameter, must be 
considered. Harvesting is where the animals are killed for consumption, and this parameter 
play an important role in the model. For example, without knowing, a farmer could harvest 
the majority of his infected animals, thus reducing the spread of the disease, and in some 
cases, eliminating it completely.
The latent period has also be taken into account. During a latent period the disease goes 
into hiding in the animal and is undetectable. It then returns to make the animal infective 
again. The length of a latent period can range from a few days to several months, depending 
on the time of infection. Diseases such as Aujeszky’s disease and Swine Fever in pigs, 
Bovine Tuberculosis (TB) and Brucellosis in cows are among these types of diseases. Bovine 
Spongiform Encephalopathy (BSE) in cows is another one of these diseases, but this is more 
difficult to model because of the human element (CJD).
The reason that we base our model on the equations in (1.2) is due to the fact that this is a 
model for herpes infections in humans and that ADV is a member of the alphaherpesvirus 
group [84], AD is an example of a S I  L I  disease, where we define the new term L.
L =  the number of latents in the population (i.e. animals 
who are infected, but for a certain period of time they 
are unable to be infectious to susceptible animals).
Another example of an S I  L I  disease would be Bovine Herpes Virus (BHV) in cattle herds [20], 
The addition of a latent period makes the modelling of the disease more difficult. In standard 
S I R  models, once an infection occurs, the next stage is recovery, through either death or 
immunity. However, with a latent period, there will be a flow between infective and latent 
for the lifetime of the animal. As one would expect, this flow will decrease over time, but 
given the relative short life span of animals bred for consumption, this is difficult to interpret 
accurately. This will be discussed in more detail in Section 3.2.1.
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Of the more recent work done on AD a considerable amount is due to mathematicians 
and veterinarians from the Netherlands. Some of the most recent work can be found 
in [15], [18], [19], [73], [84] and [85]. In the Netherlands, AD is a disease of great eco­
nomic importance due to the large scale pig production that occurs there. As a result, the 
rest of Europe is following the lead of the Netherlands in their efforts to eradicate AD.
Stochastic modelling has only recently been used in relation to AD. In some breeding units 
the numbers would be sufficiently small to require a stochastic model. Again, this is mostly 
done in the Netherlands, [20], [84]. We intend to look at both models, but we concentrate 
on the deterministic model as the number of pigs on a farm is usually large.
8
C h a p t e r  2
A n  O v e r v i e w  o f  A u j e s z k y ’s  D i s e a s e
AD is a member of the alphaherpesvirus group of diseases (SHV-1).
Aujeszky’s Disease, or pseudorabies (PRV) as it is also known, is a contagious viral disease 
that affects the central nervous system of most animals. Humans and the tailless apes 
(primates) are the only species that have immunity from AD [38]. Cattle, sheep, dogs and 
cats have been known to develop the disease. In these species it causes nervous signs, intense 
itching and is invariably fatal.
Its natural host is swine. They are the sole reservoir and usually the sole source of virus 
transmission [58]. Its main consequences are abortions and stillbirths in sows, nervous signs 
in young pigs, and respiratory disease in older pigs. Death rates can be high in young pigs, 
but as they get older, rates tend to diminish and this becomes less likely. Recovered pigs 
can act as a source of infection for uninfected pigs. These are important points with regards
2 .1  I n t r o d u c t i o n
Aujeszky’s Disease (AD) was first described in 1813 in cattle [38]. At that time the disease 
was unknown. Due to the intense irritation prior to death it was originally called ‘mad itch’. 
It was not until 1902 that the disease was given its name, by the Hungarian scientist Aladar 
Aujeszky, when he distinguished psuedorabies from rabies [84], As mentioned in Chapter 1,
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t o  t h e  d e v e lo p m e n t  o f  t h e  m o d e l.
In the USA raccoons are believed to be healthy carriers [90], [92] and in mainland Europe 
antibodies have been found in wild boar [70], [87]. The virus can also be spread by the wind 
(airborne infections), and infections of over three kilometers have been recorded [42],
2.2 D i s e a s e  c h a r a c t e r i s t i c s  a n d  c l i n i c a l  s ig n s
The clinical signs of the disease can be described under the following headings [79]:
• Pigs less than three weeks old
• Pigs three weeks to five months
• Mature pigs
• Post-mortem lesions
• Immunity
• Spread of infection
2.2.1 P ig s  less th a n  th r e e  w eeks o ld
In baby pigs, the disease may be characterised by sudden death with few, if any, clinical signs. 
Frequently death is preceded by fever, which may exceed 41°C, dullness, loss of appetite, 
vomiting, weakness, incoordination and convulsions. If vomiting and diarrhoea occur, the 
disease in baby pigs closely resembles transmissible gastro-enteritis (TGE).
In pigs less than 2 weeks old, death losses frequently approach 100%. Baby pigs may have 
become infected before birth and die within 2 days after birth, occasionally after showing 
violent shaking and shivering. Piglets infected immediately after birth may show clinical 
signs within the first 2 days of their life and they usually die before they are 5 days old. 
However, the influence of maternal antibodies does help reduce the transmission of ADV [13].
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2 . 2 . 2  P i g s  t h r e e  w e e k s  t o  f i v e  m o n t h s
After 3 weeks of age, pigs have usually developed a degree of resistance to the disease, and 
death losses may decrease from 50% in pigs exposed when 3 weeks old to less than 5% in 
pigs exposed when 5 months old. Death losses vary with different strains of the virus, and 
even in grown pigs severe death losses occasionally occur.
Fever is a prominent clinical sign in these growing pigs and is followed by loss of appetite, 
listlessness, laboured breathing, excessive salivation, vomiting, trembling and eventually 
marked incoordination, especially of the hind legs. Normally death is preceded by convul­
sions. Involvement of the respiratory tract with sneezing, rubbing of the nose and coughing 
may occur. Clear to yellowish nasal discharges may be seen. Infected pigs that recover have 
lost condition and will be slow to reach market weight.
2 .2 .3  M a tu r e  p ig s
The disease in adult pigs is usually not severe, but with some strains, deaths may occur. It is 
characterised by fever and respiratory signs, which may include nasal discharges, sneezing, 
nose rubbing and coughing. ADV is often found in conjunction with other respiratory 
diseases such as pasteurella and actinobacillus (hemophilus) pleuropneumonia. Nervous 
signs such as trembling, incoordination and itching occasionally occur, and blindness may 
follow pseudorabies infection. Vomiting and diarrhoea or constipation may be seen. Since 
1980, an acute, often fatal pneumonia caused by ADV has increased in prevalence.
This condition is most often seen in herds having a prolonged history of pseudorabies infec­
tion. However, the majority of animals often die from a fatal secondary bacterial pneumonia 
as opposed to the disease itself. Sows infected in the early stages of pregnancy may return 
to heat because of death and resorption of their foetuses (where the body re-absorbs the foe­
tus). Sows infected in middle pregnancy may eventually abort mummified foetuses, whereas 
sows infected late in pregnancy often abort or give birth to weak, trembling or stillborn pigs.
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2 . 2 . 4  P o s t - m o r t e m  l e s i o n s
No gross lesions characteristic of pseudorabies are consistently found. Small greyish-white 
spots of focal necrosis may occur in the livers and spleens of pseudorabies infected young pigs. 
Congested pneumonic lungs are commonly seen. Virus isolation and fluorescent antibody 
examination of these and other tissues will reveal if the lesions are related to the disease.
2.2 .5  Im m u n ity
When ADV enters a pig, the pig’s immune system recognizes that it is foreign. Specific cells 
in the humoral system produce antibodies that will try and kill ADV. When the disease is 
removed, these cells are no longer required and will decrease until only a few remain. These 
remaining cells are called memory cells, and their function is to remain in the animal in 
case ADV returns. If the disease returns, these memory cells activate the production of the 
antibody. If the animal has been previously exposed to ADV, the animal can respond much 
more quickly. The speed of this response will depend on a number of factors including age; 
nutritional state; health and, most importantly, the time elapsed since previous infection [37].
Recovery by swine from AD confers some resistance, sometimes for as long as twelve months. 
Re-exposure may result in reinfection, but it is usually asymptomatic. The passive immunity 
passed on from an immune sow to her offspring through the colostrum may protect the piglets 
for 5 to 10 weeks, after which they gradually become fully susceptible. However, the passive 
immunity may be too low to protect the piglets, hence the offspring of immune sows also 
may die of AD.
One of the reasons the disease continues to exist is due to the ability of the virus to establish 
a latent infection in pigs. During latency, the virus goes into hiding in the animal, and the 
animal appears healthy. However, the virus can be brought out of hiding during a process 
called reactivation [84]. Reactivation results in the shedding of the infectious virus causing 
its spread to uninfected animals. It has been shown that herds can be ADV positive for up 
to five years after a clinical episode, without obvious clinical problems [17]. It is this latent 
period / reactivation which makes the disease more difficult to model.
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Recovered pigs may remain carriers of the virus and later can infect susceptible pigs or other 
animals with which they come into contact. Severe cattle losses from AD have occurred as 
a result of contact infection from apparently normal carrier swine. The disease also has 
occurred in swine farms by the introduction of carrier pigs. Vaccines have been used in 
Europe for years and in the United States since 1977 [34]. The research consensus is that 
vaccines reduce swine losses and spread of the disease, but do not totally prevent infection 
and the establishment of a carrier state in recovered swine.
Vaccines have been reported to enhance the control and eradication of AD [86]. They have 
precluded eradication for decades, because infected pigs could not be traced in vaccinated 
herds [75]. Newer ‘differentiable’ vaccines combined with their appropriate serological tests 
permit vaccinated animals to be distinguished from those infected with ‘field’ strains of the 
virus. Differentiable vaccines permit the monitoring of herd infection status in vaccinated 
herds.
2.2 .6  S p re a d  o f  in fe c tio n
ADV is spread mainly by direct contact between swine; the nose and mouth are the main 
entry points for the virus [36]. Nasal discharges and saliva contain the virus; therefore, 
drinking water, bedding and other objects such as clothing and instruments may become 
contaminated. The virus can also be spread without movement of pigs; for this reason, when 
entering swine premises clean clothes should be worn, and boots should be disinfected upon 
entering and leaving the premises.
A higher density of pigs increases ADV transmissions under experimental conditions, owing 
to the higher number of contacts between animals. In a pig - dense region, i.e regions where 
there is more than one farm (these regions are quite common in Ireland), the contacts by 
area spread increase. This is due to the fact that there will a higher number of contacts 
between animals and as a result ADV may circulate more easily [75].
The virus also may spread by the movement of air within buildings and for short distances 
outside depending upon climatic conditions. Airborne spreading in late winter and early
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spring is suspected to be over greater distances than previously thought. These airborne 
transmissions can be very difficult to contain in regions that have a high pig density.
2 .3  D i a g n o s i s  a n d  c o n t r o l
2.3.1 D iag n o sis
Isolation of ADV can be made by inoculating a tissue homogenate, for example of brain 
tonsil or material collected from the nose /  throat, into a sensitive cell line such as porcine 
kidney (PK-15) or SK 6, primary or secondary kidney cells. The specificity of the cytopathic 
effect is verified by immunofluorescence, immunoperoxidase or neutralisation with specific 
antiserum. The virus can also be identified using the polymerase chain reaction, but this 
technique is still new [23].
The clinical signs of AD are variable, so clinical diagnosis should always be confirmed by lab­
oratory tests. Several tests, including the Serum-virus Neutralisation Test (SN), Virus Iso­
lation (VI), Fluorescent Antibody Tissue Section test (FATS), the Enzyme Linked Immuno- 
Sorbent Assay (ELISA), and the Latex Agglutination Test (LAT) have been approved for 
the diagnosis of AD. Other tests are being developed. The SN, LAT, and ELISA tests detect 
ADV antibodies in serum of pigs that have been infected with the virus.
In a natural infection the disease lasts about 2 — 8 days and the ADV antibodies appear in 
the serum about day seven of infection and may persist for years [36]. The presence of ADV 
antibodies is evidence that the pig has been infected with the virus in the past or has been 
vaccinated. Absence of antibodies indicates that the animal has probably not been infected 
or that it may be in the early stages of the disease. Diagnosis of an ADV outbreak can be 
made by conducting SN tests on paired serum samples, one taken from the pig early in the 
disease, and the next three to four weeks later.
A significant rise in antibodies between the first and second bleeding indicates active ADV 
infection has been present. The SN, LAT, and ELISA are extremely reliable tests. While 
these tests accurately detect antibodies to AD, they do not differentiate between antibodies
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resulting from natural disease and those resulting from vaccination. Only the differential 
tests will permit such a distinction. Serum submitted for SN examination must be collected 
in clean, sterile tubes (not brucellosis tubes) and submitted packed in ice. If serum is badly 
haemolised or contaminated with bacteria, the SN test is unreliable.
2.3 .2  C o n tro l o f  in fe c tio n
The chances for introduction of the disease can be minimised if the owner strictly controls 
movement of people, animals and objects into swine premises, and if they have a number 
of rules/procedures implemented to protect the health of the herd. The application of the 
methods mentioned is known as Biosecurity, and it plays a very important role on the 
modern farm. Farms that have a good Biosecurity programme in operation can also reduce 
the prevalence of other diseases as well as AD.
Cats, dogs and all other animals should be kept well away from pigs. If new breeding 
stock is required, it should be added from a herd known to be AD-free, to avoid the risk of 
infection. Observations suggest purchased stock acts as a major source of virus introduction 
in a regional vaccination program [75]. All additional purchases should be tested and found 
free, isolated for at least thirty days, and then retested. Only then should they be allowed to 
enter the herd. Untested feeder pigs should never be brought onto premises where farrowing 
operations exist.
If AD occurs on a farm, the premises should be quarantined immediately, and all movement 
of animals and people should be strictly controlled. If at all possible, healthy animals 
should be separated from the infected ones, the problem here is identifying which animals 
are healthy. Dead pigs should be incinerated and recovered pigs should be sold only for 
slaughter to prevent the spread of infection around the farm and to other farms by carriers. 
The incineration of animals does not affect airborne transmissions due to the inability of the 
virus to survive in temperatures exceeding 24° C [5].
Due to the fact that Ireland has an island-based pig industry, we have a significant Biose- 
curity advantage over our European counterparts, and to some extent the UK. This was
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reflected in the superior health status of the Irish pig industry when compared with that 
of mainland Europe (a summary is provided in Table 2.1, with the necessary amendments 
following recent outbreaks of Classical Swine Fever and Foot and Mouth disease in Ireland 
and the UK) [42]. A number of pig diseases that are still endemic on European farms have 
been eradicated from Irish farms. This should be of great advantage in the eradication of 
ADV as the possibility of secondary infections are greatly reduced.
Disease Ireland U.K Europe
African Swine Fever — — +
Anthrax — + +
Aujeszky’s disease + - +
Classical Swine Fever - + +
Foot and Mouth + + +
PRCV - + +
PRRS — + +
Rabies — — +
Swine Vesicular — -- +
TGE - + +
Table 2.1: Comparison of health status: Ireland, U.K and mainland Europe
Another advantage that Irish pig producers have over their European counterparts is the 
intensity of the industry in Ireland. The majority of the producers in Ireland are intensive 
farming units, which means that only pigs are kept on the farm. This greatly reduces the 
possibility of transmissions to /  from outside influences. This can be a disadvantage in pig- 
dense regions, as the contact rate (A) is larger here than it would be on other, more isolated, 
farms.
It has been forecasted that margins in pig production will be greatly improved in period 
2000/2001 [81]. This will be of immense relief to the industry, which has seen numerous 
setbacks over the 1998 - 2000 period. Among the others things forecasted were an increase 
in production costs and an increase in pigmeat consumption in the majority of EU coun­
tries [81]. If this forecast is correct, Ireland could see an increase in demand for pigmeat, 
which would emphasis the importance of disease control so that the consumers, both here 
and abroad, can have confidence in the industry.
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2 .4  A u j e s z k y ’s  D i s e a s e  i n  E u r o p e
Only two countries worldwide with intensive pig production have managed to escape from 
ADV, Australia and Canada [48]. Every other country has had some prevalence of AD, some 
higher than others. The most intensive pig farming is done in mainland Europe and as a 
result the prevalence of AD is higher there than in most other parts of the world. With free 
trade within the EU, the spread of infection has become more difficult to contain [87].
To avoid future restrictions on free trade, member states need to achieve the same health 
status. Some countries have been more fortunate than others with regard to location, farming 
methods, climate etc., that all play an important part in the successful eradication of AD. 
At the moment the European countries can be divided into the following [87]:
• Officially AD free (OADF)
• Partially AD free (ADF)
• Infected Countries
2.4.1 O fficia lly  A D  F ree
Countries that are classified as OADF have been free of AD for at least two years. In these 
countries vaccination is not permitted. Presently, the following countres are OADF.
Denmark
Vaccination has never been used in Denmark [1].- An eradication program was put into
operation in 1983 and it operated on a test and removal basis. The initial success rate
was very good, going from 19% of infectives in 1983 to 1% in 1985. At the end of 1986 it 
was assumed Denmark was AD free as no ADV antibodies were found during serological 
examinations.
However, in the next few years various outbreaks were recorded. The main area was near 
the border with Schleswig-Holstein (Germany). This was due to the spread of airborne
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transmissions from Germany as opposed to latent infections. Since Germany introduced 
compulsory vaccinations in this area no further outbreaks have been recorded.
Sweden and F inland
A national eradication program began in Sweden in 1991 [67], that was based on serological 
testing of all pigs older than 6 months. There were 230 outbreaks recorded in 1994. A 
serological survey carried out in 1996 showed 1% of the population was positive. The infected 
animals in question were slaughtered and Sweden was given OADF status in 1996 [68], No 
outbreaks or clinical signs of ADV have ever been recorded in Finland [88].
A ustr ia  and Luxembourg  are also officially free of AD [87].
2 .4 .2  P a r t i a l ly  free  o f  A D  
United K ingdom
An official eradication scheme was put into operation in England in 1983 using test and 
removal [78]. Vaccination has never been permitted. Positive herds have decreased from 443 
in 1983 to 5 in 1989. Since October 1989, ADV antibodies have not been detected in sera 
during serological screenings.
The situation in Northern Ireland is quite different. An eradication program began in 1994 
and to begin with was quite successful. From meetings with officials from the Department 
of Agriculture for Northern Ireland (DANI), we have learned that at the present time there 
has been a series of setbacks, including an economic crisis in the pig industry. This has 
managed to make the tracing of seropositive animals extremely difficult and at the moment 
the current status of the scheme is unknown.
France
A national programme began in 1990 [87] and by the end of 1993 the prevalence had signif­
icantly decreased, and to date 21 administrative regions are officially free. The eradication
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programme is regionally controlled and has been very successful. It is based on an accurate 
census of pig herds, results of preliminary serological surveys, control of animal movement, 
financial compensation, and on an administrative structure capable of applying these mea­
sures. In the remaining regions various eradication strategies are in operation ranging from 
intensive vaccination to test and removal.
To decrease the risk of clinical AD, some farmers randomly vaccinate the breeding herds 
with a systematical serological screening of finishing herds. In regions that have a high 
prevalence of AD a more intensive vaccination programme is advised. This policy has been 
progressively implemented since 1990. The aim is to clean up all the infected herds and, to 
achieve this, all herds selling piglets must undergo serological screening three times a year. 
A certificate of AD freedom is then issued.
G erm any
Various control programmes are in operation in different regions ( ‘Bundesländer’) in Ger­
many. To date several regions have OADF status, Thüringer, Sachsen, Brandenburg, Meck­
lenburg - Vorpommern, Saarland and Saschen-Anhalt [50]. Most of the other regions are 
infected [59]. In the areas along the border with Denmark (Schleswig-Holstein, Baden- 
Wiirttemburg) vaccination has been mandatory, since 1990. Other infected areas include 
Lower Saxony (Niedersachsen) and Nordrhein-Westfalen.
All pig herds are serologically examined twice yearly to reduce costs. Following an outbreak 
of AD in an OADF region, the entire herd is slaughtered. In regions where ADV circulates, 
vaccination in breeding and fattening herds has been compulsory since 1991. In these areas 
animals with specific antibodies are slaughtered. These procedures have lead to a reduction 
from 23% in 1992 to 12% in 1993.
Wild boar have also been a complicating epidemiological factor. ADV antibodies were found 
in 1.7% of wild boar in Lower Saxony, Saschen-Anhalt and Brandenburg [70], [87]. It has 
yet to be shown if the wild boar in these regions will reduce the effectiveness of eradication. 
More information is needed before an assessment can be made.
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2 . 4 . 3  I n f e c t e d  C o u n t r i e s
B elgium
A nationwide control program officially began in March 1993 [87]. It was decided a regional 
approach would be more successful as the majority of the pig industry in located in the 
north of Belgium (Flanders), where AD is endemic. In parts of south Belgium (Wallonia) 
the prevalence of AD is low.
Vaccination in mandatory in Flanders. The breeding stock is vaccinated either twice yearly 
with inactivated vaccines or three times with live attenuated vaccines. Breeding pigs are vac­
cinated three times and fatteners once, at the start of the fattening period. All vaccinations 
are recorded and a serological follow up is made. In Wallonia, vaccination is prohibited, 
except in cases that have a high risk of infection, or on farms where animals come from 
Flanders.
Nationwide screening is underway and will assess the prevalence of ADV in all regions. An 
official declaration of OADF will be offered to herds with complete gE (glycoprotein Enzyme) 
negative status.
Ita ly  and Greece
A national control program was made compulsory in Italy in 1997 [93]. Most of the intensive 
pig farming is done in northern Italy (Lombary, Emilia - Romagna), where seroprevalence is 
high. In Greece, vaccination is performed on a voluntary basis [63], so the current prevalence 
of AD is unknown. Because Greece is a major importer of pigs, all imports are tested for 
ADV antibodies. Presently, an eradication programme is being considered.
The N etherlands
A nationwide eradication programme began in September 1993 [76]. The eradication has 
been split into three stages [15]. During the first stage, ADV transmissions were reduced, in 
the second stage, the remaining sources of ADV must be contained and eliminated. During 
the final stage, vaccination will be prohibited and test and removal will be used.
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The Netherlands is the largest pig producer in mainland Europe that is not OADF. As a 
result, a lot of work, both mathematical and otherwise, has been done on AD. The recent 
work in [20], [77], [84] and [85] has been well documented. The majority of the eradication 
programmes in the rest of Europe have been widely based on the Dutch one. To achieve 
success in reducing ADV transmissions within and between herds, the following measures 
were imposed.
1. Compulsory Vaccination
All herd owners must vaccinate against AD. The breeding herd must be vaccinated three 
times a year, replacement pigs must be vaccinated three times before service and double 
vaccination is recommended for finishing pigs. Vaccination is done only by registered vet­
erinarians and all vaccinations are recorded by the National Animal Health Service.
2. Certifying herds free of AD
In 1993 a voluntary program was implemented where herd owners could obtain ADF sta­
tus [73]. This was done to reduce ADV transmissions. For ADF herds all gE- (gE delete) 
seropostives must be eliminated. Random sampling of the breeding herd is carried out three 
times and if no ADV antibodies are found the herd is declared ADF. After obtaining ADF 
status a certain proportion of the herd have to be tested at four month intervals to retain 
ADF status. In July 1990 450 herds were ADF [87].
3. Surveillance of the gE- seroprevalence
To monitor the eradication scheme a system has been designed for regional surveillance of 
gE- seroprevalence [76].
4. Future Adaptations
From monitored results, the risk of ADV introduction will be calculated at regional level. The 
outcome will be used to enforce double vaccination of finishing pigs in high risk areas. From 
January 1996 only ADF breeding herds will be allowed to move. Presently they are beginning 
to wind down their vaccination program, and hope to be OADF in two years [21], [76].
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P o rtuga l and Spain
Currently, preparations are underway to implement an eradication programme in Portu­
gal [59]. Serological screening is being carried out and the results will be used to devise the 
control /  eradication strategy that will be used.
Like France and Germany, Spain is divided into regions for eradication purposes. An official 
eradication program is prescribed in Galicia, Cataluna, La Rioja and Navarra. Eradication 
began in Galicia in 1992. Only gE- vaccines are allowed and all sows must be immunised. 
The vaccination of fattening pigs is done on a voluntary basis. Regular screenings make it 
possible to evaluate the ADV circulation.
Eradication began in La Rioja in 1991 and in Cataluna and Navarra in 1992. Only gE- 
vaccines are allowed. Again sows must be properly vaccinated and both inactivated and 
live attenuated vaccines may be used in fattening pigs. Serological surveys of breeders are 
carried out at slaughter to evaluate the progress made [87].
2.4 .4  E a s te r n  E u ro p e a n  C o u n tr ie s
Only recently has the prevalence of AD in Eastern European countries been calculated [56]. 
AD is, or has been, an important disease in most of these countries. To date, the Czech 
Republic, Slovenia, and the Republic of Estonia have become free of AD, while Hungary, 
Russia, and Slovakia, all have some form of eradication program in operation (the last is 
expected to be AD free in 2001 [56]). Other countries, such as Poland, Albania, and Bulgaria 
are all expected to begin eradicating very soon. Little is known about the prevalence of AD 
in the remaining countries.
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2 .5  A u j e s z k y ’s D i s e a s e  in  I r e l a n d
Ireland is another country that is member of the infective group. ADV was first diagnosed 
in Ireland in 1960 [16]. Due to the intensity of the pig industry, AD increased in prevalence 
in the population. During the 1980’s inactivated vaccines were licensed to try to control the 
spread of AD. They were replaced with gE delete inactivated vaccines and have now been 
augmented by the licensing of live gE delete vaccines.
AD is a scheduled and notifiable disease in Ireland [16]. A serological survey was carried out 
in July 1992 on 9041 sera from 310 breeding herds showed 7.5% to be positive [16]. From 
Tables 2.2 and 2.3 below (taken directly from [16]) we can get an idea of the prevalence of 
AD in Irish herds. The highest number and percentage of infected herds was in Tipperary 
(42%), Cavan (26.5%) and Cork (20.3%). Overall 7.5% of the samples were positive with 
90.2% negative and the remainder inconclusive.
H erds No. B reeding  (%) No. F a tten in g  (%) T otal (%)
Positive 56 (18.1) 8(26.7) 64(18.8)
Inconclusive 41(13.2) 1(3.3) 42 (12.4)
Negative 213(68.7) 21(70) 234(68.8)
T otal 310 30 340
Table 2.2: Infection rate detected in Irish herds
% of Positive  Sam ple herds H erd s (F atten ing )
< 9 21(2)
1 0 -3 9 14(1)
4 0 - 9 9 18(2)
> 100 11(3)
Total 64 (8)
Table 2.3: Estimation of the proportion of animals positive within infected herds
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2 . 5 . 1  T h e  R e s p o n s e  t o  V a c c i n a t i o n
Vaccination of animals has been licensed in Ireland since 1983 [43]. A sample vaccination 
was carried out on a 12,000 pig fattening unit [40]. The incidence of AD séropositives in 
pigs fell from 96% before the commencement of vaccination in July 1994 (Table 2.4) to 15% 
just three months later (Table 2.5). By November, all serum samples in the fattening unit 
were tested, all were negative and have remained so subsequently.
D a te No. te s ted No. positive % positive
20.10.93 6 5 83.3
26.02.94 10 9 90
13.07.94 16 16 100
11.08.94 18 18 100
T otal 50 48 96
Table 2.4: The incidence of AD séropositives before vaccination
D ate No. te s ted N o. positive % positive
28.09.94 10 2 20
04.10.94 10 1 10
13.10.94 10 1 10
16.11.94 17 0 0
19.11.94 26 0 0
02.12.94 10 0 0
21.12.94 10 0 0
10.01.95 10 0 0
T otal 113 4 3.5
Table 2.5: The incidence of AD séropositives after vaccination
Kavanagh, [44], extrapolated these figures to that for a National Herd of 160,000 sows, 
and found that 20% were AD positive, 75% were vaccinated and 5% had circulating virus. 
Seasonal variations in pig performance were accounted for by examining similar periods in 
each year. The estimated cost of AD was ,£‘0.51 per pig based on a purchase weight of 32kg 
and a sale weight of 97kg [44], [49].
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2 . 5 . 2  P r o p o s e d  E r a d i c a t i o n  P r o g r a m m e
The proposed eradication scheme for Ireland will classify the herd status into five levels [16]:
• Officially AD free (OADF)
• AD free (ADF)
• Monitored Herds (MH)
• Infected Herds (IH)
• Non-Status Herds (NSH)
Herds that are OADF must have not been vaccinated for at least two years and must have 
had a full herd blood test with negative results. ADF status herds are similar to OADF, 
except that vaccination is permitted. For MH, a statistically valid sample of the herd is 
tested with negative results. Here vaccination is optional. In status IH, vaccination is 
mandatory as positive animals are detected. With NSH no information is available about 
the herd. It is intended that NSH do not remain in this status for very long.
If we look at Table 2.6 below, we can see that Ireland is one of the larger pigmeat exporters 
in the EU that does not have some sort of eradication scheme in operation [54], Indeed, 
50.9% of the pigmeat produced in 1999 was exported [3], From this we can gather that a 
scheme should be implemented immediately. If this is not established the closure of valuable 
export markets seems inevitable. This would have severe financial effects on an industry 
already suffering from falling pigmeat prices.
E u ro p ean  C oun try P ro d u c tio n  as a  % of C onsum ption
Denmark 425
Netherlands 275
Belgium 187
Ireland 145
Table 2.6: Pigmeat production in selected European countries
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2 . 5 . 3  E r a d i c a t i o n  C o s t s  /  P r o c e d u r e s
Kavanagh [40] conducted an investigation into the cost of an AD outbreak in a 370-sow herd 
selling fattening pigs. He estimated that the cost of an AD outbreak to be in the region of 
£9000 per 100-sow herd size. Where sows are vaccinated, the risk of a clinical outbreak of 
AD in the breeding herd is low, hence the cost of AD is primarily limited to that associated 
with virus circulation in weaners or finishing pigs. It is thought that twice yearly vaccination 
of breeding stock with inactivated ADV vaccines is capable of controlling the clinical signs 
of AD [41]. However, it may fail to eradicate ADV from the population.
More recently, some work by [44] has shown that AD can be detected by modifying the ELISA 
test and analysing the meat juices after the pigs have been harvested. With the proper 
marking, it would be possible to tell from which herd the infected animals originated. If 
all herds could be monitored for circulating virus on an ongoing basis, and strategic control 
programmes introduced on farms with circulating virus, then virus circulation could be 
eliminated. As mature seropositive sows were replaced by seronegative gilts, the virus would 
be eventually eliminated.
Recent research into eradicating AD at farm level has shown the cost of AD in an IH is 
approximately £0.50 per pig in a 5,000-place pig finishing unit. AD can be eradicated 
from finishing herds in four months, where almost all animals were seropositive at the be­
ginning [44], From this a break-even point would be reached approximately nine months 
following the completion of an eradication programme. Therefore, there are very significant 
economic advantages to be gained by eradicating AD from finishing herds. There is also 
the possibility for co-financing within the context of EU Cotmcil Decision 90/424/EEC on 
expenditure in the veterinary field, which would greatly reduce the costs incurred during an 
eradication programme [91].
At the present time, government legislation is underway to introduce the Aujeszky’s Disease 
Order. This should then bring about the introduction of an eradication scheme. From com­
munications with department officials and members of the IFA (Irish Farmers Association), 
this was proposed to commence in the spring of 2001. However, with the recent outbreak 
of Foot and Mouth Disease in Ireland, it has been put off until June 2002. From the infor­
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mation above, any scheme introduced should be well organised. An efficiently run scheme 
could be very successful in the tracing and removal of infectives from the population and 
eventually lead to the eradication of AD.
Unfortunately, the current BSE crisis in Ireland and Europe has had a twin impact on pig 
producers. The ban on meat and bone meal inclusion in animal feeds in Europe has already 
increased soya bean meal prices and pig feed prices. Secondly, the demand for pigmeat is 
not forecast to rise to the same extent as happened following the 1996 BSE crisis [82]. In 
the likely event of a continuation of the BSE crises, it is unknown the effect that it will have 
on the pig industry. If demand was to increase, then the need for ADV to be eradicated 
would be doubly important, as the pig industry would need to take full advantage of any 
short term market increases.
Also, due to the recent difficulties in the industry, a number of the smaller producers are no 
longer in existence. This makes the control of animals much easier, and hence would ease the 
administration of the implementation of a vaccination scheme. As mentioned previously, it 
is only a matter of time before economic sanctions are introduced by the EU. This would be 
disastrous for the Irish pig industry. With the mathematical models that we will develop in 
the forthcoming chapters, we hope to be able to find the appropriate parameters to attack, 
with the intention of finding the most cost effective and efficient way of eradicating ADV.
In light of a renewed interest in ADV, and our lack of suitable Irish data, it was decided 
that a Nationwide questionnaire could be created, to gather information for both our work 
and the Department of Agriculture. An outline of what was proposed to the Department 
and the Irish Farmer’s Association is contained in Appendix B.
2 7
C h a p t e r  3
D e t e r m i n i s t i c  M o d e l
3 .1  S I R  m o d e l
Before moving on to the SIL model, we develop some important concepts in the basic SIR 
model,
>
where
S + I + R  =  N
N  — the size of the population, which is constant 
A =  the daily contact rate between individuals
0 = the daily removal rate.
A considerable amount of work has been done on the equations in (3.1) [7], [14], [22], In (3.1) 
the expected duration of the infectious period is 1 //? and a force of infection A is inserted on 
all susceptibiles, which is N  to begin. From this we can show the reproduction ratio to be
-A I S  
XIS -  p i
(31
(3.1a)
(3.1b)
(3.1c)
The reproduction ratio will be discussed in more detail later. (Section 3.3). From (3.1) we 
conclude that I  initially grows with rate AN — ¡3. Hence we define the initial exponential 
growth rate as
r = X N - p
= P(Ro -  1). (3.3)
We can calculate the initial growth rate as
I(t) ~  XeTt (3.4)
where r is the initial exponential growth rate and A is as before. We define i(t) as the
incidence, i.e. the number of new cases per unit of time. (i(t) ~  d l/d t  ~  ert).
New cases at time t result from contacts with infectives that are infected at time t. We have 
the following equation for the incidence in the initial phase of an epidemic
rT2
i(t) = X p i  i ( t —u>)duj (3-5)
JT!
where, p is a probability G (0,1), u  is the infection - age, i.e., time since infection took place, 
and the infectious period has length T2 — T\. Using (3.4) we can write (3.5) as
fT2
1 =  Ap e~ruduj (3.6)
JTx
Then we can conclude that there exists a unique real root r, i.e. equation (3.6) tells us what 
the exponential growth rate is. r > 0 iff R q > 1 and vice versa. In words, we will only have 
growth in real time if and only if we have growth on a generation basis (if r =  0, R q =  1). 
If an epidemic has growth rate r, we can calculate the doubling time, i.e. the time it takes 
for the epidemic to double as
Td =  —  (3.7)r
and from (3.3) we can see that the threshold density can be calculated as
N t  =  ^ . (3.8)
If the number of susceptibles is below a critical value, the introduction of an infective will 
not give rise to an epidemic outbreak. This critical value is known as the threshold density.
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From (3.8) we can say that below Nt  we have R q < 1 and above it, we have R q > 1. This
(3.10) is negative for S  > /3/A and positive for S  < /5/A. Hence, I (S ) is an increasing 
function of S for S < /3/A and is a decreasing function of S  for S > /3/A. We observe that 
1(0) =  —oo and /(So) = Iq > 0.
Then there exists a unique point Sqq, with 0 < < So, such that /(Soo) =  0, and I(S) > 0
for Soo < S < So- The point (Sqo, 0) is an equilibrium point of (3.9) since both S '  and I '  
vanish when 1 = 0. Thus the orbits of (3.9), for to < t < oo, take the form described in 
Figure 3.1.
Looking at (3.9) again we can say that all points on the I  axis are steady states and these 
are the only ones, so J(±  oo) = 0. Using (3.12), and the fact that its values at t =  ±  oo must
will be discussed later in Section 3.3.3. The first two equations in (3.1) do not depend on R  
and we may consider these separately from the third:
^ S ( t )  = - X I S  (3.9a)
at
I ( t ) = X I S - p i .  (3.9b)
Chb
( . )
( . a)
The orbits of (3.9) are the solution curves of the first order equation
d i XIS -  p i  
dS ~ -X  I S
(3.10)
(3.11)
Integrating (3.11) and rearranging, we have, for some constant C ,
C = y  In S(t) -  S(t) -  I{t) A
(3.12)
and we can say (3.12) is independent of t. Then we write (3.12) as
I(S) = J0 +  S0 - S  + ^ l n £ (3.13)
where So, I  a are the initial number of susceptibles and infectives at time t = to. Note: 
So, Jo > 0, as mentioned in Chapter 1.
To analyse the behaviour of the curves of (3.9) we use (3.10). From this we can say that
3 0
In fe c t iv e s
Susceptibles
Figure 3.1: Orbits of (3.9)
be equal, we can say
Y In S(+oo) — 5(+oo) = ^  In JV-jV (3.14)A A
and we can rewrite (3.14) as
¡aS J £ )  _  « j f c l . , ) .  (3.15)
We let s =  S /N  denote the proportion s of susceptibles S  in the total population. We define 
s(oo) to be the proportion of susceptibles at the end of an outbreak. Hence we have 1 — s(oo) 
to be the final size, s(oo) is a root of (3.15). We can then rewrite (3.14) as
lns(oo) = i?o(s(oo) — 1  ^ (3.16)
and we define (3.16) as the final size equation. Here we define the final size to be the fraction 
of remaining susceptibles in the population after an outbreak has occurred. The final size 
depends on the reproduction ratio, R,q of the infection and the initial number of susceptibles 
in the population.
When, R q < 1 the root is s(oo) = 1, which means that the introduction of an infective into 
the population does not lead to a major outbreak. When Ro > 1 there exists a unique root 
in (0,1), (the root s(oo) = 1 persists, but becomes redundant). We conclude that a certain 
fraction, s(oo), avoid infection with the disease, and s(oo) is completely determined by Rq 
via (3.16) (the larger the value of R q the smaller s(oo) will be) [22],
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We can also calculate the value of S  for which the epidemic reaches its peak. A necessary 
condition for this is for I  to be maximal, (i.e. dl/d t = 0, d?I/dt2 < 0, which is true). As
^  =  ( \ S - / 3 ) I  (3.17)
and 7 ^  0, we can say that for I  to be maximal we need S  =  /3/A, which holds with the
threshold density in (3.8).
The root s(oo) of (3.16) is a decreasing function of ño- Using (3.2) we can say that i?o is 
an increasing function of N. Hence we can say that the root s(oo) becomes smaller when 
N  increases. This is essentially an overshoot phenomenon, i.e. there will be many new cases 
after size of S  has dropped below Nt , because there are many infectives in the population.
From the results above we can draw the following conclusions:
• An epidemic will occur only if the number of susceptibles in the population exceeds
the threshold density.
• The spread of a disease does not stop when S = 0, but when 1 = 0.
Using all of the information above we can now prove the famous Threshold Theorem of epi­
demiology, which was first proved in 1927 by Kermack and McKendrick [46]. This states that 
if the number of susceptibles So is initially greater than, but close to, the threshold density, 
we can estimate the number of individuals that ultimately become infective. Specifically, if 
S0 — N t  is small compared to N t,  then the number of individuals who become infective is 
approximately 2(So — N t )-
Theorem  3.1 Let So = Nt  + vi and assume that ui/Nt  is very small compared to one. As­
sume, that the initial number of infectives, Iq, is very small. Then the number of individuals 
that ultimately become infective is 2v\.
Biocorollary 3.1:
When a disease is introduced into the population the level of susceptibles is reduced to a 
point as far below the threshold density as it originally was above it.
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proof:
Letting t approach infinity in (3.13) gives
0 =  J 0 +  5 0 - 5 0 0  +  ^ 1 1 1 - ^ . ( 3 .1 8 )
If Jo is very small compared to 5o we can neglect it, and (3.18) becomes,
S>
So
So -  (So -  Soo)
o =  So — Sqo +  Nt  In 
= S0 — Sqo + Nt  In
So
=  50 - S o o + i V T l n [ l -  ( ‘90~ l5,°O)
So
(3.19)
Now, if So — Nt  is small when compared with Nt , then 5o — S00 will be small compared to 
So- Consequently, we can truncate the logarithm part of (3.19) using the Taylor series.
In 1 /S 0 — So \   /  So SooN t / ¿0 ^oo \) \  ~  V Sn ) ~  2V 5n )
1 S o - S \ 2
V 50
after two terms. Then (3.19) becomes
So
0 =  S0 — Soo — Nt  ( ~~g ^°° ) ~
+ (3.20)
So
Nt (S W ? o o \2 
2 V So
= (So -  Soo) J ^ ( 5° -S °o ) (3.21)
Solving for (So — Soo), we see that
S o - S « ,  =  2 S „ ( ^ - l )
=  2 (Nt  +  t'l) Nt  +  v\ 
Nt
= 2(Nt  + u1) ^ -  
=  +
=  2v\. o
Throughout the course of an epidemic it is extremely difficult to accurately ascertain the 
number of new infectives being produced each day or week. Usually the number of infectives 
is not recorded, but the number of removals are. So, in order to be able to compare the 
model in (3.1) with that of data from an actual epidemic, we must find the quantity dR/dt 
as a function of time. From (3.1) and using the fact that S +  I  +  R  =  N, we can say
- R ( t )  =  P ( N - S - R ) ( 3 .2 2 )
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and also observe that,
dS -AS 
dR ~  /?
Solving (3.23) and putting into (3.22) we get
(3.23)
- R ( t )  = ß ( N - S 0exp-ßR/X - R ) .  at
(3.24)
After some algebraic calculations involving the Taylor series and the hyberbolic tangent 
function, we can write (3.24) as
' 2 (€0t
where
and
A
dt **> -  - 0 (3.25)
£ =  ( i ) * [ f f i - o , + y , * (£ ~ -a r
r  =  t o n h - ' i ^ - l ) .
Equation (3.25) is defined as the epidemic curve of the disease [46], and is shown in Figure 3.2. 
It illustrates the common observation that in an actual epidemic, the number of infectives 
climbs to a peak value and then begins to fall away.
2r time
Figure 3.2: Epidemic curve of the disease
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3 . 2  A D  M o d e l
As mentioned in Chapter 1, AD can be classed as an SIL  model. Unfortunately, SIL  models 
are more difficult to work with than S IR  models. This is because there is a continuous flow 
from the infectives to the latents and vice versa. Also, there is no R  term, so it is possible 
for the disease to remain in the population for a considerable time. For convenience, we 
rewrite here the equations of Hethcote’s model that was mentioned in Chapter 1. For ease 
of notation we write d(-)/dt as (■)' and (-)(t) as (•)
S'(t) =  - \ I S  + (5i +  Ql) -  (¿i + a i ) 5 - a i /  (3.26a)
I ' ( t ) =  XIS — 7 i l  — 5\I (3.26b)
R'(t) = 1 — S(t) — I(t). (3.26c)
From (3.26) we create our model for AD. The main differences between (3.26) and our model
are the additional L and P  terms and the harvesting parameter, mentioned in Chapter 1. 
We take our model of AD to be:
S'(t) = a N  A1^  (n + E)S  kS (3.27a)
I n '(t) = X1- ^ -  -  {fi + E)In  -  /3In  +  8L (3.27b)
Iv 'it) = V  N  [n + E)IV rjlv + j L (3.27c)
L'(t) = —7  L + rjly — (m +  E)L  + (3In  — SL (3.27d)
P '( t ) = KS - ( p  + E ) P - X v 1^ - (3.27e)
where we define the following parameters
A =  the daily contact rate between individuals 
Ay = average level of protection 
a =  the birth rate 
ji =  the death rate 
E  =  the harvesting rate
¡ 3 , r )  =  the rate of relapse from 1 I y  respectively
5,7  = the reactivation rate from In ,Iv  respectively
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k  =  the vaccination rate
Ijy = where infection occurs from a non-vaccinated animal 
I y  = where infection occurs from a vaccinated animal
We take a compartment model of ADV to be and the new term
H + E |^  + E + E
a U P
§
K D U v T
V
r ------
|X + E n + E
Figure 3.3: Compartment model of AD
P  = the number of protecteds in the population (i.e. animals who have been 
vaccinated against AD and for a while are unable to become infective)
As before
S + I  + L + P = N.
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3 . 2 . 1  M o d e l  A s s u m p t i o n s
The model defined in (3.27) is NOT a coupled model, but instead it incorporates two separate 
models, non-vaccinated and vaccinated. This is done to make the model more realistic, as 
we assume that the farmer is either vaccinating or not (it does not make economic sense to 
begin a vaccination scheme and not complete it). Hence, for example, a transmission from 
Jy —>■ L —>• J/v is not possible. We will work with both models, but later on we will just 
concentrate on the vaccinated model as we believe that the majority of the larger producers 
are vaccinating [44],
The environmental capacity of AD is ignored. This is where the disease is transmitted 
between a herd from animals other than swine. As mentioned in Chapter 1, this is a problem 
in mainland Europe, where antibodies have been detected in wild boar [84], and also in the 
USA, where raccoons are believed to be carriers of the disease [92], There are no wild boar 
in Ireland, and the threat of infection from raccoons is unlikely. Also, as most farms are 
intensive pig producing units, this threat can be ignored.
As mentioned in Chapter 1, the population considered has constant size N  which is suffi­
ciently large so that the sizes of each class can be considered as continuous variables instead 
of discrete ones. As a result we can say that births equal deaths plus harvesting (a = /i + E) 
(this constraint will be relaxed later in Chapter 5). As farmers work on an all in - all out 
basis, this is not an unrealistic assumption. Individuals are removed by death from each 
class at a rate proportional to the class size with proportionality constant /i, which is called 
the daily death removal rate. The average lifetime is l/(/i +  E).
If the model is to include vital dynamics, then it is assumed that births and deaths from 
natural causes and slaughtering occur. We also assume that there are no deaths from ADV, 
which is based on previous work done by [72]. We make the important assumption that all 
newborns are born protected due to maternal antibodies. Hence, the a N  term is in S  only. 
However, these antibodies do not last for very long and the piglets are usually vaccinated in 
weeks 10 and 14 after birth [13].
The population is uniform and homogeneously mixing. This means that every pig has an
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equal chance of meeting every other pig that are housed in their particular compartment. 
The daily contact rate A is the average number of contacts per infective per day. Thus the 
incidence (number of new cases per unit time) is XIS/N. We also define Aj = XI/N  to be 
the force of infection, i.e. the average number of contacts with infectives per unit time.
A contact of an infective is an interaction, which results in infection of the other individual 
if they are susceptible. The daily contact rate A is fixed and does not vary seasonally, as it 
does with other diseases [2], We use the ‘true mass action’ transmission terms XIS/N  and 
X IP /N , rather than the ‘classical mass action’ transmission term A IS. It has been argued 
that the former is more accurate than the latter [28], [57].
The incubation period for ADV is usually one week and sometimes less [36]. Hence our 
model has a latent period after infection as opposed to other diseases where the latent 
period occurs before infection. This is contrary to the usual terminology in epidemiology, in 
which the latent period is the time from infection until the individual becomes infectious [25], 
but as ADV has the ability to remain in the pig for life, we feel that our latent period after 
infection is more appropriate.
To begin with, the latent period is zero, i.e. we are assuming the disease is starting in a 
herd for the first time and therefore there will be no resurgence of the disease from previous 
infection. Vaccination is usually three times a year depending on the type of pigs that 
are vaccinated [84], For example, piglets are vaccinated and age 10 and 14 weeks, while 
fattening herds are usually double vaccinated [76]. In comparison with single vaccination, 
double vaccination significantly reduces the risk if extensive virus spread [74], [76]. Antibody 
titres are usually not measured, i.e. the loss of immunity in the herd is not taken into account.
The vaccination rate is a very important aspect of the vaccinated model given the fact that 
vaccination does not give life long immunity as it does with other diseases. Hence we will 
have to take re-vaccination and loss of immunity into account. This will be looked at in 
more detail in Section 3.5.3.
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3 . 3  R e p r o d u c t i o n  R a t i o
The reproduction ratio was first discussed in Section 3.1. Now we discuss in more detail one 
of the most important parameters used in disease modelling. We observe that secondary 
infections are produced at a certain rate throughout the lifetime of the infectious individual. 
Of these, a fraction will return from the latent period to become the second generation of 
infectious individuals. We therefore define, R q, the reproduction ratio, to be:
number of secondary infections x expected lifetime of infectives
the expected survivors of the latent period
Note:
The reproduction ratio that we discuss in this section is not the same as the reproduction 
rate, that was discuss in great detail in [2] and [7]. The following work on the reproduction 
ratio is in line with the more recent work in [19] and [22].
The reproduction ratio can provide significant insight into the transmission dynamics of a 
disease and can guide strategies to control its spread [35]. For our model of AD we have 
R n  which represents the reproduction ratio for non-vaccinated and Ry  which represents 
the vaccinated population. We would expect R n > R y  according to the definition of the 
systems. Much work has been done on R q in recent years [2], [19].
3.3.1 C a lcu la tio n  of R N, R y
We can calculate R n  using the equations in (3.27) and the formula in Diekmann [22]
(3.28)
where
In words A(u) is the expected infectivity at time u  after infection took place. By infectiv- 
ity, we mean the probability of transmission given a contact between a susceptible and an 
infective of disease age ui (w is the infection-age mentioned in Section 3.1).
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Because we are interested in the total number of individuals infected by one infectious
individual during its total infectious period [85], the infectivity A(co) can be calculated from
the following equations
/ '  = - a l - f i l  + SL (3.29a)
V  = - a L  + p I - Ô L  (3.29b)
so that 7(0) = 1,L(0) =  0 .
From (3.29a), we can write L in terms of I
L =  I ( / '  +  (a  + jW). (3.30)
Putting (3.30) into (3.29b) gives
| ( I ( / '  + (a + /3 / ) ) '  =  p i - ( a  + 5 ) \ ( l '  + (a + p l )  (3.31)
and we can simplify (3.31) to
I "  + {2a + 0 + 6)1' + a{a + p  + 6)I =  0. (3.32)
The general solution of (3.32), from [14], is
/'(£) = Cie-*1 + C2e - (a+ /W  . (3.33)
The next thing that we need to do is to find C\ and C2 for t = 0 and 7(0) =  1, L(0) = 0. 
From (3.33) we can say Ci + C2 = 1 • Putting this information into (3.30) gives
i ( / ' ( 0 ) +  (<* + /?)) =  0 (3.34)
which holds when /'(0) =  —(cv + ft) .
Differentiating (3.33) gives
-f-7' =  -a C ie -« 1- { a  + /3 + 5)C2e-(a+f}+S)l. (3.35)
at
Putting / '(0) = —[a+ /3) into (3.35) gives
— (or + /3) =  —o:Ci — (ct + (3 + ¿)C*2
4 0
and using the fact that C\ + C2 = 1, we have
13 +  5 ’ * /3 +  S
U sin g  (3.28) a n d  (3.33) we c a n  say
r*00
R n  =  A [  ( ______- _____e ~ a t  _ L  ___e-(a+/3+5)t\ faJ0 I  (3 + 6e + p + 6e ) dt
A(c>! +  5)
a ( a  +  /3 +  6)'
H en ce  w e can  now  say
R n  =  (3-36)
a ( a  +  p  +  0)
P ro m  th is  we c a n  say  t h a t  th e  critical reactivation rate,  i.e. th e  re a c tiv a tio n  r a te  fo r w h ich  
R n  >  1, c a n  b e  c a lc u la te d  as
J  =  a ( a '+ / ? ~ A ) . (3.37)
A — a
N o t e :
1. R n  c a n  a lso  b e  c a lc u la te d  u s in g  s ta b il i ty  a n a ly s is  (see A p p e n d ix  A  fo r fu r th e r  d e ta ils ) .
2. I f  A is sm a ll c o m p a re d  w ith  a,  i.e. in  m o d e l te rm s , if  th e  c o n ta c t  r a te  is sm a lle r  th a n  th e  
b i r th  r a te ,  R n  w ill b e  less t h a n  1  a n d  as a  re s u lt  th e  d isea se  c a n  b e  re m o v ed  m o re  easily  
fro m  th e  p o p u la tio n . I f  A >  a  +  ¡3, R n  >  1, re g a rd le ss  o f  <5. W e c a n  a lso  say  th a t  w h en
A <  a (a +  - +  ^  <=> R n <  1  (3.38)
a  +  0
so sm a ll en o u g h  A (re g a rd le ss  o f  a ,  ¡3, S) a id s  th e  rem o v a l o f  A D V .
3. R n  d o es  n o t  d e p e n d  o n  th e  size o f  th e  p o p u la t io n  ( th e re  is no  N  te r m  in  (3 .3 6 )), so th e  
size o f th e  p o p u la t io n  d o es  n o t  h av e  an y  b e a r in g  o n  c o n tro l m e a su re s . T h is  is c o n tra ry  to  
e a r lie r  w ork  in  [2], [72], b u t  in  lin e  w ith  m o re  re c e n t w o rk  in  [12], [84],
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3 .3 .2  F u rth er  R0 ca lc u la tio n s
I t  h a s  b e e n  sh o w n  t h a t  w h e n  Rq  <  1 , a n  in fe c tio n  w ill fa il to  s p re a d  a n d  w ill e v e n tu a lly  fad e  
o u t, w ith  o n ly  a  few  in fe c te d  in d iv id u a ls  ( th is  is k n o w n  as  a  m in o r  o u tb re a k )  [85]. O n  th e  
o th e r  h a n d , w h en  Rq >  1 th e  in fe c tio n  w ill sp re a d , r e s u lt in g  in  m a n y  in fe c te d  in d iv id u a ls  
(m a jo r  o u tb re a k ) , o r a n  in fe c tio n  can , by  ch an ce , fad e  o u t  e a r ly  (i.e. a t  th e  e a r lie s t s tag es) 
re su ltin g  in  o n ly  a  few  in fec tiv es  (m in o r o u tb r e a k ) .
T h e  n e x t th in g  w e do  is to  d e te rm in e  Rq  a t  d iffe ren t sca les , i.e. a t  th e  o n e  e n d  w i th  h e rd s  
as u n its  a n d  a t  th e  o th e r  e n d  w ith  c o m p a r tm e n ts  as u n its .  W e define
Rind =  th e  lio  b e tw e e n  in d iv id u a ls
Rherd — th e  R q b e tw e e n  h e rd s
Rcomp =  th e  R q b e tw e e n  c o m p a r tm e n ts
(if Rind >  1  th e  size o f  th e  h e rd  is p a r t ic u la r ly  im p o r ta n t) .
W ith  re g a rd  to  v a c c in a tin g  a  reg io n , A D V  m u s t  n o t b e  a llow ed  to  s p re a d  e x te n s iv e ly  a f te r  
in tro d u c tio n  in to  a  p o p u la tio n . T h is  a b ility  to  s p re a d  is m e a s u re d  b y  Rherd■ I f  Rherd <  1 
very  few  h e rd s  w ill b e c o m e  in fec tive . O n  th e  o th e r  h a n d , i f  Rherd >  1 m a n y  h e rd s  m ay  
b eco m e in fec tiv e . So A D V  c a n  b e  e ra d ic a te d  fro m  a  re g io n  w h e n  Rherd <  1-
I f  we co n sid e r t h a t  a  p ig  p o p u la t io n  is m a d e  u p  o f  u n i ts  (w e u se  u n its  to  d e te rm in e  Rq  
a t  d iffe ren t scales; a t  o n e  en d  th e  reg io n  w ith  th e  h e rd s  as u n its  a n d  a t  th e  o th e r  e n d  
c o m p a r tm e n ts  w ith  th e  p ig s  as u n its ) . T h e se  u n i ts  w ill in te r a c t  w ith  u n its  in  th e ir  ow n 
g ro u p  (h e rd ) a n d  w ith  u n i ts  in  o th e r  g ro u p s . W e c a n  e s t im a te  R q  fo r u n i ts  w ith in  a  g ro u p , 
a n d  also  for g ro u p s . W e a lso  n e e d  to  d e riv e  a  r e la t io n s h ip  b e tw e e n  R q  o f g ro u p s  ( G r )  
a n d  w ith  Ro  o f u n its  ( U r )  w ith in  th e se  g ro u p s . T h is  h a s  b e e n  d o n e  e x te n s iv e ly  in  th e  
N e th e r la n d s  [84], [85].
W e m ak e  th e  fo llow ing  a d d it io n a l  a ssu m p tio n s :
•  g ro u p  in fe c te d  w h en  >  1 u n its  in fe c te d
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•  c o n ta c t b e tw e e n  g ro u p s  is th e  n u m b e r o f  tra n s m is s io n s  o f  A D V  p e r  u n i t  o f  t im e  o f a  
u n i t  o f  a  g ro u p  w ith  a  u n i t  o f  a  d iffe ren t g ro u p  (AG r )
•  n u m b e r  o f  u n its  in  a  g ro u p  is c o n s ta n t.
I f  w e r e tu r n  to  o u r  o r ig in a l d e fin itio n  o f R q a t  th e  b e g in n in g  o f  th e  se c tio n  w e c a n  now  say  
t h a t  R q is th e  p ro d u c t  o f  th e  su scep tib le s  in  a  g ro u p  (G s ) ,  th e  in fe c tiv ity  o f  a  g ro u p  (G[)
a n d  th e  c o n ta c t r a te  b e tw e e n  g ro u p s  (AG r ), o r in  m a th e m a tic a l  te rm s:
G r  =  (G s ) ( G i ) (XGr ) . (3.39)
T h e  su sc e p tib il i ty  o f  a  g ro u p  (Gs)  is th e  sam e  as th e  th e  su sc e p tib il i ty  o f  a  u n i t  (gs) a n d  
in fe c tiv ity  o f a  g ro u p  (G j)  is th e  sa m e  as in fe c tiv ity  o f  a  u n i t  (gi) t im e s  th e  av e rag e  ta k e n  
over a ll in fec tio u s  u n its  (n u m b e r o f  in fec tio u s  u n i ts /g ro u p )  d u r in g  a n  o u tb re a k . W e ca ll 
t h is th e  total average. T o  c a lc u la te  th e  total  average,  m in o r  a n d  m a jo r  o u tb re a k s  a re  ta k e n  
in to  ac c o u n t a n d  th e  p o s s ib ility  o f  p e rs is te n c e  o f  in fe c tio n  w ith in  th e  g ro u p . B ecau se  o f  
p e rs is te n c e , th e  total average n u m b e r  o f in fec tio u s  u n i ts  c a n  b e  g re a te r  t h a n  th e  t o ta l  n u m b e r  
o f  u n its  p re se n t in  th e  g ro u p .
F or th e  c o n ta c t r a te , th e  h e rd  size m u s t b e  ta k e n  in to  a c c o u n t, hen ce  A G r  is th e  c o n ta c t 
r a te  o f  a  g ro u p  w ith  a  u n i t  o f  a n o th e r  g ro u p . W h e n  th e  ‘re c e iv in g ’ g ro u p  h as  S  in d iv id u a ls , 
A G r  beco m es A S G r ,  s o  (3 .39) b ecom es
G r  =  (gs ) (gi) (n u m b e r  o f  in fec tio u s  u n i ts /g ro u p ) (A G # )  (3.40)
a n d  we w rite  (3.40) as
)A U r )
w h ere  U r  is th e  s u s c e p tib ilty  o f a  u n i t  t im e s  th e  in fe c tiv ity  o f  a  u n i t  t im e s  th e  c o n ta c t r a te  
b e tw e e n  u n its . H ence
G r  =  (Ur ) (n u m b e r  o f  in fec tio u s  u n its  p e r  g ro u p ).?7
w h ere  T  is th e  re la tiv e  c o n ta c t r a te  o f a  u n i t ,  i.e.
c o n ta c t r a te  o f a  u n i t  w ith  u n its  in  a  d iffe ren t g ro u p  
c o n ta c t r a te  o f a  u n i t  w ith  u n i ts  in  i ts  ow n  g ro u p
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A s th e  tra n sm is s io n s  b e tw e e n  p igs w ith in  h e rd s  is g re a te r  t h a n  tr a n s m is s io n s  b e tw e e n  p ig s  
o f  s e p a ra te  h e rd s , we c a n  safe ly  say, T  <  1. T h e n  w e c a n  a lso  say
Rcomp =  Rind, ( to ta l  n u m b e r  o f  in fec tio u s  p ig s  p e r  c o m p a r tm e n t)  (T )
T o b e  a b le  to  w ork  o u t  th e  d y n a m ic s  w ith in  th e  c o m p a r tm e n ts  to  a  su ffic ien t a c c u ra cy  a  
s to c h a s tic  m o d e l is n ecessary . T h is  w ill b e  lo o k ed  a t  in  C h a p te r  4.
3.3.3 Threshold D ensity
T h e  c r ite r io n  R q >  1 fo r a n  o u tb re a k  o f  th e  d isease  c a n  e q u iv a le n tly  b e  e x p re sse d  as th e  
re q u ire m e n t t h a t  th e  p ro p o r t io n  o f  su sc e p tib le s  in  th e  p o p u la t io n  exceeds a  c e r ta in  threshold 
density, S  >  N t , (w h ere  N  is  th e  to ta l  p o p u la t io n )  w ith  th e  d e fin itio n
N T =  J -  (3.41)
in  te rm s  o f o u r  m o d e l, th e  th re s h o ld  d e n s ity  fo r th e  non-vaccinated  m o d e l c a n  b e  w r i t te n  as
*  =
T h is  is a  v e ry  im p o r ta n t  p a ra m e te r  in  o u r  m o d e l as w h e n  th e  su sc e p tib le s  a re  below  N t , 
R n  <  1 a n d  th e  ch an ces o f  a n  o u tb re a k  o c c u rr in g  a re  v e ry  sm a ll c o m p a re d  to  w h en  th e
su sc e p tib le s  a re  ab o v e  N t - H ow ever i t  is s till  p o ss ib le  fo r Rpj >  1  a n d  a n  o u tb re a k  n o t
o c c u rrin g , b u t  th is  w o u ld  b e  v e ry  u n fo r tu n a te  (for th e  d isease ).
F o llow ing  o n  fro m  th is  we c a lc u la te  th e  init ial  exponential growth rate fo r th e  non-vaccinated 
m o d e l to  b e
rjq =  A N  — ( a  +  /3 ) . (3.43)
W h e n  N  is la rg e  in  (3 .43), th e  in it ia l  g ro w th  ra te  w ill b e  q u ite  la rge . T h is  is w h a t  we w ould  
e x p e c te d  to  h a p p e n  if  a n  o u tb re a k  o c c u r re d  in  a  fu lly  su sc e p tib le  p o p u la t io n .
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3 . 4  N o n  V a c c i n a t e d  M o d e l
3.4.1 Introduction
F ro m  (3 .27), d ro p p in g  th e  suffix  TV, we can  w rite  th e  S I L  m o d e l as
r e
S ' ( t )  =  a N  -  A ^  -  (/z +  E ) S  (3 .44a)
rq
I ' ( t )  =  A - ^ - ( v  +  E ) I - / 3 I  +  6L  (3 .44b)
L ' ( t )  =  p I - 6L - ( f i  +  E ) I .  (3 .44c)
F or co nven ience  we w rite  th e s e  e q u a tio n s  in  te rm s  o f f ra c tio n s  o f in d iv id u a ls  in  each  class. 
D efine s  =  S / N ,  i =  I / N ,  I =  L / N .  T h e  e q u a tio n s  in  (3 .44) beco m e
s ' ( t )  =  a  — Xis — (fi +  E ) s  (3 .45a)
i ' { t )  =  Ai s - { n  +  E ) i - p i  +  6l (3 .45b)
l ' ( t )  =  p i  -  61 -  fa  +  E ) l  (3 .45c)
w h ere
s - f i  +  i =  1. (3.46)
For c o m p u ta t io n a l  e ase  we r e tu r n  to  th e  o r ig in a l n o ta t io n  o f  S,  I  a n d  L  a n d  we in tro d u c e  
th e  c o n s ta n t  p o p u la t io n  re s tr ic t io n  ( a  =  ¡j. +  E).  H ence  (3 .45) b eco m es
S ' { t )  =  a  -  X I S  — a S  (3 .47a)
I ' ( t )  =  X IS  — a l  — p i  +  ÔL (3 .47b)
L '{ t )  =  p I - 6L - a L  (3.47c)
and
S  +  I  +  L  =  1. (3.48)
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3 .4 .2  N o n  V a c c in a te d  M o d e l
W e c a lc u la te  th e  e q u ilib r iu m  p o in ts  o f  (3.47) to  b e
( , * )  =  (1 , 0, 0) (3.49)
w h ich  we define  to  b e  th e  d isease  free  e q u ilib r iu m  (D F E ), a n d
(3-50)
w here
A (a  +  Æ)
a ( a  + /3 -f- S)
a n d  we d e fin e (3 .50) as th e  d isease  p re se n t e q u ilib r iu m  (D P E ).
A t th e  D P E  th e  force of infection,  f irs t m e n tio n e d  in  S e c tio n  3 .2 .1 , sa tis fie s  th e  e q u a tio n
so th a t  th e re  is a  p o s itiv e  force of infection w h e n  R n  >  1 .
T h e o r e m  3 .4 .1  The D F E  (3-49) always exists. (1) This equilibrium is asymptotically stable 
when R n  <  1 and unstable when R n  >  1. (2) When the D P E  (3.50) exists, i.e. for  R n  >  1, 
it is asymptot ical ly stable when R n  >  1 .
Biocorollary 3.4-1'.
I f  th e  re p ro d u c t io n  ra t io  exceeds one, a ll so lu tio n s  (ex cep t th e  D F E ) w ill a p p ro a c h  th e  
D P E  a n d  th e  d isease  w ill re m a in  en d em ic  in  th e  p o p u la t io n . H ence , th e  su sc e p tib le  f ra c tio n  
d ecreases  as th e  in fec tiv e  fra c tio n  in c reases , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e 
in fec ted . I f  th e  r e p ro d u c tio n  ra t io  is less t h a n  one, a ll so lu tio n s  a p p ro a c h  th e  D F E , a t  w h ich  
th e y  w ill re m a in . H ence , th e  su sc e p tib le  f ra c t io n  in c rease s  as  th e  in fec tiv e  f ra c tio n  d ecreases  
to  zero , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e  su sc e p tib le . W h e n  th e  re p ro d u c tio n  
ra t io  eq u a ls  one, o n ly  th e  D F E  ex is ts .
A i  =  a ( R N  —  1) (3.51)
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F ir s t  we lin e a rise  th e  e q u a tio n s  in  (3 .47), th is  is d o n e  u s in g
8 i  =  8 - S * t / !  =  / - / * ,  L X = L - L * 
= * S  =  S i +  S*,  I  =  h + I \  L  =  L X +  L*
w h ere  (S*,I*,L*)  a re  th e  e q u ilib r iu m  p o in ts . W e c a n  w rite  (3 .47) as
5 '( f )  =  a - \ { h + I * ) ( S i + S * ) - c t ( S i + S * )  (3 .52a)
I'(t) = \ {h +I* ) (S i  + S ' ) - ( a  + 0 ) { X i+ r )  + S$* + L*) (3 .52b)
L'(t) =  f i(h + I * ) - S { l i + L * ) - a ( L i + L * )  (3 .52c)
O b serv e  th a t ,  by d e fin itio n  o f th e  e q u ilib r iu m  s ta te s ,  t* — AI * S *  — a S *  =  0, XI *S * — ( a  +  
¡5)1 * - f  6L*  =  0, 0 1 *  — 5L* — a L *  =  0, w hich  c an ce ls  o u t  th e  a p p a re n t  n o n -h o m o g en eo u s
te rm  in (3 .52). Ig n o rin g  th e  n o n  lin e a r  te rm s  a n d  d ro p p in g  th e  suffix  o n e , we c a lc u la te  th e
lin ea rised  m a tr ix  o f  (3 .47) to  be:
- ( a + A J * )  - A S *  0 \  / S \
XI* X S * - { a  +  0 )  S J  . (3 .53)
0 0  —( a  +  S)J \ l J
Proof of Theorem (3-4-1):
(1) P u t t in g  th e  D F E  in  (3.49) in to  (3 .53) we g e t
' - a  - A  0 \
0 A - ( a  +  /3) 6 (3.54)
0 0  - { a  +  8 )J
N ex t we le t (3 .54) b e  A . Now we n e e d  to  find  th e  so lu tio n s  o f
det{  A  -  p i )  =  0 (3.55)
for th e  e ig en v a lu es  p  o f  A . T h is  is k n o w n  as th e  c h a ra c te r is t ic  e q u a tio n , a n d  we c a lc u la te  it  
to  be
p^ +  dif-'? H- &2P +  03 =  0 (3.56)
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w hore
ttl “  2 “  +  A ( ^ _ 1 )  +
<5A
cuR n
«2
03
=  A(ar +  6) -  l )  +  a ( a  -  A)
w h ere  R n  is a s  b e fo re .
W e c a n  u se  th e  R o u th -H u rw itz  te s t  [80] to  d e te rm in e  th e  s ta b il i ty  o f  (3 .56) w ith o u t  h a v in g  
to  solve th e  e q u a tio n . T h is  say s t h a t  g iven
c(/i) =  p n 4- & ip n * + , . . .  +  o.n — 0
A i  =  « i ,  A 2 =
th e  R e (p i)  <  0 V i ,  i f  th e  p r in c ip a l m in o rs  A i ,  A o , . . . ,  A n a re  a ll p o s itiv e , w h ere
a i  1
&z 0,2
N o te  th a t  am =  0 V m  >  n  in th e  c o n s tru c tio n  o f  A , ab o v e , V i. A p p ly in g  th e  R o u th -  
H u rw itz  te s t  we h av e  A i =  a i ,  A 2 =  01.02 — 0.3 a n d  A 3 =  0.3 (01.02 — 03).
I f  R n  <  1:
I f  R n  <  1 we c a n  show  th a t  0 1 , 03 >  0, h en ce  A i  >  0. F o r a i  >  0 w e need
A ( a - f 5 ) A !  >  a ( A - a )  (3 .57)
w h ere
Ai =  i h ~ u
W e know  th a t  Ai >  1, as R n  <  1, so  we ca n  say  th a t  a A A i >  cvA. T h e  r ig h t  h a n d  s id e  o f
(3.57) is less t h a t  aA , as all p a ra m e te rs  a re  p o s itiv e , so  we c a n  say  th a t
o;AAt >  a ( A - a ) .  (3 .58)
H ence (3.57) is t r u e ,  hen ce  a 2 >  0. For A 2, A 3 >  0 , we need  to  look a t  w h e th e r  o r n o t 
a  1.02 >  «3, i-e-
\  X
^ 2 a  +  AA2 -1— -jj— ^ A ( a  4- S)A% + o :{ a  — A^ >  aA(cv +  i ) A 2 (3.59)
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where Ai is as before, and
W e know  a\ ,  a 2 , a3 >  0. S ince R n  <  1, we a lw ays h av e  A i ,A 2 >  1 a n d  A i >  A2, hen ce  we 
c a n  say  th a t
2aX (a  +  <5)Ai >  a \ ( a  +  5)A 2 . (3.60)
I f  th e  re m a in in g  te rm s  o n  th e  le ft h a n d  side  o f  (3 .59) a re  n o n n e g a tiv e  w e c a n  say  t h a t  (3.59) 
is tru e ,  i.e , we n e e d
( 2a 2 +  oiXh.2 +  ——^ (o: — A) +  A2(a: +  i ) A i  ( h^-2 ^ >  0 (3.61)
a n d  we ca n  w rite  (3 .61) as
a 2( 2 a  +  A A 2 - 2 A ) + A 2A 2 ( A 3 - a )  +  - 4 ^ - f o 2 +  AA3 - a A N) >  0 (3.62)
cxR n  \  J
w h ere  A 3 =  ( a  +  i ) A i .  W e know  A i, A2 >  1 a n d  we c a n  see t h a t  a ll te rm s  o n  th e  left h a n d  
s ide  o f  (3.62) a re  p o s itiv e . H ence  (3.62) is tru e .
I t  follow s th a t  (3.61) is tru e ,  a n d  fro m  th is  we c a n  say  t h a t  (3 .59) is a lso  tru e .
A j >  0 V i 6 [1,3]
Re(pi)  <  0
U sin g  T h e o re m  A .1.2 we c a n  show  th a t  pi a re  a s y m p to tic a l ly  s ta b le  w h e n  th e y  a re  <  0. 
H ence  th e  D F E  (3.49) is a s y m p to tic a lly  s ta b le  w h e n  R n  <  1.
If Rn > 1:
I f  R n  >  1, we c a n  show  th a t  a\  >  0 a n d  03 <  0. T h u s  A i  >  0. N ow  A 3 =  <23.A 2. I f  
A 2 >  0, th e n  A 3 <  0, a n d  u n s ta b le , w h ile  i f  A 2 <  0, th e n  A 3 >  0, so a g a in  u n s ta b le . H ence, 
u s in g  th e  converse  o f th e  R o u th -H u rw itz  te s t ,  we can  say  t h a t  n o t  a ll p r in c ip a l  m in o rs  a re  
p o s itiv e , h e n ce  n o t  a ll e igenvalues h av e  n e g a tiv e  re a l p a r t .
A s o n e  e ig en v a lu e  is p o s itiv e  we c a n  u se  T h e o re m  A .1.2, to  say  t h a t  th e  D F E  (3.49) is 
u n s ta b le  w h e n  R n  >  1-
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(2) N ex t we p u t  th e  D P E  in  (3.50) in to  (3.53) to  give
x
¡In& R n  a . ,  0
a X ( R N - l )  f a - ( a  +  0 )  6 ] (3.63)
0 0  —( a  +  5),
As b e fo re  we fin d  th e  c h a ra c te r is tic  e q u a tio n  a n d  th is  t im e  we c a lc u la te  i t  to  b e
p 3 +  b\p 2 +  b2p +  63 =  0 (3.64)
w h ere
61 =  7 ^ + a { R N  +  1)
i>2 =  a A ^ l  — j j — j  +  6X +  cx2R n
b3 =  ocX{a +  ¿ ) ( l  -
A gain  u s in g  th e  R o u th -H u rw itz  te s t  we h av e  A i =  6i ,  A 2 =  b\.b2 —b  ^ a n d  A 3 =  63(^ 1 .62—¿>3)-
I f  R n  <  1:
I f  R.,\ <  1, th e n  b\ >  0 a n d  63 <  0. U sin g  th e  sa m e  a rg u m e n t a s  t h a t  for th e  D F E  
w h en  R h  >  1 we can  say  th a t  n o t a ll e ig en v a lu es  have n e g a tiv e  rea l p a r t .  W e know  th a t  
A 3 =  63A 2, a n d  a s  b efo re , w h en  A 2 >  0, A ;t <  0 a n d  v ice v e rsa . H ence , u s in g  th e  converse  
o f  th e  R o u th - I Iu rw itz  te s t ,  we c a n  say  th a t  n o t a ll p r in c ip a l m in o rs  a re  p o s itiv e , hence  n o t 
a ll e igenva lues h av e  n e g a tiv e  re a l p a r t .
A s o n e  e ig en v a lu e  is p o s itiv e  we can  use  T h e o re m  A. 1.2, to  say  th a t  th e  D P E  (3.50) is 
u n s ta b le  w h en  iiyv <  1 -
I f  R n  >  1:
I f  R n  >  1, th e n  61, 621 &3 >  0. H ence  A i >  0. For A 2,A 3 >  0 we n eed  61.62 >  63, i-c.
—— (- o (/? /v  +  1 )^ (arAA3 +  ¿A +  >  q;A(g; +  <$)A3 (3.65)
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w h ere
Á3 1 R n  '
W e k now  b\, 62, 63 >  0. E x p a n d in g  th e  le ft h a n d  s id e  o f  (3 .65) a n d  ju s t  w ritin g  th e  A3
te rm s , w e h av e
a 2\ ( R N  +  1 )A 3 >  a \ ( a  +  5)A 3 . (3.66)
U sing  a  >  5, a n d  R n  >  1, we c a n  say  th a t
a { R N +  1) >  a  +  6 (3.67)
H en ce  (3.66) is tru e . A s a ll o th e r  te rm s  o n  th e  le ft h a n d  s id e  o f  (3 .65) a re  p o s itiv e  we can
say  th a t  th is  is a lso  tru e .
=» A  i >  0 V i 6 [1,3]
=> Re(pi )  <  0 V i
U sin g  T h e o re m  A . 1.2 we ca n  show  th a t  pi a re  a s y m p to tic a l ly  s ta b le  w h e n  th e y  a re  <  0. 
H ence , th e  D P E  (3.50) is a s y m p to tic a lly  s ta b le  w h e n  R n  >  1- 0
3.4.3 N on V accinated Graphs
O v er th e  n e x t  few  p ag es we d raw  so m e g ra p h s  fo r th e  non-vaccinated  m o d e l t h a t  we have 
d iscu ssed . T h e se  g ra p h s  a re  d o n e  u s in g  M a th e m a tic a  a n d  th e  d a ta  u se d  in  th e m  w as ta k e n  
fro m  o n g o in g  w ork  in  th e  N e th e r la n d s  [84], a n d  a  re c e n t I r is h  P ig  H e rd  r e p o r t  [55]. H ow ever, 
n o t a ll o f  o u t  p a ra m e te rs  have  b e e n  c a te re d  for, so som e o f  th e m , su ch  as th e  re lap se  r a te  
(5) h a d  to  b e  e s t im a te d  u s in g  p re v io u s  w o rk  d o n e  o n  A D  in  th e  U S A  [71],
W e look  a t  g ra p h s  a t  v a rio u s  s tag es  o f  a n  ep id em ic , ra n g in g  fro m  ju s t  b e g in n in g  ( /  & 0 , L  =  
0 ), to  th e  m id d le  o f  a n  o u tb re a k  ( I ,  L  >  S ). W e also  lo o k  a t  w h a t  h a p p e n s  to  S , I  a n d  L  
w h e n  R n  >  1 a n d  fo r R n  <  1, to  see if  T h e o re m  3.4.1 h o ld s . T h e  in i t ia l  p o p u la tio n  h a s
size N  =  100, a n d  th e  m a jo r i ty  o f  th e  g ra p h s  a re  r u n  f ro m  b e tw e e n  7 a n d  30 days. In  th e
fo llow ing  g ra p h s , th e  re d  lines re p re s e n t su sc e p tib le s , th e  g re e n  lines re p re s e n t in fec tives, 
a n d  th e  b lu e  lines re p re se n t th e  la te n ts .
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NF ig u re  3 .4: N o n  v a c c in a te d  V an  N es m o d e l
In  th e  g ra p h  ab o v e  we have u sed  th e  d a t a  from  [85] a s  th is  is th e  m o st re c e n t d a t a  t h a t  we 
h av e  to  w ork  w ith . If th e  g ra p h  is to  c o n tin u e  for lo n g er, all th e  p o p u la tio n  will e v e n tu a lly  
e n te r  th e  L  c o m p a r tm e n t. H e re  R n  <  1-
N
F ig u re  3.5: N o n  v a c c in a te d  V an N es m o d e l (m o d ified )
H ere , we h av e  a  s im ila r  g ra p h  to  th e  o n e  in  F ig u re  3.4, b u t  w e h a v e  m od ified  th e  d a t a  to  
s u i t  Ir ish  h e rd s  (u sin g  [55]) as  o p p o sed  to  D u tc h  h e rd s , a g a in  R n  <  1.
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Ntime
F ig u re  3.6: N o n  v a c c in a te d  S m ith  a n d  G ren fe ll m o d e l {ft >
H ere we h av e  used  d a ta  s im ila r  to  t h a t  u sed  in  [71]. W e h a v e  m od ified  it s lig h tly  to  m ak e  
th e  g ra p h  m o re  re a d a b le . A g a in , 5 , /  —+ 0 a n d  L  —> 1, a n d  we h av e  R n  <  1 •
N
time
F ig u re  3.7: N o n  v a c c in a te d  S m ith  a n d  G ren fe ll m odel {ft =  S)
H ere  we h av e  a d ju s te d  th e  p a ra m e te rs  in  F ig u re  3 .6  so t h a t  ft — 6 , w h e re a s  e a r lie r , we h ad  
ft >  6 . T h is  tim e  S  —» 0, / ,  L  —> 0.5  o f  p o p u la t io n , a n d  a s  e x p e c te d  R n  >  1.
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In th e  g ra p h  ab o v e , we have  rep la c e d  a  w ith  n w (w eek ly ), w here , a w =  (1 4- a ) 1 5^2 — 1. W e 
h av e  a d ju s te d  th e  o th e r  p a ra m e te rs  to  s u i t ,  a n d  11 n  1, S  —» 0 , a n d  I ,  L —* 0 .5 , ev en tu a lly .
F ig u re  3.9: N on  v a c c in a te d  m odel (lo n g  ep id em ic )
H ere  w e h a v e  s im ila r  d a ta  t o  t h a t  o f  F ig u re  3 .9 , b u t  w e h a v e  ru n  th e  g ra p h  o v er lo n g e r  t im e  
(o n e  y e a r) , a n d  re d u c e d  th e  (3 a n d  5 te rm s . H e re  L  —> 0.4 , a t  w h ich  t h e  p o p u la t io n  s ta y s .
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3 .4 .4  R e d u c e d  M o d e l
N ow  we re d u c e  th e  non-vaccinated  sy s te m  in  (3 .47) to  a  m o re  w o rk ab le  2 x 2  (u s in g  3.46). 
H ence , w e have
S ' ( t )  =  a  — X IS  — a S  (3 .68a)
I ' { t )  =  XIS  -  (a  +  ¡3+  6)1 + 8 ( 1 - S ) .  (3 .68b)
H ere  S(t )  is th e  p ro p o r t io n  o f a n im a ls  t h a t  a re  su sc e p tib le  a t  t im e  t,  a n d  I( t )  a re  th e
p ro p o r t io n  o f  in fe c te d  a n im a ls  a t  tim e  t. F o r th is  in te r p r e ta t io n  to  b e  c o n s is te n t w ith  th e
d y n a m ic s  o f  (3 .68), we m u s t e n su re  t h a t  th e  fo rw a rd  o rb it  o f  ev e ry  p o in t  in
T  :=  (S,  / )  6 M2 : /  >  0, S  >  0, S  +  I  <  1
to  b e  a  su b s e t o f  T . T h a t  is, if  £ =  (S, I)  £  T  we h av e  r+(£) C T.
W e c a lc u la te  th e  e q u ilib r iu m  p o in ts  o f  (3 .68) as
( S * , I * )  =  F  =  (1 ,0 )  (3.69)
w h ich  we define  to  b e  th e  d isease  free  e q u ilib r iu m  (D F E ), a n d
(< ? * ,/* )  =  P  =  (3-7°)
w h ich  we define  as th e  d isease  p re se n t e q u ilib r iu m  (D P E ) (w h ere  Rjy  is as  b e fo re ).
F o r R n  <  1 w e see t h a t  o n ly  th e  D F E  is c o n ta in e d  in  T .  F o r R n  =  1 th e  D F E  =  D P E , w hile  
fo r R n  >  1, th e  D P E  is c o n ta in e d  in  th e  in te r io r  o f  T . N ow  w e t u r n  to  th e  lo c a l a sy m p to tic  
s ta b il i ty  o f  th e  D F E  a n d  th e  D P E . M o reo v er th e  in te r io r  o f  T  ( I n t ( T ) )  is in v a ria n t in  
f in ite  t im e .
L e m m a  3 .4 .2  Let  T  =  {(S \ I )  G K 2 : I  >  0, S  >  0 , 1  +  S  <  1}. Then xq E f  implies  
tp(t, x q )  £  T  for  all oo >  t  >  0.
Proof:
S u p p o se  t h a t  xq £  T ,  a n d  le t to =  in f{ f  >  0 : (p(t, xq) £  T  fl T } . T h e n  tp(t ,xo) =  
(S ( to ) , I ( to ))  sa tis fie s  one  o f th e  fo llow ing:
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1 . •  I ( t 0) =  0, S ( t 0) >  0 , 1(to) +  S ( t 0) <  1 [1 ]
•  I ( t 0) =  0 , S(to) =  0 [2 ]
•  I(to) =  O J ( t o )  +  S(to) =  1 [?]
2. •  I(to) >  0) S(to)  =  0, 1(to) +  S(t.o) <  1 [3]
•  I ( t 0) >  0 , S ( t o) =  0 , I ( t 0) =  1 [3]
3. •  I ( t 0) >  0, S(to) >  0, 1(to)  +  S(to)  =  1 [4]
F ig u re  3.10: P o ss ib le  o u tc o m e s  fo r  <p(t,xo)
A s can  b e  seen  in  F ig u re  3.10, in  each  case , th e  m in im a lity  o f  tim e  t0 im p lie s
[ l ] / ' ( t o ) < 0  [2] S'(to) <  0
[3] S'( t0) <  0 [4] I ' ( t0) +  S ' ( tQ) >  0.
[1 ] I ' (to) <  0 [ / ( i„ )  =  0]
0 >  I'(to)  =  <^ (1 -  S(to))  >  0 if  0 <  S(to) <  1 , w h ich  is a  c o n tra d ic tio n .
H ence [1] is im p o ssib le .
[2] S'( t0) <  0 [S( t0) =  I  (to) =  0]
0 >  S'(to)  =  a  >  0, w h ich  is a  c o n tra d ic tio n . H ence [2] is im p o ssib le .
[3] S'(to) <  0 [S( t0) =  0 , I ( t 0) > 0 ]
as  in  [2], 0 >  S'(to) =  a  >  0, w h ich  is a  c o n tra d ic tio n . H en ce  [3] is im p o ss ib le .
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[4] I ' ( t 0) +  S ' ( t0) > 0
7 - [ 5 ( i )  + / ( * ) ]  =  a - a S ( t ) - a I ( t ) - p I ( t ) - 6I ( t ) + 6 - 6S(t )
(lo L
=  (a  +  6) ( l - S ( t ) - I ( t ) ) - p i ( t )  (3-71)
b u t  0 <  I'(to)  +  S'(to) =  —f3I(t) <  0, w h ich  is a  c o n tra d ic tio n . H en ce  [4] is im po ssib le .
[?] <p(t,xo) =  D F E ,
xq =  ip(—to,ip(t ,xo))  =  ip(—to, D F E ) =  D F E , w h ich  is a lso  a  c o n tra d ic tio n .
H en ce  th e re  c a n n o t ex is t 0 <  to <  oo su ch  th a t  (p( to,xo)  ^  T  w h e n e v e r x  o G T ,
L e m m a  3 .4 .3  T + (£) C T  for  all £ G T .
Proof:
C a n  b e  o b ta in e d  b y  fo llow ing  th e  ty p e  o f  re a so n in g  in  L e m m a  3.4 .2 . o
C o n tin u in g  th is  a rg u m e n t, we see t h a t  th e  b o u n d a ry  o f  T  c a n n o t b e  re a c h e d , even  in  in fin ite  
tim e , e x c e p t fo r th e  D F E .
L e m m a  3 .4 .4  Suppose xq G T  ■ Then  T + (a;o) c f  or oj(xq) =  DFE.
Proof:
B y  th e  ab o v e  a rg u m e n t r + (xo) (£_ T ,  o n ly  if
lim  cj)(t,xo) =  Xb G d T . (3.72)t—>oo
T h e n  xt, m u s t  b e  a n  e q u ilib r iu m  p o in t , v iz  th e  D F E  a n d  th e  r e s u lt  fo llow s. To see th a t  
sa tis fy in g  (3.72) is a n  eq u ilib riu m , n o te  fo r a n y  S  >  0 t h a t
4>(S,Xb) =  (¡>\S, lim  <f)(t, a^o)) =  lim  (j)[S,(j>(t,\ t—>oo /  t—foo \ Xo
=  lim  (j)(S +  to, a?o) =  x b (3.73)t—>oo
h en ce  xi> is a n  e q u ilib r iu m  p o in t. o
N ex t we lo o k  a t  th e  loca l a sy m p to tic  s ta b i l i ty  (LA S) o f b o th  th e  D F E  a n d  th e  D P E .
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T h e o r e m  3 .4 .5  1. (i) I f R n  <  1, then the DF E  is a hyperbolic equilibrium. I t  is, moreover,  
a stable node.
(ii) I f R n  >  1, then the D FE is a saddle.
2. (i) If  R n  <  1, the the D P E  is ^  T .
(ii) I f R n  >  1, then the D P E  is a hyperbolic equilibrium. Moreover,  i t  is a stable equilibrium.
3. I f R n  =  1, the DF E  =  DPE,  is a unique equilibrium with eigenvalues  0, — p*, where p* >  0
Biocorollary 3.4-5:
I f  th e  re p ro d u c t io n  r a t io  exceeds one, a ll so lu tio n s  (ex cep t th e  D F E )  w ill a p p ro a c h  th e  
D P E  a n d  th e  d isease  w ill re m a in  en d em ic  in  th e  p o p u la t io n . H ence , th e  su sc e p tib le  f ra c tio n  
d ec reases  as th e  in fec tiv e  fra c tio n  in c rea se s , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e 
in fec ted . I f  th e  re p ro d u c tio n  r a t io  is less t h a n  one, a ll so lu tio n s  a p p ro a c h  th e  D F E , a t  w h ich  
th e y  w ill re m a in . H ence , th e  su sc e p tib le  f ra c t io n  in c rea ses  as th e  in fec tiv e  f ra c tio n  decreases 
to  zero , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e  su sc e p tib le .
Proof:
1. (i), (ii) F o llow ing  o n  fro m  T h e o re m  (3 .4 .1) we c a lc u la te  th e  lin e a r is e d  m a tr ix  o f  (3.68) to  
be:
P u t t in g  th e  D F E  in  (3.69) in to  (3.74) w e have
(3.75)
W e c a lc u la te  th e  c h a ra c te r is tic  e q u a tio n  o f  (3.75) to  b e
A  (p) =  p 2 +  a p  +  c2 =  0 (3.76)
w h ere
Ci — 2 a  +  /3 +  5 — A 
c2 =  a ( a  +  (3 +  i ) ( l  — R n ).
1. (ii) is a u to m a tic  as th e  p ro d u c t  o f th e  e igenvalues o f  (3 .75) is P1 P2 =  c2 <  0, w h en  
R n  >  1- H en ce  (3.75) h a s  a  p a ir  o f e igenvalues o f o p p o s ite  sign . S u p p o se  R n  <  1. T h e n
( '2  > 0, this implies that
A < a ( a  4- ¡3 4  S) 
a- \-  6
(3.77)
h en ce
a ( t t  +  4- 5)
=  a  4  ( a  4  /3 +  <5) 1 ----------- r l  >  0.
L a +  oJ
a  +  5
(3.78)
I f  (3 .75) h a s  a  p a i r  o f re a l  e igenvalues p i , p 2, th e n  p \ p 2 >  0 a n d  p\  4  p -2 < 0 ,  so  w e have 
Pi <  0, P2 <  0 a n d  th e  D F E  is a  s ta b le  n o d e  a n d  is a lso  h y p e rb o lic . W ritin g
Cl =  a - t - A f —------ l ' ) J C2 =  «A ( —------- l )  —
\ a N  * >
A 5
/  'ON
w h ere  a ^  =  a / ( a  +  S) R n , we see  t h a t  th e  d is c r im in a n t o f  A  is
D  =  c i 2 — 4c2
-  [Q - A( ^ - 1) ] 2+4Ai  > °- (3.79)
2. (i) is e v id e n t fro m  [4]
(ii) a t  th e  D P E , th e  J a c o b ia n  is
J d p e  =
- a R N \
^ ( * * - 1 ) - *  - & )  '
(3.80)
T h e  c h a ra c te r is t ic  e q u a tio n  is
A  (p) =  p 2 -+■ d \ p  4* d/i — 0
w h ere
\  f  i  
di  -  a R N 4  —j r -  , d2 =  A ( a  +  6) ( l  -  — )
(3.81)
a R jv  ’ '  ^ R n  1
F or R N >  1, we h a v e  b o th  d\ >  0, dy >  0. I f  th e  so lu tio n s  r?A(p) =  0, p i , p 2 a re  rea l, th e n  
p i +  p 2 <  0 a n d  p i , p2 >  0 so b o th  m u s t b e  n e g a tiv e , a n d  th e  e q u ilib r iu m  is b o th  h y p e rb o lic  
a n d  s ta b le . O n  th e  o th e r  h a n d  if p i , p 2 a re  co m p lex , th e n  p  =  R e(p i )  =  /? e (p 2) sa tis fy  
2p — ~ d \  <  0, a n d  th e  e q u ilib r iu m  is a g a in  h y p e rb o lic  (m o reo v er it  is a  s ta b le  fo cu s).
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3. R n  =  1 im p lies  t h a t  th e  D F E  =  D P E  =  (1 ,0). F o r th e  J a c o b ia n  a t  th e  D F E , we have 
c h a ra c te r is tic  p o ly n o m ia l A (p )  =  p2 +  c\p,  w h e re  c\  >  0. H en ce  e ig en v alu es  a re  —c\  a n d  0.
A b s e n c e  o f  l i m i t  c y c le s :
D efine  th e  s im p ly  c o n n e c te d  reg io n
£  =  { { S , I )  : /  >  0, S  >  0, S  +  7  <  1}
a n d  B  : £  —)■ M : B ( S , I )  =  1 / / .  N o te  th a t  B  G C'{£) .  T h u s , fo r (S , I ) G £:
V . ( B F ) ( S , I )  =  ^ ( B M S J ) )  +  ~ ( B f 2 ( S: I))
=  - ^ ( j ( a - a S - X I S ) )  +  ^ ( j ( X I S  -  ( a  + 0  +  5)1 + 6 ( 1 - S ) ) )
=  - X - a j  +  5 ( l - S ) - ^ j  (3.82)
a n d  (3.82) ca n  b e  s im p lified  to
+  A +  (3.83)
a n d  we c a n  see t h a t  (3 .83) is n eg a tiv e .
B y  T h e o re m  2, §3.9 in  [65] th e re  is no  c lo sed  o rb it  ly in g  e n tire ly  in  S.  N o te , how ever th a t
T  =  £ U { ( S ,0 )  : 0 <  S' <  1} (3.84)
so th is  does n o t p re c lu d e  th e  ex is ten ce  o f a  lim it cycle  in  T .  B y  th e  fo rw a rd  in v a ria n c e  o f 
T  u n d e r  th e  flow, a  lim it cycle in  T  m u s t c o n ta in  p o in ts  in  b o th  £  a n d  th e  low er b o u n d a ry  
B l  =  { (S,  0) : 0 <  S' <  1 } o r b e  r e s tr ic te d  to  th e  low er b o u n d a ry  B i  =  {(S', 0) : 0 <  S  <  1 }.
H ow ever, a p a r t  fro m  th e  e q u ilib r iu m  (1 ,0 ), th e re  is n o  s u b s e t  o f  B l w h ich  is  in v a r ia n t u n d e r  
th e  flow. T h e re fo re  a n y  lim it cycle in  T  m u s t c o n ta in  b o th  p o in ts  in  £  a n d  in  B^.  In  fac t, 
th e  lim it cycle c a n  o n ly  c o n ta in  iso la te d  p o in ts  in  B T h e re fo re , th e re  e x is ts  £ =  (So, Jo) 
w ith  So >  0, Iq >  0, So +  /o  <  1 on  th e  lim it cycle L  a n d  to >  0 (p o ss ib ly  ¿o =  ° ° )  su ch  th a t  
<p(£,f0) =  (S , 0), fo r som e 0 <  S  <  1, w h e re  (S , 0) G L. C le a r ly  by  L e m m a  3 .4 .2 , io c a n n o t 
b e  fin ite . H ence  io =  °o , so
lim  <p(U) =  (S,  0) (3.85)
t—too
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w h ich  im p lies  t h a t  th e  a d d it io n a l  D P E  =  (S, 0) is a n  e q u ilib r iu m  o f  th e  sy s te m , a  c o n tra ­
d ic tio n  as S  <  1. T h e re fo re  th e re  is no  lim it cycle in  T .  T h is  y ie ld s
P r o p o s i t i o n  3 .4 .6  (3.68) has no limit cycles in T .
Proof: A s above. o
F o r R n  <  1, th is  e n a b le s  us to  show  th a t  u>(£) =  F  fo r a ll £ 6 T .
P r o p o s i t i o n  3 .4 .7  If R n  <  1, then w (£) =  F  for  all £ 6 T .
Proof:
F or R n  <  1, th e  D P E  is a  sad d le , b u t  is n o t  c o n ta in e d  in  T-  T h e re  is o n ly  o n e  e q u ilib r iu m  
in  T ,  th e  D F E , w h ic h  is a  s ta b le , h y p e rb o lic  e q u ilib riu m . T h e re fo re , n o  s e p a ra tr ix  cycle can  
b e  c o n ta in e d  in  T .  B y  P ro p o s it io n  (3 .4 .6 ), th e r e  a re  n o  l im it cycles in  T .  H ence , b y  th e  
G e n e ra liz ed  P o in c a re  B e n d ix so n  T h e o re m  (T h e o re m  2, §3.9 in  [65]), i t  follow s th a t  w (£) =  
D F E . o
C o n sid e r R n  >  1. A s b e fo re , th e re  a re  tw o  e q u ilib r iu m  p o in ts  a t  D F E  =  (1, 0): th e  D F E  is 
a  sa d d le  p o in t ,  w h ile  D P E  is a  s ta b le  e q u ilib r iu m . B y  p re v io u s  c a lc u la tio n s , we know  th a t  
th e  sy s te m  h as  n o  lim it cycle in  T .  I t  m e re ly  re m a in s  to  sho w  t h a t  th e re  is n o  s e p a ra tr ix  
cycle c o n ta in e d  in  T .  I f  su ch  a  s e p a ra tr ix  cycle  e x is ts , i t  m u s t b e  p a r t  o f  th e  u n s ta b le /s ta b le  
m an ifo ld  o f  th e  D F E .
S u p p o se  t h a t  we c a n  p ro v e  th a t  th e  (local) u n s ta b le  m a n ifo ld  p o in ts  in to  th e  in te r io r  o f T ,  
w hile  th e  (local) u n s ta b le  m a n ifo ld  a p p ro a c h e s  th e  D F E  fro m  b e lo w  th e  S —ax is , as show n  
in  F ig u re  3.11. A s th e  D F E  is a  h y p e rb o lic  e q u ilib r iu m , th e  s ta b le  m a n ifo ld  th e o re m  te lls  us 
t h a t  th e  d ire c tio n s  o f th e  s ta b le  a n d  u n s ta b le  m an ifo ld s  o f  th e  l in e a r is a tio n  o f  th e  sy s te m  a t  
th e  D F E  a re  th o se  o f  th e  lo ca l s ta b le  a n d  u n s ta b le  m an ifo ld s  o f  th e  o r ig in a l sy s te m  a t  th e  
D F E  (see T h e o re m  4.7  in  [27]). W e p rove , in  L e m m a  3 .4 .9  below , t h a t  th e  m an ifo ld s  o f th e  
l in e a r is a tio n  h av e  th e  d ire c tio n s  th a t  w ere  c la im ed  fo r th e  n o n lin e a r  sy s te m  above.
I t  is now  e v id e n t t h a t  th e  sy s te m  c a n n o t h av e  a  s e p a ra tr ix  cycle. C o n s id e r  xq 6 I n t ( T )  H
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F ig u re  3.11: D ire c tio n  o f  u n s ta b le  m an ifo ld
tou(F).  T h e n , th e re  e x is ts  t* >  0 (w hich  ca n  b e  in fin ite )  su c h  th a t  ip(t*,xo)  G d T  for som e 
( 5 * , /* )  F  (n o te : tp(t*,xo) =  [S*, I*) ) ,  a  n o n -e m p ty  p a r t  o f  T + (xo) m u s t lie o u ts id e  T
for a  cycle  to  e x is t. I t  now  o b ta in s  th a t  t* =  oo, a s  t* <  oo v io la te s  L e m m a  3.4.4. B u t as
e x p la in e d  e a r lie r  (cf. L e m m a  3.4.2) th is  im p lie s  t h a t  (S * , I *) is a n  e q u ilib r iu m  p o in t, w hich 
is a  c o n tra d ic tio n .
P r o p o s i t i o n  3 .4 .8  If R m >  1, then w (£) =  P  for  all f  G T / { F } .
Proof:
B y th e  a b o v e  a rg u m e n t, n o  s e p a ra tr ix  cycle  is c o n ta in e d  in  T ,  a n d  no  lim it cycle  is in T  by 
P ro p o s it io n  3.4.6; th e re fo re , by  th e  G e n e ra liz ed  P o in c a re  B e n d ix so n  T h e o re m , it  follow s for 
a ll £ G T  th a t  e i th e r
w (£) =  P  or  w (£) =  F.  (3.86)
C o n s id e r £ G T / { F } .  T h e n  w (£) =  F  o n ly  if  £ is on  th e  s ta b le  m a n ifo ld  o f th e  D F E . T h e
a rg u m e n t p re c e d in g  th is  p ro p o s itio n  in d ic a te s  th a t  no  p a r t  o f  th e  s ta b le  m an ifo ld  o f th e  
D F E  is c o n ta in e d  in  T .  T h e re fo re  we m u s t have w (£) =  P .  o
L e m m a  3 .4 .9  Let £u, £ s be the unstable and stable manifolds of the linearisation of the 
system, at the DFE. Then there exists — 1 <  t -  <  0 such that £ u =  { ( .i:,i_ .r)  : x  G M} and
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t+ >  0 such that £ s =  { (x ,< + i )  : x  €  R}
Proof:
T h e  s ta b le  m an ifo ld  a t  th e  D F E  h as  d ire c tio n
w h ere  p _  <  0 a n d
is th e  d ire c tio n  o f  th e  u n s ta b le  m an ifo ld  a t  th e  D F E , w h ere  p+  >  0. T o  sho w  th a t  o n e  b ra n c h  
o f  th e  u n s ta b le  m an ifo ld  p o in ts  in to  th e  in te r io r  o f  T ,  we m u s t show  th a t  0 <  (oc +  p ) / A <  1.  
T h is  is e q u iv a le n t to  p ro v in g  0 <  p+  <  A — a ,  o r  th a t  A (A  — a )  > 0 ,  w h ere  A  is th e  
c h a ra c te r is t ic  p o ly n o m ia l o f  th e  J o f e > w h ich  sa tis fie s  A ( p ± )  =  0.
F ig u re  3.12: D ire c tio n  o f  A (p)
For p _  <  0 <  p + we have:
•  0 >  —a  >  p -  <=> A  (—a )  <  0
•  0 < / 9_ < A  — a  A (A  — a)  >  0.
S ince A (p) =  p2 +  C\p +  C2 , w h ere  Ci,C2 a re  a s  m e n tio n e d  p rev io u sly , a  l i t t le  a lg e b ra  co n firm s
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th a t
A ( A - a )  =  X/3 > 0,
as re q u ire d . N o te  t h a t  A -  a  >  0, as  n eed ed , since  >  1 im p lies
a  +  p  +  5X
— >  a c* +  5 >  1 .
(3.S7)
(3.88)
L e tt in g  t -  =  — ( a  +  p + )/A  suffices.
T o  show  t h a t  th e  s ta b le  m an ifo ld  c a n n o t e n te r  T ,  it  is e n o u g h  to  sho w  t h a t  ( a  +  p _ ) /A  <  0. 
T h is  is e q u iv a le n t to  p ro v in g  th a t  A ( —a )  <  0. A g a in , i t  is s tra ig h tfo rw a rd  to  co m p u te  
A ( —a )  =  —A<5 <  0, as n eed ed . P u t t in g  t + =  — [ a  +  p - ) / A  suffices. o
T h e re fo re , lo ca l to  th e  D F E , th e  p h a se  p o r t r a i t  o f  th e  l in e a r  (a n d  h e n c e  n o n lin e a r)  sy s te m  
is d e sc r ib e d  below .
Note:
x+  a re  ju s t  th e  e ig en v ec to rs  a sso c ia te d  w ith  th e  e igenvalues p +  o f th e  J d f e -
3 .4 .5  A n  A l t e r n a t i v e  A s s u m p t i o n
In  th e  m o d e ls  th a t  we have looked  a t  so fa r , we have se t d iffe re n t p a ra m e te rs  for th e  ra te  o f 
re la p se  (/?) a n d  th e  re a c tiv a tio n  r a te  (<S). S o m e e a r lie r  w ork  d o n e  o n  A D  [72], [84], [85], h as
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se t th e se  p a ra m e te rs  to  b e  eq u a l. In  m o d e lin g  te rm s , th e y  a re  a s su m in g  t h a t  all a n im a ls  
th a t  e n te r  th e  la te n t  p e r io d  w ill e v e n tu a lly  b eco m e in fec tiv e  a g a in , w h ich  we be lieve  to  b e  
in c o rre c t. I f  we w ere to  ta k e  th is  a p p ro a c h , th e  e q u a tio n s  in  (3 .47) ta k e  th e  fo rm
S' ( t )  =  a  — XI S  — a S  (3 .89a)
I ' ( t )  =  A I S - a l - p i  +  p L  (3 .89b)
L \ t )  =  p i - p L - a L  (3.89c)
F ro m  (3.89) we c a n  c a lc u la te  th e  re p ro d u c tio n  ra t io  to  b e
Ra  =  (3.90)
a ( a  +  2 P)
C o m p a r in g  R a  above, w ith  t h a t  o f  R n  p re v io u s ly  c a lc u la te d  w e ca n  show  t h a t  R a  >  R n-  
H ence, i t  w ill b e  m o re  d ifficu lt to  g e t R a  <  1 th a n  R n -  A s a  r e s u l t  th e  d isease  w ill b e  m o re  
d ifficu lt to  e ra d ic a te . H ence, fo r o u r  m o d e l to  b e  m o re  a c c u ra te , we s e t  P >  6 . T h e n  we can  
show , th e  sm a lle r  S is c o m p a re d  w ith  /3, th e  ea s ie r it  is fo r R n  to  re m a in  below  one.
W e c a n  a lso  say  th a t  w h en  we h av e  n o  d e a th s  (a  =  0 ), b u t  th e  re a c tiv a tio n  r a te  is p o s itiv e  
(5 >  0 ), in fe c te d  in d iv id u a ls  w ill e i th e r  a lw ays b e  in fe c tio u s  o r  w ill v is it  th e  L c o m p a r tm e n t 
in fin ite ly  o ften . E a c h  v is it  w ill b e  e x p o n e n tia lly  d is t r ib u te d  (e _/?t), so  th e  e x p e c te d  to ta l  
tim e  s p e n t in  L  w ill b e  in fin ite , i.e ., w h e n  a  =  0, 6 >  0, w e h av e
R n  =  o o . (3.91)
So, fro m  a  d isease  p o in t o f  v iew , w h e n  th e  s i tu a t io n  in  (3 .91) o c c u rs , th e  d isease  w ill a lm o st 
su re ly  re m a in  en d em ic  in  th e  p o p u la t io n . In  o rd e r  to  p re v e n t  th is , w h e n  th e  b i r th  a n d  
d e a th  r a te s  a re  zero  ( a  =  0), th e  re a c tiv a tio n  ra te  must  b e  k e p t v e ry  sm a ll o r, ev en  b e t te r ,  
b e  re d u c e d  to  zero . H ow ever, if  a n  a n im a l su rv iv es  in fe c tio n  fro m  A D V , i t  h a s  b u ilt  u p
som e re s is ta n c e  to  re in fec tio n , a n d  is less likely  to  b eco m e  in fe c te d , o r  re -in fe c ted . H ence,
re a lis t ic a lly  sp e a k in g , th e  s i tu a t io n  in  (3 .91) is u n lik e ly  to  o ccu r.
3.4.6 R educed Graphs
In  a  s im ila r  w ay  to  t h a t  o f th e  non-vaccinated  m o d e l, w e k now  d o  som e g ra p h s  fo r th e  
re d u c e d  m o d e l. A s b e fo re , we lo o k  a t  g ra p h s  a t  v a rio u s  s ta g e s  o f  a n  ep id em ic , ra n g in g  from
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ju s t  b e g in n in g  ( /  «  S ) ,  to  th e  la te r  s ta g e s  o f a n  o u tb re a k  ( I  >  S) .  W e a lso  look  a t  w h a t 
h a p p e n s  to  S  a n d  I  w h e n  Rpj >  1 a n d  R n  <  1 to  see if  t h e  T h e o re m s  h o ld .
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Infectivas
Suscep tib les
F ig u re  3.14: R ed u ced  m odel ( s ta r t  o f  ep id em ic )
H ere  a n  o u tb re a k  is b eg in n in g , a n d  we c a n  see  t h a t  im m ed ia te ly , th e  in fec tive»  in c rea se  u n til  
th e  th re s h o ld  is reach ed . A fte r  th is  p o in t  th e y  b e g in  to  fall aw ay. H e re  /2/v =  0.3 , a n d  we 
h av e  se t  a  to  b e  la rge , if th e  g ra p h  co n tin u e s , we have S  —> 1 a n d  /  —» 0.
Infectivas
Suscep tib les
F ig u re  3.15: R e d u c e d  m o d e l (m id d le  ep id em ic )
H ere  we h av e  an  even  sp lit  in th e  p o p u la t io n , t h a t  co u ld  go e i th e r  way. A t firs t S  — I,  b u t  
th e n  th e y  b o th  d ie  off, S  m o re  qu ick ly , o n ly  for S  to  in c re a se  w h en  1 =  0 . H e re  R n  =  2 .
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Infactives
Suscep tib les
F ig u re  3.16: R e d u c e d  m odel (en d  ep id em ic )
H ere  we h av e  p assed  s a tu ra t io n  p o in t  in  th e  p o p u la tio n , in  w h ich  we h a v e  m o re  in fec tives 
th a n  su scep tib le s . T h is  g ra p h  is ru n  for o n e  y e a r  a n d  a s  e x p e c te d , 7 —» 0 (n o b o d y  to  in fec t)  
a n d  S  —> I as a  is in c re a se d  (a ll n e w b o rn s  a re  su sc e p tib le ) .
In fe c tiv e s
Susceptib les
Figure 3.17: Reduced model (end epidemic)
Mere we h av e  7¿¿v >  2 , a n d  a s  c a n  b e  seen , it tak es  o n ly  a  v e ry  s h o r t  t im e  for th e  su sc e p tib le s
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to  b e  re d u c e d  to  zero . E v en tu a lly , I  —> 0 for th e  sa m e  re a so n s  as befo re , a n d  th e n  th e  
su sc e p tib le  p o p u la t io n  grow s ag a in .
I t  c a n  b e  seen  fro m  F ig u re s  3 .14 to  3.17 for th e  re d u c e d  m o d e l, a n d  for F ig u re s  3.4 to  3.9 
fo r th e  non-vaccinated  m o d e l, th e y  a re  o n ly  as a c c u ra te  as th e  d a ta  th a t  is u se d  in  th e m . 
A s m e n tio n e d  in  C h a p te r  1, th is  w as o n e  o f o u r  m a in  p ro b le m s  w h e n  we b e g a n  th is  w ork , 
i.e. th e  lack  o f  su ita b le  d a ta  av a ilab le  for I r is h  h e rd s . W e h a v e  e s t im a te d  w h e n e v e r p o ssib le , 
b u t  fo r th e  g ra p h s  to  b e  as a c c u ra te  as p o ss ib le , th e  n e c e ssa ry  d a ta  m u s t  b e  o b ta in e d . U n til 
th e n , we c a n  o n ly  s p e c u la te  as to  th e  a c c u ra cy  o f  th e  g ra p h s  ab o v e . F o r in s ta n c e , in  th e  
m a jo r i ty  o f  th e  g ra p h s  above, th e  in fe c te d  p o p u la t io n  always  seem s to  d ie  o u t, no  m a t te r  
w h a t th e  in i t ia l  c o n d itio n s  a re  se t a t . Surely , th is  c a n n o t b e  th e  case  all th e  tim e ?
F o r th e  g ra p h s  in  b o th  th is  se c tio n  a n d  th e  p re v io u s  o n e  w e c a n  see t h a t  th e  threshold densi ty , 
N t , seem s to  b e  ra n g e  fro m  b e tw e e n  60%  a n d  80%  o f th e  p o p u la t io n , w ith  th e  e x c e p tio n  
o f  F ig u re  3.17, w h ere  i t  is h ig h e r, as e x p e c te d . T h e  o b se rv a tio n s  m a d e  a t  th e  s t a r t  o f  th e  
c h a p te r  seem  to  h o ld  t r u e  also , i.e. w h e re  th e  s p re a d  o f th e  d ise a se  o n ly  s to p s  w h e n  1  =  0 . 
W e c a n  also  see th a t  ev en  th e  s lig h te s t ch an g e  in  th e  r e la t io n s h ip  b e tw e e n  /3 a n d  5 h a s  m a jo r  
im p lic a tio n s  w ith  re g a rd s  to  w h e th e r  th e  d isease  w ill re m a in  in  th e  p o p u la tio n .
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3 .5  V a c c i n a t e d  M o d e l
3.5.1 Introduction
T h e  p u rp o se  o f  a  vacc ine  is to  s t im u la te  th e  im m u n e  s y s te m  in  su c h  w ay  t h a t  th e  re sp o n se
o f  th e  h o s t to  in fec tio n s  w ill b e  less h a rm fu l for th e  h o s t [39]. T h e  re a so n  th a t  we v ac c in a te
a g a in s t A D V  a re  th ree fo ld :
•  th e  p ro b a b ili ty  o f  in fe c tio n  w h e n  ex p o sed  is g re a tly  re d u c e d  (re d u c e d  su sc e p tib ility )
•  th e re  a re  few er c lin ica l signs w h en  in fe c te d  (c lin ica l p ro te c tio n )
•  th e re  is less in fe c tiv ity  w h e n  in fe c te d  (red u ced  in fe c tiv ity )
T h e  o th e r  rea so n s  w h y  v a c c in a tio n  o f  A D V  is im p o r ta n t  a re  w ell d o c u m e n te d  a t  th e  s ta r t  
o f  C h a p te r  2. W h ile  v a c c in a te d  p ig s  c a n  s t i l l  b eco m e  in fe c te d , la b o ra to ry  a n d  fie ld  ex p e ­
rien ce  in d ic a te  t h a t  v a c c in a te d  h e rd s  w ill h av e  a  s ig n ific a n tly  low er in c id en ce  of new  in fec­
tio n  [64], [86]. In d e e d , s tu d ie s  have sh o w n  th a t  if  a  v a c c in a tio n  p ro g ra m m e  ca n  in d u ce  h e rd  
im m u n ity  to  a  d eg ree  t h a t  v iru s  tra n s m is s io n  in  th e  p o p u la t io n  is su ffic ien tly  red u ced , A D V  
w ill e v e n tu a lly  b e  e lim in a te d  [74], [76]. In  a d d it io n  to  th e  m o d e l a s s u m p tio n s  m e n tio n e d  in  
S e c tio n  3 .2 .1 , we also  a ssu m e  th a t  a ll new  a n im a ls  (fro m  b i r th s  a n d  p u rc h a se s )  a re  v a c c in a te d  
b e fo re  b e in g  in tro d u c e d  in to  th e  p o p u la tio n .
T h e  la te n t  p e r io d  is v e ry  im p o r ta n t  w h e n  a n im a ls  a re  v a c c in a te d . A s m e n tio n e d  ea rlie r, 
la te n tc y  ca n  b e  d e sc r ib e d  as a  p e r io d  o f  q u iescence , a f te r  w h ich  th e  a n im a ls  m ay  b ecom e 
re in fe c ted . I t  h a s  b e e n  sh o w n  th a t  v a c c in a tio n  b e fo re  e x p o su re  h a s  l i t t le  o r  n o t effect on  
th e  r a te  o f  e s ta b lish m e n t o f  v iru s  la ten cy , b u t  t h a t  v a c c in a tio n  re d u c e s  sh e d d in g  a f te r  su b ­
se q u e n t re a c tiv a tio n , a n d  i t  c a n  re d u c e  th e  m e a n  d u ra t io n  o f th e  in fec tiv e  p e r io d  by  u p  to  
2 day s [69], [72]. H ow ever, m o re  re c e n t w ork  h a s  p ro p o s e d  t h a t  u s in g  q u a n ti ta t iv e  P C R  
assay s allow s th e  s im u lta n e o u s  d e te c tio n  a n d  d if fe re n tia tio n  o f  tw o  s tr a in s  o f  h e rp esv iru s . 
T h e n , a  th o ro u g h  u n d e rs ta n d in g  o f  th e  m ech an ism s by  w h ic h  v acc in es  p re v e n t la te n c y  sh o u ld  
c e r ta in ly  h av e  a  la rg e  im p a c t o n  th e  efficiency o f  in fe c tio n  c le a n -u p  e ffo rts  in  h e rd s  [62].
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3 .5 .2  V a cc in a ted  M o d e l
F ro m  (3 .27), a n d  fo llow ing  th e  sam e m e th o d s  t h a t  we u se d  fo r th e  non-vaccinated  sy s te m , 
we ta k e  th e  vaccinated  m o d e l to  b e
S' { t )  =  a  — (a  +  k ) S  (3 .92a)
I ' ( t )  =  Xv I P - a I ~ r ] I  +  j L  (3 .92b)
L ' ( t ) =  —j L  +  7]I — a L  (3.92c)
P' ( t )  =  k S  — a P  — XVI P  (3 .92d)
w h ere
S  +  I  +  L  +  P  =  1. (3.93)
B y  a  m e th o d  s im ila r  to  t h a t  u se d  to  o b ta in  R n  in  S e c tio n  3 .3 .1 , we c a lc u la te  th e  r e p ro d u c tio n  
ra t io  for th e  vaccinated  m o d e l fro m  (3.92) to  b e
=  A y « ( a + 7 )  (3 .94)
a ( a  +  k) (a  +  rj +  7 )
W e also  c a lc u la te d  (3 .94) u s in g  s ta b il i ty  a n a ly s is  - th is  is d o n e  in  A p p e n d ix  A . F o r v iru s  
e ra d ic a tio n , i t  is e s se n tia l t h a t  R y  <  1. T h e  o b se rv a tio n  t h a t  R y  am o n g  fin ish in g  p igs vac­
c in a te d  tw ice  exceeds u n ity , do es n o t, how ever, im p ly  th a t  v a c c in a tio n  w ill n o t  succeed  [76]. 
W e now  su p p o se  t h a t  a  perfect  v a c c in a tio n  is av a ilab le  a n d  t h a t  we a re  a b le  to  keep  a  c e r ta in  
fra c tio n , qv, v a c c in a te d  a t  a ll tim es . T h is  a s s u m p tio n  is b a se d  o n  a n e c d o ta l ev id en ce  from  
v e te r in a r ia n s  in  I r e la n d  [44]. T h e n , fro m  a  d isease  re p ro d u c t io n  p o in t o f  v iew , a  f ra c tio n  o f
o f c o n ta c ts  w ill b e  wasted  o n  p ro te c te d  a n im a ls . W e c a n  th e re fo re  w rite  th e  e x p e c te d  ra t io
fo r th e  v a c c in a te d  m o d e l as
E { R V) =  (1 - q v) R y .  (3.95)
F ro m  (3.95) we c a n  say  th a t  w h en
qv >  1 -  (3.96)
th e  d isease  w ill b e  e ra d ic a te d . In  te rm s  o f  R y  in  (3 .94) ab o v e , w e w rite  qv as
[(A y« - a ( a  +  « ) ] ( a  +  7 ) -  a i j {a  +  k ) f0
Qv —  t  7 ; \
A y K ( a  +  7 )
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as a  >  7i we can say a ~  (a +  7 ) and so (3.97) becomes
3.5.3 A verage level o f protection
S om e co n s id e ra b le  t im e  w as sp e n t o n  seek in g  a  fo rm u la  to  d e sc r ib e  th e  r a te  a t  w h ic h  p ro te c ­
t io n  w ears  off, i.e, th e  r a te  a t  w h ich  a n im a ls  go fro m  th e  p ro te c te d  s ta te  to  th e  su sc e p tib le  
s ta te . P re v io u s  w o rk  o n  A D V  m o d e llin g  h a s  n o t looked  a t  th is ,  so we w ere  u n s u re  o f  th e  m o st 
a p p ro p r ia te  m e th o d  to  use. F in a lly , we a ssu m e d  t h a t  th e  v acc ine  w ears  off ex p o n en tia lly . 
H en ce  we ca n  w rite
\ v (t) =  A ( c - e ~ ut) (3.99)
w h e re  c >  1 , t  is m e a su re d  in  u n its  o f  1  m o n th  a n d  u is th e  level  o f  v a c c in a tio n , w h ich  is 
d iffe ren t fro m  k w h ich  is th e  rate o f  v a c c in a tio n . In  m o d e l te rm s , w e h av e  fu ll v a c c in a tio n  
w h e n  v  =  00 a n d  n o  v a c c in a tio n  w h en  u =  0.
W e kno w  fro m  w ork  p re v io u s ly  d o n e  o n  o p tim iz a tio n  o f  v acc in es  [73], [85], t h a t  th e  b e s t 
s tr a te g y  is to  v a c c in a te  th re e  tim e s  a  yea r. H en ce  w e can  w rite  (3 .99) as a n  a re a , i.e.
r 4
Av
1  r
=  4 J 0 X v ^ dt
=  — ¡4c — — f  1 — e 1 (3.100)
4 L v  \  )  \
a n d  we define  (3.100) as th e  average level of protection.  F ig u re  3.18 is a  g ra p h ic a l re fe rence  
to  th e  average level of protection.  H ere  w e b e g in  w ith  a  fu ll level o f  v a c c in a tio n , as t im e  
co n tin u es  v a c c in a tio n  w ill w ear off e x p o n e n tia lly . A t so m e  p o in t  (vp ) th e  fa rm e r  w ill revac- 
c in a te  h is h e rd  (w e a ssu m e  th a t  th e  fa rm e r  is u s in g  a n  o p tim a l v a c c in a tio n  policy , hence  
he  re v a c c in a te s  a f te r  4 m o n th s )  a n d , a g a in , we a re  b a c k  a t  fu ll p ro te c tio n . A g a in , he  w ill 
re v a c c in a te  a n d  as  b e fo re  fu ll im m u n ity  is re s to re d .
F ig u re  3.15 is no  lo n g e r v a lid  if  th e  fa rm e r do es n o t re v a c c in a te  o n  tim e . So, if  th e  fa rm er 
w a its  fo r lo n g er th a n  th e  o p tim a l t im e  ( >  4 m o n th )  a n d  th e  v a c c in a tio n  w ears  off, th e  
a n im a ls  w o u ld  b eco m e  fu lly  su scep tib le . I f  a n  o u tb re a k  w as to  o ccu r, th e  fa rm e r  w ould
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Vp vp t im e  (m o n th s)
F ig u re  3.18: A v erag e  level o f  p ro te c t io n
have to  b e g in  th e  v a c c in a tio n  p ro g ra m  a g a in , as h e  o r  sh e  w o u ld  n o t  know  w h ich  an im a ls  
w ere o rig in a lly  p ro te c te d . T h e re fo re  i t  is o f  p a ra m o u n t  im p o r ta n c e  t h a t  once  a  v a c c in a tio n  
schem e h a s  b e g u n , th e  fa rm e r  must  m a in ta in  i t ,  a n d  m a k e  su re  i t  is o p tim a l. O th e rw ise  th e  
fa rm e r  ru n s  th e  r isk  o f  actually  in c re a s in g  th e  p o s s ib ility  o f  in fec tio n .
C o n sid e r th e  tw o e x tre m e  cases in  (3 .100). T h e  f irs t is t h a t  p ro te c tio n  is  a b o u t  to  w ear 
off, w h ich  o ccu rs  as t  —» oo, a n d  th e  seco n d  is im m e d ia te ly  a f te r  re v a c c in a tio n  h a s  o c c u rre d  
(t  —> 0). In  th e  f irs t case, we have , fro m  (3 .100), A y(oo) =  Ac. W h e n  th e  fa rm e r  h as  
re v a c c in a te d , we w ill h av e  A y(0) =  A(c — 1). In  te rm s  o f  o u r  m o d e l, in fe c tio n  is c / ( c  — 1) 
t im e s  m o re  likely  w h e n  th e  p ro te c tio n  is v e ry  low . ( A  ra n g e  o f  v a lu es  fo r Ay ca n  b e  fo u n d  
in  A p p e n d ix  C)
Note:
B y  m a n ip u la t in g  th e  e q u a tio n s  in  (3.92) we c a n  show , fro m  a  b io lo g ica l p o in t  o f  v iew , w h a t 
th e  a d d it io n  o f  th e  d e lay  te rm  m e a n s  to  th e  p o p u la tio n :
•  T h e  su sc e p tib le s  re m a in  u n c h a n g e d . T h e  d e lay  te r m  is n o t  in  S
•  T h e  in fec tiv es  w ill d ec rea se  b e c a u se  o f  th e  de lay
•  T h e  la te n ts  w ill a lso  d ec rease
•  T h e  p ro te c te d s  w ill in c rease  b e c a u se  th e  level o f p ro te c t io n  w ill r ise  as  th e  d e lay  te rm
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slows down the outward flow.
( S * , I * , L * , P * )  =
K '  \ a  +  k  a  +  k J
a n d  th e  D P E
(,s *, i *, l *, p *) =  ( - g - , - g - ( f l V _ i )  ar] ( R v - i )  K )
v a  +  K Ay A y (a  +  7 J (a +  K ) R y /
w h ere  R y  is as b e fo re .
The equations in (3.92) have two equilibrium points, the D FE
(3.101)
(3.102)
T h e o r e m  3 .5 .1  The D F E  (3.101) always exists. (1) This equilibrium is asymptotically  
stable when R y  <  1 and unstable when R y  >  1. (2) When the D P E  (3.102) exists, i.e. for  
R y  >  1, i t  is asymptot ical ly stable.
Biocorollary 3.5.1'.
I f  th e  re p ro d u c tio n  r a t io  exceeds one, a ll so lu tio n s  (e x c e p t th e  D F E )  w ill a p p ro a c h  th e  D P E  
a n d  th e  d isease  w ill re m a in  en d em ic  in  th e  p o p u la t io n . H en ce , th e  su sc e p tib le  a n d  p ro te c te d  
fra c tio n s  w ill d ec rea se  as th e  in fec tiv e  f ra c t io n  in c rea ses , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  
w ill b eco m e in fe c te d  (o r la te n t) .  I f  th e  r e p ro d u c tio n  r a t io  is less th a n  one , a ll so lu tio n s  
a p p ro a c h  th e  D F E , a t  w h ich  th e y  w ill re m a in . H ence , th e  su sc e p tib le s  a n d  p ro te c te d s  
in c rease  as th e  in fec tiv es  dec rease , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e e ith e r  
su sc e p tib le  o r p ro te c te d . W h e n  th e  re p ro d u c t io n  r a t io  eq u a ls  one, o n ly  th e  D F E  ex is ts .
Proof:
F or ease  o f  n o ta t io n  we le t Ay =  A a n d  we p ro c e e d  in  th e  sa m e  m a n n e r  as t h a t  o f  th e  p ro o f  
o f  T h e o re m  (3 .4 .1 ).
1. T h e  lin e a r ise d  m a tr ix  o f  (3.92) is:
(3.103)
( S \
!
/ —(a  +  k ) 0 0 o N f S \
I 0 A P *  — ( a  +  rj) 7 XI* I
L 0 V - ( a +  7 ) 0 L
\ P ) \  K - A  P * 0 — (a  +  XI * ) ) \PJ
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p 4 +  / i p 3 +  f i p 2 +  h p  +  /4 =  0 (3.104)
Putting the D FE  (3.101) into (3.103) we calculate the characteristic equation to be
j Xk
w h ere
A =  3 a  + k + — -  l)
a  +  k  \  /£;/ /
( 3 a  +  / i ) A / i /  1 \  „ .
h  =  S r d - W - 1) + “ (3“ + 2 ' t > a + K
A  =  « V  +  „ )  +  a A " (3;  +  ( ^  -  l )  -  - ^ L ( 2a  +  «)
a  +  K \  R y  ' a  +  k
f i  =  a 2A /i^ -^----- l) ~  a 7^K .
In  e q u a tio n s  f \  to  /4 ab o v e  we h av e  s lig h tly  m o d ified  th e  R y  te r m  in  (3 .94). W e k now  th a t
a »  7 , h e n ce  a  ~  ( a  - f  7 ). So w e a p p ro x im a te  (3.94) by
\ k
R Vi =  7 -  77 , — T . (3.105)
( a  +  / i ) ( a  +  77 +  7 )
F o r ease  o f  n o ta t io n , we now  le t i?Vi =  R y .
A s befo re , we c a n  use  th e  R o u th -H u rw itz  te s t  to  d e te rm in e  th e  s ta b il i ty  o f  (3 .104 )  w ith o u t 
h av in g  to  solve th e  e q u a tio n . In  th e  n o ta t io n  o f  th e  R o u th -H u rw itz  te s t  we h av e  A i  =  / 1 , 
A 2 =  f l - f i  “  /3 ,  A 3 =  ~  h )  ~  f i  2■ f i  a n d  A 4 =  /4 A 3 .
I f  R y  <  1 :
I f  R y  <  1 w e c a n  show  t h a t  / 1 , / 2 >  0, h e n c e  A i  >  0. B y  re a r ra n g in g  w e c a n  say  th a t  
fo r /3 to  b e  p o s itiv e  we n eed
a 2 ( a  +  k )2 X k  a ( 3 a  +  2 k ) ( —------ l )  >  j X k ( 2a  +  k) . (3 .106)
V R y  /  J
T h e  te rm  in s id e  th e  sq u a re  b ra c k e ts  in  (3 .1 0 6 )  is p o s itiv e , as R y  <  1, so b o th  sides a re
p o sitiv e . W e kno w  t h a t  a »  7  a n d  so a ( 3 a  +  2/i)  >  7 (2a  +  re). H ence , i t  follow s t h a t  (3 .106)
is tru e ,  so >  0.
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F or >  0 we n e e d  to  show  th a t  / 1./2  >  / 3, i-e we n eed
i l i i l 2 +  a ( 3 a  +  / i ) (3 a  2/c) >  a 2 ( a  -\- k ) -f-
a j X n  
a  +  k
(3.107)
w h ere
a  +  KV R y  '
f22 — (3 a  +  / i ) ( f i i  -f- 3 a  -f- k ) —
j Xk 
a  +  k
W e re a r ra n g e  (3 .107) as
i !  1 i^2 “I- 2a ( 2a  k )2
a j X n  
a  +  k
(3.108)
(3.109)
th e  r ig h t h a n d  s id e  o f (3 .109) w ill b e  sm a ll c o m p a re d  to  th e  le ft h a n d  side , as  th e  a j X n  te rm  
w ill b e  v e ry  sm all. C o n c e n tra tin g  on  th e  le ft h a n d  side  o f  (3 .109). T h e  2 a ( 2 a  +  k )2 te rm  
is p o s itiv e , a n d  w e k now  th a t  >  0 (as R y  <  1), so w e a re  le ft w ith  W e re a rra n g e  
(3.108) to  give
'yXn
(3 a  +  k ) ( i i i  +  3 a  +  «) >
a  +  k
(3.110)
a n d  we c a n  ea s ily  show  th is  to  b e  tru e ,  so O 2 is p o s itiv e . F o llow ing  o n  fro m  th a t ,  a g a in  
o m itt in g  th e  2 a ( 2 a  +  k )2 te rm , a n d  e x p a n d in g  th e  f ) i i i 2 te rm , we w rite  (3 .109) as
7 Xk
(3 a  +  /i)2f i i  +  (3 a  +  /c )ii2 >  — a ^
a  +  k
(3.111)
fu r th e r  e x p a n d in g  (3.111) we can  w rite  i t  as
A/tf2
a  +  k ■7 +
X k  
a  +  k
(3 a  +  K)2 ( - ^ - - l )  - 0 7 ] >  0 ( 3 .1 1 2 )
as  R y  <  1 we c a n  show  th a t  (3.112) is t ru e ,  w h ich  m ean s  t h a t  (3 .111) is t ru e ,  w h ich  in  tu r n  
m e a n s  t h a t  (3 .109) is tru e . H ence  A 2 >  0.
W e c a n  w rite  ¡4  a s
a  X k l Y - L - i \  - 1 ]
A  R y )  a .
if  th e  te rm  in s id e  th e  sq u a re  b ra c k e t is p o s itiv e  th e n  >  0. H ence , if
a  +  71
R y a
(3.113)
(3.114)
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a ( a  +  « ) ( «  +  7  +  t?) 
Xn(a  +  7 )
then /4 >  0. We write (3.114) as
>  1. (3.115)
O b se rv in g  (3.115) we c a n  see th a t  th e  left h a n d  s id e  is, in  fa c t,  1 / R y  b e fo re  we a p p ro x im a te d  
it  in  (3 .105). A s R y  <  1, we ca n  say  th a t  th e  o r ig in a l R y  ( in  (3 .94)) is a lso  less th a n  one. 
H ence  (3.115) is t ru e , w h ich  m ean s  t h a t  (3 .113) is t r u e ,  h e n c e  >  0.
In  o rd e r  fo r u s  to  show  t h a t  A 3 >  0, w e h av e  a lre a d y  sh o w n  t h a t  / 1./2  >  / 3, so  we n eed  to  
show  t h a t  -  h )  >  fx 2- /4- F ir s t ,  we look  a t  /1  2./4 i.e
(3 «  +  k +  i^ i)2 . (a 2( a  +  « ) f i i  — tryA/c) (3.116)
w h ere  SI 1 is as befo re . W e have  a lre a d y  c a lc u la te d  / 1./2  — fz  to  b e
i ) 1 Q2 +  2 a ( 2 a  +  /i)2 -  E U b l . (3 .1 1 7 )
a  +  n
U sin g  (3.117) a n d  (3 .116) we can  w rite  / 3C/1./2  -  h )  >  fx 2 - h ,  as
^ 3 O 1 O2 +  2 a ( 2 a  +  k )2 — >  (3a  _ |_  K  - f  Q 1 ) 2(q;2(q; +  k ) ^  — a j X n )  (3.118)a  +  k
w h ere
i i 3 =  a 2 ( a  +  k) +  a ( 3 a  +  2 /i)i2 i — —------ ("20; +  «')
a  +  k \  J
E x p a n d in g  b o th  sides o f  (3 .118), a n d  a f te r  so m e h ea v y  c o m p u ta tio n s  w e have
7TlO] 2 +  7T2f2l +  7T3 >  0 (3.119)
w h ere
7Ti =  a ( 3 a  +  2k )^2  +  cryArt — 2 a 2 (o; +  / i ) ( 3 a  +  k ) — a 2(a  +  k )Q\
7T2 =  a 2(a  +  k )^2  +  2 a 2(3 a  +  2 « ) ( 2 a  +  n)2 +  2 a 2^XK(3a  +  k )
2/o„. ,a ;(3 a  +  n)2(a  +  k) — ^ K f a 2(3o; +  k ) +  (2 a  +  k ) ^ )  
a  +  k \  /
7T3 =  2 a 3 ( a  +  n )( 2 a  +  k ) 2 +  a 'y X n ( 3 a  +  2k)2 — o P 'y X K ------------- K- ( 2 a  +  k
OL K  V
3
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N e x t we n eed  to  show  if  (3 .119) is t r u e  o r n o t. S ta r t in g  w ith  7Ti, a n d  u s in g  th e  d e fin itio n  o f 
^2 in  (3.108) we ca n  say
7Ti =  a ( 3 a  +  2 / i ) (3 a  +  k ) +  a j X n  — a 2( a  +  k ) |^2(3a +  k ) +  i i i j  
a.'yAn
a  +  k
a n d  we c a n  re w rite  (3 .120) as
^ 3 a  +  2 k J (3.120)
7Ti =  a ( 3 a  +  k) (3 a  -f  k ) (3 a  +  2 k ) — 2 a ( a  +  k )
“ V—
01
+  a'yXn 1  -
3 a  +  2k 
a  +  k
+  a i l i  [" (3 a  +  k ) (3 a  +  2k ) — ( a  +  k ) 
L'--------------------- ------------------------
02
(3.121)
03
A s a ll p a ra m e te rs  in  (3 .121) a re  p o s itiv e , w e c o n c e n tra te  o n  # i, 62, $3 , to  d e te rm in e  th e  sign  
o f 7r i . E x p a n d in g  9\ gives
61 =  a ( a  +  /i) [7 a 2 +  7 a / i  +  2k 2
w h ich  is p o s itiv e . S im ilarly ,
w h ich  is also  p o s itiv e , a n d
62 =  9 a 2 +  9 a / i  +  2 /i2 — ( a  +  k )
03 =  — a-y \K(2a  +  k )
(3.122)
(3.123)
(3.124)
w h ich  is n eg a tiv e . H ow ever, by  e x p a n d in g  61 in  (3 .122), we c a n  show  th a t  6 \ >  63 . H ence, 
a d d in g  e q u a tio n s  (3.122) to  (3.124) we c a n  say  th a t  7Ti >  0.
M oving  o n to , 7T2, we c a n  w rite  th is  as
7T2 =  0,2 a 2( a  +  / i ) -----^2a  +  k ) j  +  a 27 A/t[^2 (3a  +  k ) — - ——-------------
a  +  k a  +  k
+  a 2 I" 2 (3 a  +  2/ t ) (2a  +  k ) 2 — (3 a  +  /c)2 ( a  +  k) 
L'--------------------------------------------------------------- 'I
(3.125)
£3
W e c a n  w rite
d  =  a 4 +  / i (2 a  +  « ) ( a 2 — 7 A) (3.126)
78
62 =  3 ( a  +  « ) ( a  +  k ) — 3 ( a  +  2k ) (3.127)
w h ich  is a lso  p o sitiv e . F in a lly , e x p a n d in g  63, we g e t
15a2 +  21a2K + l l a K 2 +  2k 3 (3.128)
w h ich  is a lso  p o s itiv e . H ence , a d d in g  e q u a tio n s  (3 .126) - (3 .128) w e c a n  say  t h a t  7r2 >  0.
F in a lly , we have
7T3 =  cr/A k  (3 a  +  k) 2 — a 2 +  2 a ( 2 a  +  k) 2 a 2 ( a  +  / i ) -----—----- ( 2 a  +  k )  (3 .129)
L'_______ _ ______ L a  +  k \  / J
which is positive. Similarly,
n
T2
F ro m  in sp e c tio n  n  >  0, a n d  we c a n  w rite  72 as
T 2 =  a 4 +  / i ( a 2 — 7 A )(2a  +  k )  (3 .130)
w h ich  is c e r ta in ly  p o s itiv e , h en ce  7r3 >  0. N ow  t h a t  we k n o w  7ri, 7r2,7r3 >  0, w e c a n  co m b in e  
(3 .121), (3 .125) a n d  (3.129) to  say  t h a t  (3.119) is t ru e ,  h e n c e  we h av e  finally  sh o w n  A 3 >  0. 
W e kno w  t h a t  A 4 =  / 4.A 3 , a n d  as w e have  sh o w n  th a t  b o th  a n d  A 3 a re  p o s itiv e , hen ce
A 4 >  0.
=> A  i >  0 V i e  [1,4]
=> Re(pi)  <  0
U sin g  T h e o re m  A. 1.2 we c a n  show  th a t  pi a re  a sy m p to tic a l ly  s ta b le  w h en  th e y  a re  <  0. 
H en ce  th e  D F E  (3 .101) is a s y m p to tic a lly  s ta b le  w h en  R y  <  1.
If R y > 1*
I f  R y  >  1 we see t h a t  /1  >  0 a n d  / 4 <  0, hen ce  A i  >  0. W e k n o w  th a t  A 4 =  / 4.A 3 a n d  
/ 4 <  0. H ence , if  A 3 >  0, th e n  A 4 <  0 a n d  if  A 3 <  0 th e n  A 4 >  0. So, u s in g  th e  converse 
o f  th e  R o u th -H u rw itz  te s t  w e c a n  say  t h a t  n o t  a ll  p r in c ip a l  m in o rs  a re  p o s itiv e , hen ce  n o t 
a ll e igenvalues have  n e g a tiv e  re a l p a r t .
H ence , we c a n  say  t h a t  th e re  e x is ts  a t  le a s t one  e ig en v a lu e  w ith  p o s itiv e  re a l  p a r t .  A s one  
eigen v a lu e  is p o s itiv e  we c a n  u se  T h e o re m  A .1.2, to  say  t h a t  th e  D F E  (3 .101) is u n s ta b le  
w h e n  R y  >  1.
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P 4 + 3 i P 3 +  92P2 + 5 3 P  +  04 =  0 (3.131)
(2) Putting the DPE (3.102) into (3.103) we calculate the characteristic equation to be
w h ere
g  i =  a ( 2  +  R y )  +  k
Xk  /  ( a  +  7 ) \
92 =  an,  + W ^ ) \ a - - R r )
= a2Itv(a-hK) +  {2a  +  \(a ~
( a  +  K)  \  K y  /
93
2 ,  / ,  M  a 2j Xkgt  =  a  Xk  1 -  —  ) ------------ --------—
V R y ) a  +  K
w h ere  R y  is as  b e fo re  a n d
=  (1 +  R y ) { a  +  k ) +  R y
A g ain  u s in g  th e  n o ta t io n  o f th e  R o u th -H u rw itz  te s t  we have  A i  =  g\ ,  A 2 — g i -92 ~  S3 , 
A 3 =  .73(51 -92 ~  93) ~ 9 i  2-94 a n d  A 4 =  g4 A 3.
If R-v > 1:
I f  R y  >  1 th e n  we c a n  see t h a t  g \ , <72, Qz >  0, hen ce  A i  >  0. F o r g\  >  0 we need
1 _ J _  >  (3 . 132 )
R y  a  -f- k
a n d  we c a n  w rite  (3 .132) as
i -  <  (3 .133)
R y  a  +  k
E a rlie r  in  th is  p roo f, w e used  th e  a p p ro x im a tio n  a  ~  a  +  7 , now , u s in g  th e  fac t th a t  
a  +  K oi a  +  K ~ 7 , we c a n  w rite  (3 .133) as l / R y  <  1, w h ic h  is t r u e  as R y  >  1, hen ce  (3.133) 
a n d  (3 .132) a re  tru e ,  h en ce  g.\ >  0.
F o r A a  >  0 we n eed  .91.52 >  93, a n d  we c a n  w rite  th is  as
( 2 a  +  k  +  a ./i i /) (S i4 —  i'll) >  c t R v [ ( x  +  n )  — (2 a  +  k ) Q \  (3.134)
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w h ere  i l l , i l j  a re  as b e fo re . W e c a n  re a rra n g e  (3 .134) as
Cl1\ (2 a  +  k  +  a R v )  >  a R y ( a  - f  re +  f i j )  (3 .135)
a n d  w e c a n  fu r th e r  re d u c e  (3 .135) to
a R y  2(1 +  a  +  k) +  (2a  +  /c)ii;| >  a R yC l \  (3 .136)
as R y  >  1 , w e c a n  say  th a t  (3 .136) is tru e , h en ce  (3 ,134) is t r u e ,  so  A 2 >  0.
F o r A 3 >  0 w e have  a lre a d y  sh o w n  th a t  ¡71.52 >  53 hi (3 .1 3 4 ), so  we n e e d  t;o show  th a t
53(5i-52 -  53) >  5 i 2 -54 ■ (3 .137)
W e know  th a t  b o th  sk ies  o f  (3 .137) a re  p o s itiv e , so s t a r t in g  w ith  5 i 2.54, a n d  using  th e  
a p p ro x im a tio n  th a t  we c a lc u la te d  for g.\ in  (3 .133) we c a n  w r ite  th is  as
—a 2( a  +  « ) i i i ( 2 a  -f re +  a R y )  2 (3 .138)
a n d  we ca n  w rite  (3 .137) as
( ( 2 a  +  k ) +  a iZ y J i is  >  a R y ( a  +  K +  i1i)  (3 .139)
w h ere
£^ 5 =  +  a 2( a  +  « ) ( 2 a  +  k  +  a R y ) i l \  • (3 .140)
W e c a n  w rite  (3 .140) a s
R y  [ a  - f  « )(1  -f R y )  +  1] +  a 2(2 a  +  k  +  a / ? y ) ( l  — R v )  (3 .141)
a n d  we ca n  w rite  (3 .141) as
( a  +  « ) ( !  — a 2) +  i?V [l + »  +  K -  a 2] . (3 .142)
A s a ll p a ra m e te rs  6  (0 ,1 ) , we c a n  show  th a t  (3 .142) to  b e  p o s itiv e , hen ce  (3.140) is a lso
p o sitiv e , h e n ce  th e  left h a n d  s id e  o f  (3 .139) is p o s itiv e . W e can  w rite  th e  r ig h t h a n d  s id e
(3 .139) as
a ( a  +  k )2R v  +  a A « ( l  — R v ) . (3 .143)
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W e know  t h a t  R y  >  1, h en ce  th e  seco n d  te rm  in  (3 .143) is n e g a tiv e . W e c a n  w r ite  (3 .139)
cxAk R v  +  ( (2 a  +  « ) 4- aR.\/)Clr> >  <*[a  +  k )2R v  +  &Xk  (3 .144)
as R v , l h  >  0, we ca n  re a r ra n g e  (3 .144) to  show  th a t  it  is t r u e .  H en ce , A 3 >  0. As <74 >  0, 
we ca n  say  th a t  A ,| >  0.
=» A* >  0 V t  G [1,4]
=i> Re(pi)  <  0
U sin g  T h e o re m  A .1.2 we can  show  th a t  pi a re  a s y m p to tic a l ly  s ta b le  w h en  th e y  a re  <  0. 
H ence  th e  D P E  (3.102) is a s y m p to tic a l ly  s ta b le  w h e n  R v  < 1 .  0
3.5.4 V accinated Graphs
In  th is  se c tio n  we look  a t  so m e  g ra p h  o f  th e  v a c c in a ted  m o d e l t h a t  we h a v e  ju s t  s tu d ie d . T h e  
in it ia l  c o n d itio n s  w ill b e  th e  sa m e  as th a t  for a ll th e  g r a p h s  Lhat we h av e  d o n e  p rev io u sly , 
a n d  now  th a t  we h av e  a n  e x t r a  c o m p a r tm e n t, P ,  a n d  th e  b ro w n  lin e  w ill re p re s e n t  th e  
p ro te c te d s . In  a ll th e  fo llow ing g ra p h s , we a ssu m e  th a t  th e re  is a t  le a s t o n e  in fec tive .
In  F ig u re  3.19 th e  in tro d u c tio n  o f  a n  in fec tive  cau ses  L  to  rises a n d  n o t I.  T h is  w ould  
load  o n e  to  th in k  th a t  th e re  is a b o u t  to  b e  an  o u tb re a k  in  th e  p o p u la tio n , ev en  th o u g h  we 
a re  v a c c in a tin g . H ow ever, th e n  L  b e g in s  to  d ec rea se , a n d  i f  th e  g ra p h  is r u n  over a  lo n g er 
p e r io d , we see t h a t  5 , P  —► 0.5 o f  th e  p o p u la t io n . T h is  c o u k l bo d u e  to  a n  o v e re s tim a tio n  o f  
th e  p a ra m e te r  77, w h ich  m e a su re s  loss o f  in fec tio u sn ess .
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Figure 3.19: Full vaccination (v = 1)
H ere  we h a v e  u =  1 , i .e  full v a c c in a tio n  in  th e  p o p u la t io n . H en ce , Xy — 0 .05, a n d  we h av e  
a  v acc in a tio n  ra te , k  =  0 .5 , as  h a lf  o f  th e  p o p u la t io n  a re  a lre a d y  p ro te c te d .
N
In  th is  g ra p h  we h av e  re p la c e d  a  w ith  a W) w here  a w =  (1 +  a ) l / b2 -  1 as w e d id  in  F ig u re  
3 .11. H e re  w e h av e  u  — 0 .75 , h en ce  Xv 0 .0 6  a n d  k  =  0 .25.
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NF ig u re  3.21 : EAill v a c c in a tio n  (lo n g e r, v  — 0 .75)
T h is  g ra p h  h as  th e  sa m e  in it ia l  c o n d itio n s  as F ig u re  3 .20 , b u t  we have  ru n  i t  fo r  o n e  y ea r. 
N o tice , h o w  a f te r  a n  in it ia l  rise , th e  in fec tiv es  a n d  th e  la te n ts  d ec rease , a lb e i t  slow ly, w hile  
th e  p ro te c te d s  rise. E v e n tu a lly , S  —> 0.15 , I , L  —* 0 a n d  P  —> 0.85.
N
H ere  we look a t  w h a t  h a p p e n s  as we co m e  to  th e  en d  o f  th e  v acc in a tio n  p e r io d . W e see  th e  
p ro te c te d s  a re  d e c re a s in g  ra p id ly  w hile  th e  la te n ts  a r e  in c re a s in g .
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NF ig u re  3 .23: F u ll v a c c in a tio n  (lo n g e r, u =  0 .25)
R u n n in g  F ig u re  3 .22  o v er a  lo n g er p e r io d  o f tim e , we ca n  see th a t  th e  p ro te c te d s  will e v e n tu ­
a lly  in crease , b u t  th e  d ise a se  w ill re m a in  in  th e  p o p u la t io n , a s  o p p o se d  to  d y in g  o u t , w h ich  
w ill h a p p e n  in F ig u re  3.21.
N
F ig u re  3.24: Full v a c c in a tio n  (v  =  0 .0 1 )
H ere  we a re  a t  th e  e n d  o f  th e  v acc in a tio n  p e r io d , a n d  th e re  is no  re v a c c in a i ion. In  th is  case, 
P  —» 0, L  —* 1 FOUR  t im e s  fa s te r  th a n  it  d o es  in  F ig u re  3 .22 . E v en tu a lly , a f te r  th re e  y ears ,
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all a n im a ls  b eco m e  su sc e p tib le .
N
T h is  is a n  in te re s tin g  g ra p h , as  b o th  a, R y  <  1, w ith  =  0 .01 , b u t  S, P  d e c re a s e  a lm o s t 
im m ed ia te ly . E v e n tu a lly , S, P  in c rease , b u t  w hy  th e y  d e c re a se  a t  th e  b e g in n in g  c o u ld  a g a in  
be d u e  to  an  o v e re s tim a tio n  o f so m e o f  th e  p a ra m e te rs .
3 .5 .5  R e d u c e d  M o d e l
F o r c o m p u ta tio n a l  ease  w e re d u c e  th e  sy s te m  in  (3.92) to  a  3 x  3, u s in g  (3 .93) to  give
S ' ( t ) — a  — (a +  n) S
l ' ( t ) =  XVI P - («  +  77 +  7)7  +  7 ( 1  - S - P )
P'(t) = nS — aP — XylP
w h ere , once ag a in ,
S + I  + L + P = 1.
T h e  e q u a tio n s  in  (3 .145) have  tw o  e q u ilib r iu m  p o in ts , th e  D F E
(S*,  7*, P*)  =  (  “  o , - ^ - )
V a  +  K  a  +  A t /
a n d  th e  D P E
(.S * , I * , P *) =  f — ——  , (7?y — 1 )) 7------ ~ vd—)\ a - \ - K  Ay (a; +  / i ) 7 iy /
w h ere  Ry  is as befo re .
T h e o r e m  3 .5 .2  The D FE (3.147) always exists. (1) This equilibrium is asymptotically  
stable when R y  <  1 and unstable when R y  >  1. (2) When the D P E  (3.148) exists, i.e. for  
R y  >  1, i t  is asymptotically stable.
Biocorollary 3 .5 .2 :
I f  th e  re p ro d u c tio n  ra t io  exceeds one, a ll so lu tio n s  (ex cep t th e  D F E ) w ill a p p ro a c h  th e  D P E  
a n d  th e  d isease  w ill re m a in  en d em ic  in  th e  p o p u la t io n . H ence , th e  p ro te c te d  f ra c tio n  d ec rease  
as th e  in fec tiv e  f r a c t io n  in c reases , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e  in fec ted . 
I f  th e  r e p ro d u c tio n  ra t io  is less th a n  one, a ll  so lu tio n s  a p p ro a c h  th e  D F E , a t  w h ich  th e y  w ill 
re m a in . H ence , th e  p ro te c te d  f ra c tio n  in c rea se s  as th e  in fec tiv e  f ra c t io n  d ec reases  to  zero,
9
a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e  su sc e p tib le . W h e n  th e  re p ro d u c tio n  ra t io  
eq u a ls  one, o n ly  th e  D F E  ex ists .
(3 .145b)
(3.145c)
(3.146)
(3.147)
(3.148)
(3.145a)
87
Proof:
T h e  p ro o f  o f  th is  th e o re m  is v e ry  s im ila r  to  t h a t  o f  T h e o re m  3 .5 .1 , a n d  as su c h  a  d e ta ile d  
p ro o f  is u n n ecessa ry . o
In  T h e o re m  3.5.1 we d id  n o t ta k e  in to  a c c o u n t th e  d iffe rences t h a t  c a n  o c c u r in  A a t  th e  
b e g in n in g  a n d  e n d  o f  th e  p ro te c tio n  p e r io d . N ow , we lo o k  a t  th e  sy s te m  in  (3 .145) w ith  
th e  in te n tio n  on  see in g  w h a t h a p p e n s  a t  th e  b e g in n in g  a n d  e n d  o f  th e  p ro te c tio n  p e rio d . 
W e a lso  m ak e  th e  a d d it io n a l  a s s u m p tio n  th a t  once  th e  level o f  p ro te c tio n  h a s  w o rn  off, an  
o u tb re a k  o f  th e  d isease  will  o ccu r. T h is  m ay  n o t  n ec e ssa rily  b e  tru e . I t  m ay  b e  a  case  th a t ,  
u n fo r tu n a te ly  fo r A D V , th e  fa rm e r h a s  b e e n  v a c c in a tin g  o p tim a lly  a n d  th e  a n im a ls  m ig h t 
have  b u il t  u p  su ffic ien t im m u n ity  to  lim it th e  n u m b e r  o f  new  in fec tiv es , th u s  re d u c in g  th e  
p o ss ib ility  o f  th e  d isease  sp re a d in g . O r i t  m a y  b e  th e  case  t h a t  th e  n ew ly  in fe c tio u s  an im a ls  
a re  h a rv e s te d  b e fo re  th e y  have a  chance  to  s p re a d  th e  d isease .
E n d  o f  P r o t e c t i o n  /  B e g i n n i n g  o f  O u t b r e a k
A t th e  e n d  o f  th e  p ro te c t io n  p e r io d , we know , fro m  sp e a k in g  w ith  v e te r in a r ia n s  ac tiv e ly  
w o rk in g  o n  A D V , t h a t  w h en  a  h e rd  a re  fu lly  v a c c in a te d , th e  ch an ce  o f  a  re a c tiv a tio n  (7 ) 
o c c u rr in g  is e x tre m e ly  sm a ll, as  th e  ch an ce  o f  re la p se  (77) i ts e lf  is v e ry  sm all. H en ce  we can  
ig n o re  th e  7  te rm  fro m  o u r  e q u a tio n s  in  (3 .145). F o r ease  o f  n o ta t io n  w e se t £ =  Xy{c)  a n d  
so (3.145) beco m es
S' ( t )  =  a - { a  +  K) S  (3 .149a)
I ' ( t )  =  t I P - { a  +  rj)I (3 .149b)
p ' ( t )  =  n S - c t P - £ I P .  (3.149c)
A s b e fo re  w e c a n  c a lc u la te  th e  re p ro d u c tio n  r a t io  fo r th e  e q u a tio n s  in  (3 .149) to  b e
 ^ (3 ' 150)( a  +  rj)(a +  k )
a n d  we c a n  c a lc u la te  th e  e q u ilib r iu m  p o in ts  o f (3 .149) to  b e
8 8
( S* , I* ,P*) =  ( - g -  " )
\ a  +  K £ (a  +  K)rÍM'
which is the DFE, and the DPE is
(3.152)
T h e o r e m  3 .5 .3  The D F E  (3.151) always exists. (1) This equilibrium is asymptotically  
stable when R m  <  1 and unstable when R m  >  1■ (2) When the D P E  (3.152) exists it  is
asymptotically stable.
Biocorollary 3 . 5 .3 :
I f  th e  r e p ro d u c tio n  r a t io  exceeds one, a ll so lu tio n s  (e x c e p t th e  D F E )  w ill a p p ro a c h  th e  D P E  
a n d  th e  d isease  w ill re m a in  en d em ic  in  th e  p o p u la t io n . H en ce , th e  su sc e p tib le  a n d  p ro te c te d  
fra c tio n s  w ill d e c re a se  as th e  in fec tive  f ra c tio n  in c reases , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  
w ill b e c o m e  in fec ted . I f  th e  re p ro d u c tio n  r a t io  is less t h a n  one, a ll so lu tio n s  a p p ro a c h  th e  
D F E , a t  w h ich  th e y  w ill re m a in . H ence , th e  su sc e p tib le s  a n d  p ro te c te d s  in c rease  as th e  
in fec tives d ec rease , a n d  e v e n tu a lly  th e  e n tire  p o p u la t io n  w ill b eco m e  e i th e r  su sc e p tib le  o r 
p ro te c te d . W h e n  th e  re p ro d u c tio n  ra t io  e q u a ls  one , o n ly  th e  D F E  ex is ts .
Proof:
T h e  p ro o f  o f  th is  th e o re m  is o f a  s im ila r  n a tu r e  to  t h a t  o f  th e  p ro o f  o f  T h e o re m  (3 .5 .1 ), 
how ever i t  is less c o m p lic a te d  d u e  to  th e  fa c t t h a t  we h av e  re d u c e d  th e  sy s te m  a n d  have 
o m itte d  th e  7  te r m  fro m  o u r  eq u a tio n s .
T h e  lin e a rise d  m a tr ix  o f (3 .149) is:
f s V  /-(<* + «0 0 0 \ f s \
/  =  0 £ P * - ( a  +  7 ) £I * I  . (3 .153)
W  V k -(p* - ( a + s n j  \ p j
(1) P u t t in g  th e  D F E  in  (3 .151) in to  (3 .153) we c a lc u la te  th e  c h a ra c te r is t ic  e q u a tio n  to  b e
p 2 +  hifP’ +  h ip  +  /13 =  0 (3.154)
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w h ere
hi  =  2a  +  /i +  ~“ T ~  (  /T------0
a  +  K \ l i M  '
h2
R m
a ( a  - f  k ) +  (2a  +  -------- l )
a  4- K V R m  /
' R m
As b efo re  w e a p p ly  th e  R o u th -H u rw itz  te s t  to  g e t A ] =  / i i ,  A -2 — / t i . / i2 —/13 a n d  A 3 =  /i3 .A 2. 
If Rm < 1;
I f  R m  <  1 , th e n  hi ,  I12 , h‘s >  0, lienee A i  >  0. F o r A 2 >  0 we n e e d  to  sh o w  th a t  !i\ .h2 >  h3,
(2a  +  k +  A i ) . ( ( 2 a  +  k )A i +  a ( a  +  « ))  >  a ( a  +  k ) A i (3 .155)
w h ere
A . = a  -f- K \ R m  j 
E x p a n d in g  th e  le ft h a n d  s ide , we c a n  w rite  (3 .155) as
(2 a  +  « ) .  [ (2 a  +  « )A i +  a ( a  +  « ) +  A i 2] >  0 (3.156)
a n d  we know  th a t  A | >  0, as R m  <  1) h en ce  (3 .156) h o ld s , so we c a n  say  t h a t  A 2 >  0. W e
know  th a t  A 3 =  /i3 . A 2 , a n d  we have a lre a d y  sh o w n  th a t  b o th  ft 3 a n d  A 2 a re  p o sitiv e , so 
A 3 >  0 .
=» A i >  0 V i e  [1,3]
=> Re(pi)  <  0
U sing  T h e o re m  A . 1.2 we c a n  show  t h a t  pi  a re  a s y m p to tic a lly  s ta b le  w h en  th e y  a re  <  0.
H ence  th e  D F E  (3 .151) is a sy m p to tic a lly  s ta b le  w hen  R m  <  1-
If' R m > 1:
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F or R m  >  1) n o te  th a t  /13 <  0. W h a te v e r  th e  s ig n  o f  A 2 is, A 3 w ill b e  th e  o p p o s ite , as 
A 3 =  /13 A 2. H en ce  we k now  th a t  n o t a ll  p r in c ip a l  m in o rs  a re  p o s itiv e , so u s in g  th e  converse  
o f  th e  R o u th -H u rw itz  te s t ,  w e c a n  say  t h a t  n o t  a ll e ig en v alu es  h av e  n e g a tiv e  re a l  p a r t .
H ence , w e c a n  say  th a t  th e re  ex is ts  a t  le a s t one  e ig en v a lu e  w ith  p o s it iv e  r e a l  p a r t .  A s one 
e igen v alu e  h a s  a  p o s itiv e  re a l  p a r t  we c a n  u se  T h e o re m  A .I .2, to  say  t h a t  th e  D F E  (3.151) 
is u n s ta b le  w h en  R m  >  1 .
(2) P u t t in g  th e  D P E  (3.152) in to  (3 .153) w e c a lc u la te  th e  c h a ra c te r is t ic  e q u a tio n  to  b e
P 3 +  j i P 2 +  h P  +  h  =  0 (3.157)
w h ere
j i  =  a ( l  +  R m ) +  ft
j 2 - a R M (c>L +  ft) +  ( l  -  — )
a  +  f t \  K m j
A s b efo re  we a p p ly  th e  R o u th -H u rw itz  te s t  to  g e t A i  =  j \ , A 2 =  j i - j '2 ~  j z  a n d  A 3 =  J 3.A 2. 
f  R m  >  1 :
W h e n  R m  >  1, j i ,  j 2, h  >  0- H ence A i  >  0. F o r A 2 >  0, w e n eed  j i ..72 >  h ,  i-e.
( a ( l  +  R m )  +  ft) • ( & R m (01. +  ft) — a A i)  >  —a ( a - f f t ) A i  (3.158)
w h ere  A i is as b e fo re . E x p a n d in g  th e  left h a n d  s id e  o f  (3 .158) w e c a n  w rite  i t  as
( a  +  k) [ (a  +  ft) +  chR m \ >  c c A i. (3.159)
A s R m  >  1, we k now  th a t  A j <  0, so th e  r ig h t h a n d  s id e  o f  (3 .159) is n e g a tiv e . W e know  
th a t  th e  le ft h a n d  s id e  is p o s itiv e , so (3 .159) is t r u e ,  w h ich  m e a n s  t h a t  A 2 >  0. H ence  
A 3 >  0 as b o th  A 2 >  0 a n d  a re  p o s itiv e .
=» A j >  0 V t  e  [1,3]
=> Re(pi)  <  0
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U sing  T h e o re m  A .1.2 we ca n  show  th a t  pi a re  a s y m p to tic a l ly  s ta b le  w h e n  th e y  a re  <  0. 
H ence  th e  D F E  (3 .151) is a sy m p to tic a lly  s ta b le  w h e n  R m  > 1 -  o
E n d  o f  O u t b r e a k  /  B e g i n n i n g  o f  P r o t e c t i o n
For con v en ien ce , we a ssu m e  th a t  th e  fa rm e r  h a s  re v a c c in a te d , w h ich  is w h a t  b rin g s  a b o u t th e  
e n d  o f  a n  o u tb re a k . J u s t  b e fo re  v a c c in a tio n , in fe c te d  a n im a ls  m a y  m ak e  u p  a  co n sid e rab le  
p ro p o r t io n  o f  th e  to ta l  p o p u la tio n . W e k now  t h a t  b o th  th e  re la p se  (7 ) a n d  re a c tiv a tio n  
(77) r a te s  w ill b e  q u ite  p ro m in e n t, b u t  th e  c o n ta c t r a te  w ill b e  re d u c e d  as th e re  w ill b e  less 
su sc e p tib le s  to  in fec t. O n  th e  o th e r  h a n d , th e  v a c c in a tio n  r a te  w ill b e  h ig h , A y(oo) =  A(c—1). 
H ence , w e c a n  r ig h t th e  e q u a tio n s  in  (3 .145) as
S' ( t )  =  a  — ( a +  k ) S  (3 .160a)
I ' ( t )  =  XI P  — ( a  +  rj +  7 ) /  +  7 (1  — S  — P )  (3 .160b)
P ' { t )  =  k S  — a P  — X I P  (3.160c)
a n d  we c a n  see t h a t  th e  sy s te m  in  (3.160) is th e  sam e  as th e  s y s te m  in  (3.145) so th e re  is 
no  n e e d  fo r us to  p ro v e  T h e o re m  3.5 .2  fo r th e  sy s te m  in  (3 .160).
N ow  t h a t  we h av e  lo o k ed  a t  th e  sy s te m  a t  th e  b e g in n in g  a n d  e n d  o f  a n  o u tb re a k , we can  see 
th a t  re g a rd le ss  o f  w h a t th e  c u r re n t s ta te  o f  th e  d isease  is in  th e  p o p u la t io n , th e  re p ro d u c tio n  
ra tio , R y ,  w h ich  is R m  in  th is  in s ta n c e , is s till  o f  c r it ic a l im p o r ta n c e .
3.5.6 Further R educed M odel
In te g ra t in g  (3 .145a) gives
S( t )  =  e ' ^ + ^ S o  +  e ~ ^ +K)t f ' ' a e ^ a+K)sds
Jo
_  e-(a + « ) i i e-(a + « )i _  I ' j  +  e-(a + K )*£ 0
a  +  k V )
=  — --------1- ( S o -------(3.161)
a  +  K \  a  +  k /
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T h e  e x p o n e n tia l  te rm  in  (3.161) goes to  zero  as t  goes to  in fin ity  fo r la rg e  t,  so  w e a re  ju s t
le ft w ith  th e  f irs t te rm . N ow  if  we p u t  t h a t  in to  (3 .145a) w e c a n  a p p ro x im a te  th e  sy s te m  of
e q u a tio n s  in  (3 .145), for la rg e  t, b y  th e  2 x 2  s y s te m
l ' ( t )  =  A y l P  — ( a  +  rj +  7 ) /  +  7  f  —  -----------p ) (3 .162a)
\ a  +  k  J
P ' f t ) =  — a P - X v I P . (3 .162b)
a  +  k
T h e  e q u a tio n s  in  (3 .162) have  tw o  e q u ilib r iu m  p o in ts , th e  D F E
( I * , P * )  =  (3 1 6 3 )
\  a  +  k J
a n d  th e  D P E
(r , P * )  =  (3 .164)
w h ere  R y  is as  befo re .
T h e o r e m  3 .5 .4  The D FE (3.163) always exists. (1) This equilibrium is asymptotically  
stable when R y  <  1 and unstable when R y  > 1 .  (2) When the D P E  (3.164) exists it is 
asymptotically stable when R y  >  1.
Proof:
th e  p ro o f  o f th is  th e o re m  is v e ry  s im ila r  to  t h a t  o f  T h e o re m  3.5 .1 . o
W e co u ld  c o n tin u e  to  w ork  w ith  th e  e q u a tio n s  in  (3 .162), b u t  as th e y  a re  o n ly  v a lid  for 
la rg e  i, i t  w as d e c id e d  n o t  to  p u rsu e  w o rk  o n  th is  m o d e l, as  th e  m o d e l in  (3 .145) is m o re  
ac c u ra te . In  th e  n e x t  sec tio n , w e w ill look  a t  w h a t  w o u ld  h a p p e n  to  th e  e q u a tio n s  in  (3.145) 
a n d  (3 .162) if  th e  d isease  w as p e rio d ic .
3.5.7 R educed Graphs
N ow  we d o  som e g ra p h s  for th e  re d u c e d  m o d e ls  t h a t  we h av e  lo o k ed  a t . A s b efo re , we look  
a t  g ra p h s  a t  v a rio u s  s tag es  o f  a n  ep id em ic , ra n g in g  fro m  ju s t  b e g in n in g  (I  <C 5 ) ,  to  th e  la te r  
s tag es  o f  a n  o u tb re a k  ( I  >  S).  W e a lso  lo o k  a t  w h a t  h a p p e n s  to  P  a n d  I  w h e n  R y  >  1 a n d  
R y  <  1, to  see if  T h e o re m s  (3 .5 .1 ), (3 .5 .2) a n d  (3 .5 .3) h o ld .
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F ig u re  3.26: B e g in n in g  o f  O u tb re a k  /  E n d  o f  V acc in a tio n
In  th e  g ra p h  above, a n  o u tb re a k  o f th e  d ise a se  h a s  ju s t  o c c u rre d  a n d  as su ch  w e h av e  R y  >  1 , 
(2 .1 ), w hich  m e a n s  t h a t  th e  d isea se  will b e c o m e  ra m p a n t  in  th e  p o p u la tio n .
F ig u re  3 .27: E n d  o f O u tb re a k  /  B eg in n in g  o f  V a c c in a tio n
H ere  v a c c in a tio n  h as  b eg u n  ag a in , a n d  th e  in fec tiv o s a re  d r iv e n  to  zero . F o r so m e  reaso n  th e  
in fec tiv es  rise  in itia lly , w ith  e v e ry th in g  e lse  fa lling , la te r  ( <  100 d ay s)  th e y  b eg in  to  d ro p  
a n d  we a re  j u s t  left w ith  th e  p ro te c te d s , i.e . P  -*  1.
9 4
F ig u re  3.28: B eg in n in g  o f O u tb re a k  /  E n d  o f  V a cc in a tio n
In  th is  g ra p h , we h av e  in tro d u c e d  o n e  in fec tiv e  in to  th e  p o p u la t io n , a n d  i t  h a s  h a d  d ev as­
ta t in g  co n seq u en ces.
N
F ig u re  3.29: E n d  o f O u tb re a k  /  B eg in n in g  o f  V a cc in a tio n
H ere  we h a v e  re - in tro d u c e d  v a c c in a tio n  in to  th e  p o p u la tio n , a n d  th is  d r iv e s  th e  in fec tiv es  to  
zero. W e o n ly  look  a t  tw o g ra p h s  o f th is  ty p e  as th e  e a r lie r  g ra p h s  a ie  m o re  re a lis tic .
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3 .6  P e r i o d i c  I n f e c t i o n
I t  h a s  b e e n  sh o w n  th a t  in  h ig h ly  c o n c e n tra te d  h e rd s , A D V  a p p e a rs  to  cycle  c o n tin u o u s ly  [79], 
a n d  in  so m e cases th e  re a c tiv a tio n  o f  A D V  fro m  la te n t  a n im a ls  o c c u rs  p e r io d ic a lly  [52]. Som e 
w ork  d o n e  in  [25] h a s  sh o w n  th a t  SEI  m o d e ls  c a n  have  p e r io d ic  so lu tio n s  w ith  in c id en ce  
XIS, b u t  n o t w ith  in c id en ce  AIS/N.  To re fre sh  th e  r e a d e r ’s m em ory , we b e g a n  w ith  a n  
in c id en ce  r a te  o f  A IS/N,  b u t  th is  w as c h a n g e d  to  A IS  w h e n  th e  m o d e l w as re fo rm u la te d . 
H ow ever, as th e  m o d e l d ev e lo p ed  ea rlie r  is o f  SIL  ty p e , w e a re  u n s u re  as  to  w h e th e r  o r  n o t 
th is  th e o ry  w ill h o ld . A n o th e r  p ro b le m  is t h a t  in  S ec tio n  3 .4 .4  w e h a v e  sh o w n  th a t  th e re  
is n o  p o s s ib ili ty  o f  lim it cycles o c c u rr in g  in  th e  2 x 2 non vaccinated  m o d e l, so we have 
no  p e r io d ic  so lu tio n s  in  th is  m o d el. W e a re  u n s u re  w h a t a ffec ts  th is  h a s  on  th e  vaccinated 
m o d el.
I f  w e c o n s id e r t h a t  in fe c tio n  did o c c u rre d  p e rio d ica lly , in s te a d  o f  u s in g  e i th e r  (3.99) or 
(3 .100) w e in tro d u c e  a(t )  in to  th e  m o d e l, w h e re  a( t ) is p e r io d ic  in  t  w ith  p e r io d  T . W h a t we 
a re  say in g  is t h a t  a(t)  w ill rep lace  Xy  in  (3 .145). I n s te a d  o f  h a v in g  a n  in fec tio u s  p e r io d  w h en  
we s to p  v a c c in a tin g , o r w h e n  th e  v a c c in a tio n  level is be low  a  c e r ta in  th re s h o ld ; in fe c tio n  w ill 
o c c u r p e rio d ica lly , re g a rd le ss  o f  v a c c in a tio n . R e c e n t w ork  c a rr ie d  o u t  in  th e  N e th e r la n d s  h a s  
sh o w n  t h a t  in  su ffic ien tly  la rg e  h e rd s , in fe c tio n  will  o c c u r re g a rd le ss  o f  w h e th e r  v a c c in a tio n  
o ccu rs  o r  n o t [77]. H ere  we ta k e  th is  a  s te p  f u r th e r  a n d  a ssu m e  th a t  n o t  o n ly  w ill in fec tio n  
o ccu r, b u t  t h a t  it  w ill do  so p e rio d ica lly . A g a in , m u c h  like th e  average level of protection,  
l i t t le  w ork  h a s  b e e n  d o n e  on  th is .
I f  w e c a n  fin d  a  reg io n , say  T , w h ich  c o n ta in s  no  s ta t io n a ry  p o in ts  a n d  w h ich  t ra je c to r ie s  
e n te r  b u t  do  n o t  leave, w e ca n  u se  th e  P o in c a re  - B e n d ix so n  T h e o re m  to  show  t h a t  a t  le a s t 
one p e r io d ic  so lu tio n  e x is ts  [27]. A lso , a c c o rd in g  to  B e n d ix so n ’s c r ite r io n , if  th e  d iv e rg en ce  o f 
th e  v e c to r  fie ld  d oes n o t ch an g e  s ig n  o r d o es  n o t  v a n ish  id e n tic a lly  in  so m e  s im p ly  c o n n e c te d  
d o m a in , say  Tv-,  th e n  p e r io d ic  so lu tio n s  a re  n o t p o ss ib le  in  T v  [60], W e c a lc u la te  th e  
d iv e rg en ce  o f  (3 .145) as
H  +  § 7  +  | p  =  ~~ ( a (7  — P )  +  (3 a  +  ?? +  7  +  re)) • (3.165)
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P u t t in g  th e  D F E  a n d  D P E  in to  (3 .165) w e have , s ta r t in g  w ith  th e  D F E ,
— f ( 3 a  +  77 +  7  +  f t ) ------ (3.166)
a  +
w h ich , a c c o rd in g  to  B e n d ix so n ’s c r ite r io n , p e r io d ic  so lu tio n s  a re  p o ss ib le  o n ly  w h en  Aft <  
( a  +  f t) (3 a  +  r) +  7  +  ft). P u t t in g  th e  D P E  in to  (3 .165), we get
-  ( c R v  +  ( 2 a  +  r, +  7  +  « )  -  ( q  ) ,  (3 .167)
w h ich  h a s  p o ss ib le  p e r io d ic  so lu tio n s  w h e n
A ft <  ( a  +  « ) i ? v ( a (  2 +  Ü V ) +  77 +  7  +  ft).
U n fo r tu n a te ly , as we h av e  no  re a lis tic  v a lu es  o f th e  p a ra m e te rs  m e n tio n e d , i t  is d ifficu lt for 
u s  to  c a lc u la te  w h e th e r  o r n o t th e se  in e q u a litie s  h o ld .
W e c a lc u la te  th e  line a r is e d  m a tr ix  o f (3 .162) to  b e
i V  _  / XP*  — ( a  +  77 +  7 ) A /*  — 7  \ f l
P )  V ~ X P * —( a  +  X I * ) )  \ P
a n d  w e f in d  th e  e igenvalues o f  (3 .168), a t  th e  D F E , as
(3.168)
ip — ( a  +  ip) ±  s j ( a  +  ij; — <p)2 +  4 [ ( a  +  7 )</? — a-0] (3.169)
w h ere , ip =  a  +  r/ +  7  a n d  99 =  A f t/(a  +  ft). L e tt in g  ip =  a  +  ip, (3 .169) beco m es
p  =  ±  \ / ( a  +  7 ) ( a  +  V1) — “ V1 (3.170)
a n d  w e c a n  see t h a t  th e  sq u a re  ro o t  te r m  in  (3 .169) w ill b e  p o s itiv e . F o r b ifu rc a tio n  to  
o ccu r, we n e e d  6 =  0 a n d  —4 a c  <  0. W e c a n  o n ly  have  6 =  0 w h e n  <p =  a  +  ip, b u t  a t  th is  
p o in t we c a n  see t h a t  —4 ac  >  0, h en ce  th e  c o n d itio n s  o f  th e  H o p f  B ifu rc a tio n  T h e o re m  a re  
v io la te d , so n o  b ifu rc a tio n  e x is ts  a t  th e  D F E  [80].
A t th e  D P E , th e  e igenvalues o f  (3 .168) a re
1
P =  2
>pi — (a R y  +  ip) ±  \ J (a R y  +  ip — ty?)2 +  4 [ (a  +  7 V 1 — aRyip ]  (3.171) 
w h ere , ip is as b e fo re , a n d  =  A « / ( a  +  n ) R y .  L e ttin g  ip\ =  a R y  +  ip, (3 .171) b ecom es
p =  ± \ / ( a  +  7 ) {o iRy  +  ip) — a R y i p  (3.172)
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a n d , as  b e fo re , th e  sq u a re  ro o t te rm  in  (3 .171) w ill b e  p o s itiv e . So, s im ila r ly  to  th e  D F B  
ab o v e , we ca n  say  th a t  no b ifu rc a tio n  e x is ts  a t  th e  D P E .
In tro d u c in g  a(t)  in to  th e  m o d e l, we ca n  w rite  (3 .145) as 
S' ( t )  =  a — ( a  +  K)S
I ' ( t )  =  Xa ( t ) I P  — ( a +  i] +  7 ) /  4- 7 ( 1  ~  S  — P )
P ' { t )  =  kS — a P  — Xa.{t)IP.
W e can  say  t h a t
S '  +  I '  +  P '  =  ( a  +  7 ) (1  — (S  - f  /  +  P) )  — r j l .
N ex t, le t
P  =  1 - { S  +  I  +  P )
=► P '  =  - ( S '  +  I '  +  P ' )
=» P '  =  — ( a  +  7 ) P  — t ] I .
F or / ( 0 )  =  It , P { 0) =  Pt  a  T -p e r io d ic  so lu tio n  is a d m it te d  i f  a(l )  is T -p e r io d ic .
/  K ' d t  =  K { T ) - K {  0 ) =  0 
Jo
fo r K  =  I,  P .
F ro m  th is  w e have  (for 7)
J  -  ( a  +  71 +  j )  f T  I ( t ) d t  +  —1 —r T  -  7  I '  P ( t )  =  0 Jo a  +  K) Jo
w h ere
J  =  X [ r  a{ t ) I ( t ) P{ t ) d t .
Jo
S im ila rly , we ca n  w r ite  (for P)
rj1
——— T  -  J  -  a  P{t)dt.  =  0.
Oi +  K Jo
(3 .173a)
(3 .173b)
(3.173c)
(3.174)
(3.175) 
We can
(3 .176)
(3 .177)
(3.178)
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( a +  ?? + 7 ) /  T  -  ( « + 7 ) /  P ( f ) d i
Jo  \ a + K /  ,/o
Adding (3.177) and (3.178) we have
=> ^  [ T I { t )d t  =  a  +  V f  1  — 1  f r  P { t ) d t ) .  (3 .179)T/o (a + 7, + 7) V(a + «) T  J0 K '  J v 1
W e define  th e  av e rag e  n u m b e r  o f in fcc ted s  as
i  r T 
1 -  t [
a n d  th e  av e rag e  n u m b e r  o f  p ro te c te d  as
i  r T 
P  =  T  J0 P{t)dL
H ence, (3 .179) ca n  b e  w r it te n  as
j  _  «  +  7 _____________a  +  7  p
( a  +  ï; +  7 ) ( a  +  k) a  +  rj +  j
=  (3 1 8 0 )  
w h ere , / i y  is as b e fo re , a n d  0 <  / ,  P  <  1 a n d  I  +  P  +  a / ( «  +  a )  <  1 .
3 . 7  B i o l o g i c a l  I m p l i c a t i o n s
T h ro u g h o u t th e  co u rse  o f  th is  p a r t ic u la r ly  long c h a p te r , w e have  seen  th e  c r it ic a l im p o r ta n c e  
o f  th e  re p ro d u c t io n  ra tio , in  i ts  v a rio u s  fo rm s. T h is  is i l lu s tr a te d  in  T h e o re m  3 .4 .5 , w here  
we can  see th e  im p o r ta n c e  o f  k eep in g  th e  re p ro d u c tio n  ra t io  below  1 . I f  7i/v, R v  <  1  we h av e  
seen  th a t  th e  d isease  will d ie  o u t  itse lf, re g a rd le ss  o f  w h e th e r  o r n o t v a c c in a tio n  is p ra c tis e d . 
F u r th e rm o re , if  a  fa rm e r  is to  in tro d u c e  a  v a c c in a tio n  p ro g ra m , it  is  o f  p a ra m o u n t  im p o r ta n c e  
th a t  h e  m a in ta in s  it: o th e rw ise  h e  ru n s  th e  risk  o f  in c re a s in g  th e  p o ss ib ility  o f  in fec tion .
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C h a p t e r  4
S to ch a stic  M od el
4 . 1  I n t r o d u c t i o n
R a n d o m  p e r tu rb a t io n s  m a y  d ecisive ly  affect th e  lo n g - te rm  b e h a v io u r  o f  d y n a m ic a l sy s tem s. 
W e h av e  a lre a d y  sh o w n  in  C h a p te r  3 t h a t  w e h av e  a s y m p to tic a l ly  s ta b le  e q u ilib r iu m  p o in ts  
fo r b o th  th e  non-vaccinated  a n d  vaccinated  sy s tem s. H o w ev er th e re  m a y  b e  a  n o n -zero  
p ro b a b il i ty  t h a t  r a n d o m  effects w ill m ove th e  sy s te m  o u t o f  th e  d o m a in  o f  a t t r a c t io n  o f  th e  
e q u ilib r iu m  p o in t.
I n  su ch  a  case, th e  s y s te m  w ill e v e n tu a lly  leave th e  d o m a in  o f a t t r a c t io n  w ith  p ro b a b ili ty  1. 
T h e  d e te rm in is tic  co n c e p t o f  s ta b i l i ty  n o  lo n g e r ap p lie s . W e c a n  re p la c e  in  w ith  th e  e x p e c te d  
tim e  e la p se d  b e fo re  leav in g  th e  d o m a in  o f  a t t r a c t io n . T h is  is k n o w n  as th e  persistence of  
the sys tem  [51].
4 . 2  B a s i c  S t o c h a s t i c  M o d e l
A m o n g  th e  re c e n t w ork  d o n e  o n  s to c h a s tic  m o d e llin g  o f  in fe c tio u s  d iseases  we have s tu d ie d  
is [7], [8], [11], [22], [26] a n d  [53]. A s fa r  as s to c h a s tic  m o d e ls  o f  A D V  a re  co n cern ed ,w e  have 
b e e n  in flu en ced  b y  th e  w ork  o f  [20], [84], W e p re se n t th e  m a in  id eas  o f  th e  g en e ra l m o d e l 
h e re , b e fo re  c o n s id e rin g  A D V  in  th e  n e x t sec tio n . W e b e g in  w ith  a  s im p le  p o p u la t io n  g ro w th
100
t h a t  h a s  in i t ia l  v a lue  N( 0)  =  No,  w h ere  N( t )  is th e  size  o f  th e  p o p u la t io n  a n d  a(t )  is 
th e  re la tiv e  g ro w th  ra te . I f  a(t )  is n o t  co m p le te ly  k n o w n , b u t  s u b je c t  to  so m e  ra n d o m  
e n v iro n m e n ta l effects, we w rite
a{t )  =  r ( f )  +  t/>(i). (4-2)
w h ere  r( t )  is th e  d e te rm in is t ic  c o m p o n e n t a n d  th e  r a n d o m  v a ria b le  ip(t) is th e  noise.
U sing  (4 .2) we w rite  (4 .1) as
j t N { t )  =  j V ( i ) [ r ( t ) + W ) ] .  (4-3)
W ritin g  (4 .3) in  in te g ra l fo rm  we have
N( t )  =  No 4- f  r ( s ) N ( s ) d s  +  I  i p (s )N (s )d s .  (4.4)
Jo Jo
T h e  noise  te rm  in (4 .4) ca n  b e  ex p re ssed  as B( t ) .  W e c a n  now  w rite  (4 .4) as
N( t )  =  N q +  f l r ( s ) N ( s ) d s  +  f  i p ( s ) N( s ) d B( s )  (4.5)
Jo Jo
a n d  we c a n  w rite  (4 .5) in  d iffe ren tia l fo rm  as
d N( t )  =  r { t ) N( t ) d t  +  ^{ L) N{ t ) dB{ t )  on  t  >  0 (4.6)
w ith  in it ia l  va lu e  N ( 0) =  No  a s  befo re .
U sin g  I to ’s fo rm u la , [26], (4 .6) b ecom es
logyV (i) =  log N q +  J  ( r ( s )  — ^  +  j  ip{s)dB(s)  (4.7)
so  we can  c a lc u la te  th e  im p lic it so lu tio n  o f  (4.6) to  be
N ( t )  =  Nq  ex p  ^ J  ( r ( s ) - ^ Y ^ j d s  +  i>p[s)dB{s)j  . (4.8)
model
j t N{t) =  a(t)N(t) (4.1)
1 0 1
S u p p o se  in  a  p o p u la t io n  o f  TV, th e re  a re  in it ia lly  N  — 1 su sc e p tib le s  a n d  1 in fec tiv e , a n d  
define  V(s,l ){t)  to  b e  th e  p ro b a b il i ty  t h a t  th e re  a re  S  su sc e p tib le s  a n d  7  in fec tiv es  a t  tim e  t. 
G iv en  th a t  th e  in te n s i ty  o f t r a n s i t io n  fro m  s ta te  to  s ta te  is in d e p e n d e n t o f  th e  p a s t  h e a lth  o f 
th e  a n im a ls , a n d  th a t  th e  in te n s ity  o f  t r a n s i t io n  d e p e n d s  o n ly  o n  th e  s ta te ,  V( s j ) ( t )  is th e
t r a n s i t io n  m a tr ix  o f  a  tim e  h o m o g en eo u s M ark o v  ju m p  p ro c e ss , o r  c o n tin u o u s  t im e  M ark o v
ch a in .
T h e  in i t ia l  s ta te  is fixed  a t  X q =  (N , N  — 1). S ta te  a t  t im e  t  is X t  G K + , th e n  co n sid e r th e
s ta te  sp ace  to  b e
<S =  {(S', 7) : S > 0 , 7 > 0 ,  S  +  I < N } (4.9)
C o n s id e r i , j  G S  a n d  ca ll, fo r j  =  (S , I )
r {s,i)(t)  :=  v i j (t)
=  P [X t =  j \ X 0 =  i]
=  n x t = j } (4.10)
if  A  is th e  m a tr ix  o f  t r a n s i t io n  ra te s , th e n
V'( t )  =  V( t ) A  
V{0)  =  I .
C o n sid e r th e  s ta te  j  =  (S , I ), th e n
' \ ( S  +  1 ) ( I  — 1 ) i =  ( 5  +  1 , 7 - 1 )
0 ( 7  +  1) ¿ =  ( 5 ,7  +  1)
- X I S - 0 I  ¿ =  ( 5 ,7 )
0 o th e r w is e .
T h u s ,
— A (S +  1 )(7  -  +  /5(7 +  l j ^ s . z + i ) ^ )
—(A 75  +  f5I)V(s,i) (t) (4.11)
A s e x p e c te d , th e  s t a t e  (S ,0) is a n  absorbing state.  B y  th is  we m e a n  a  s ta te  w here , once  th e  
sy s te m  a t ta in s  i t ,  th e  sy s te m  w ill re m a in  th e re  for a ll t im e . I n  te rm s  o f o u r  m o d e l, we have
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no infective» and 7 will remain at zero. Mathematically we write this as
^ (s ,o )W  =  m m ® -
The expected sojourn time (temporary stay) in the state can be calculated using the following 
formula (from [29])
Rs =  inf{i > 0 : X t+S #  * s}  (4-12)
B'roin (4.12) we have
W[Rs > w \X s = (S,I)] =  e-M W *  (4.13)
where
f A IS  +  01  for 7 >  1  
-A (5 ,/) =  {
[ 0  for 7 = 0 .
Hence, expected sojourn time is
r°° d/ w —  F[RS < u/IXs =  (5 ,1))dw (4.14)
Jw=o dw
and, using (4.13), we write (4.14) as
roo
/  w fL {S ,I)e -^s ’^ wdw. (4.15)
J tu= 0
Letting v =  fi(S,I)w, (4.15) becomes
roo i
/  V e  V - i Q  T\ dv  ^ 4 - 1 ^Jv= 0 ¡¿{S, I)
which we can write as
- 1 -  f° °  v e~vdv (4.17)
P-\S, I) Jo
and we can see that the integral part of (4.17) is 1  when we integrate by parts. Hence, we 
are left with
1
MS, I)
(4.18)
Suppose there is an ‘event’ (i.e. transition) at time S + w given that at time S, the system is 
in state X$ = (S, 7), and no transition occurred in (S ,S  +  w). Then we have, for infection,
A IS
P[X5+W =  ( 5 - 1 ,7  + 1)| =  (5,7), Rs = w] =  Xfg + gJ (4’19)
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using the fact that R q =  A/0, we can rewrite (4.19) as
RoS 
RoS + 1
A similar method for recovery yields
P[X5+IU = ( S , I -  1)|XS -  (5 ,1),R S = w] 
again using R q = A//3, we have
01
M S  +  01
R qS  + 1
(4.20)
(4.21)
(4.22)
In a method similar to that used in [22], we let t>e the probability that the Ith event
brought the population in state (S', I). Using (4.20) and (4.22), and provided that I  > 0, we 
can say
7^ j+ i)+ i 2 (5 +1 ,/—1 ) ( 0  +  7^+T 2(s,J+l)(0> for S' > 1 
RoS+i 2(s,/+i) (0 for S =  0,1.
2(5,7) + 1)
where
2(5,7) (0)
1 for S =  0, /  =  1, 
0  otherwise.
Following on from the calculations above, we can also introduce the R  (recovered) state. 
Suppose that at the end of an infectious period an individual dies with probability 1 — 
otherwise it enters the recovered state. Assuming that /j <  1, we can do a similar calculation 
to that for Q(s,i){l +  1) to find Q(s,i ,r)(1 +  !)• Firstly, we see that
( (S — 1, 1 +  1, R) with rateg^j^A
{ 5 ,/,R) =  < ( S , I —l,R )  with rate ( 1  — fi)I
(S , I  — 1, R + 1) with rate/j/.
Now computing the probabilities with which each of the outcomes occurs, as we did for 
(4.20) and (4.22), we have
R o^lf+ sll+ R  2(5+1,7-1,R)(l) + ft nS0sls+I+R 2(5,7+1,71-1) (0
2(s,7,R)(^ + 1 ) — <
+ /») RoS+S+f+R+l 2(5,7+1,71) (0
—  / » )  R 0 5 + 5 + 7 + R + l  2(s,7+1,K)(0 
+  fi RoS+S+f+R 2(5,7+1,ii—l) (0 
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for S > 1
for S  =  0,1,
Prom Becker [10], R.q can be estimated at the end of an outbreak by the martingale formula
where
So = the initial number of susceptibles
St = the final number of susceptibles
Zq = the initial number of infective» (which is 0 to begin)
Zt =  the final number of infectives 
Ht =  the total number of infectives.
This idea may be applied to ADV its follows. From (4.23) we can calculate a formula to 
estimate the average number of ADV infections introduced per herd per region to be
where
N f = the number of finishing herds in the region
m =  the number of compartments where specimens have been collected from herd k 
fk =  the fraction of ADV introductions that results in a major outbreak for herd k.
If we look at the fk term in (4.24) we will see that it closely resembles the threshold density, 
Nr, that was mentioned in Section 3.3.3. Hence we can say
and we can also see that (4.25) is the same as the qv term we mentioned in Section 3.5.2.
(4.23)
(4.24)
R p -1
Ro
(4.25)
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4 .3  A D  S to c h a s t ic  M o d e l
Now we introduce a stochastic model corresponding with the deterministic model of AD 
mentioned in Chapter 3. For the stochastic model of AD we will look at the non-vaccinated 
model mentioned in Section 3.4.1. For convenience we rewrite these equations
T O
S'{t) =  aN  — A—  — (/i + E )S  (4.26a)
T Q
I'(t)  = A—  — (p +  E )I -  p i  + SL (4.26b)
L'(t) = p i  - & L - { n  + E ) I . (4.26c)
As before we introduce the scaled population sizes X\ = S/N , X'¿ =  I/N , X3 = L/N, and we 
let As = A¡N. Using the constant population restriction (a = fi+E) we have X\ +X2+X3 =  1. 
Now we can reduce the equations in (4.26) to a more workable 2 x 2 . We assume that the 
inflow is deterministic in the time interval At, and is given by aN  A t, where a, N  are as 
before. The outflow and the transmissions between the parameters will be stochastic.
We assume that in the small time interval (t , t + A t), S  decreases by one and I  increases by 
one because of a transition from the susceptibles to the infectives with probability AIS At. 
The probability of more than one transition is o(At), which can be neglected for small At. 
We can summarise the transmission in the following table:
E v e n t D e s c r i p t i o n P r o b a b i l i t y
x\ —> x\ + 1/N birth of susceptible aN  A t
Xi —» X\ — 1/N, X2 —>■ X2 +  1/N infection of susceptible AsN x \x2A t
X2 -» X2 -  1/N, X3 x 3 +  1/N recovery of infective PNx2A t
x 3 ->■ x 3 — 1/N, x2 ->• x2 + 1/N reactivation of latent 5Nx2A t
xi —y x\ — 1/N removal of susceptible a N x \A t
x2 -> x 2 -  1/N removal of infective a N x2A t
£ 3  -» £ 3  -  1/N removal of latent a N x3A t
Table 4.1: Probabilities of possible events occurring in population
From Table 4.1 we can obtain the conditional first moments of the changes of x\ and x2,
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over the time interval A t We define A x\ to be
{— jj with probability XsN x\X2A t  +  a x \N A t0 with probability 1  — XsNxiX2A t — aNAt. — a x \N A t  + ji  with probability a N A t.
The standard formula for the expected value of Ax'i is (from [26])
m
E [Aa.'i] =  J2'P[A®i = qj]qj. (4.27)
i= 1
Hence we can calculate E [Aasi] as
E[Aa;i] — —a A t.N  — -^XsNxiX 2A t — -^ a x \N  A t + o{At)
— a A t — ~ X sNx\X2A t —-^ a N  A t (4.28)
and, in a similar way, we can say that
E[Aar2] =  -^ A sN x x x iA l-  ^ f iN A t  + ~ 6N A t~  — a N A t.  (4.29)
The reason why we do not cancel the N  and l /N  terms in both (4.28) and (4.29) will be
seen in the calculation of the second moments. For the second moments we use
Tit
E((AiCi)2] =  J ] P [ A a = i j ] ^ .  (4-30)
Using (4.30) we can say that
E[(Aa?i)2] =  (oAf) 2 +  XsNx^XzAt + - ^ a N x i A t  (4.31)
and
E [(A.T2 )2] = - ^ 2 XsN x xx2A t -  ~ f3 N x 2A t  + ^ S N x 2A t + -±~2a N x2A t . (4.32)
We can observe that the variances of A x x and A x 2 equal the second moments up t.o o((Ai)2). 
Now
1
by{t i ,s i ,x 2) =  lim —- E [Aari]At—>0 At
=  a  — XsXix2 — atx\ using E[A®i] from (4.28) (4.33)
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and by the sam e argument
Under the assumption of continuity, we can now approximate the stochastic jump process
by a system of stochastic differential equations of Itô type. By convention, such equations
can be written as
4
dxj = bj (xi, x2) dt + ajk (xi , x2) dW f . (4.35)
k— 1
This is shorthand for the system of random integral equations
4 rt
b 2 ( t \ , X \ , X 2 )  =  \ s X y X 2 - 0 X 2  + 5 X 2 - OiX2 . (4.34)
Xt =  XoJ + I bj[xi(s),x2(s)]ds + Y ' f  orjfc[a;1 (s),.'r2 ('S)]iiVVi(s) (4.36) 
Jo k=l Jo
wliere j  = 1,2, t  > 0, and r/VV, are the increments of the independent Wiener process VV,(i),
i = 1 ,.. .,  4 following [26], [53].
Our problem is to determine the functions bj,crj in (4.35), (4.36). Since (i()(>o is a diffusion 
process, we have
j i m ^ [ E [ / ( a ; t)|^o =  ® ]-/(® )] =  A f(x )  (4.37)
where
i ,l <l pp. t ltj a t
A m  =  +  « '38>
n = l k= l  1= 1
and d =  2,(x x,x 2) [53]. Using (4.37) and (4.38) with f(x )  =  x, f ( x  1 ,^ 2 ) =  X1X2, we have
E [XI-a*] = tbi{x)+0{t)  
E [(XI -  Xi)(Xf -  xk)} =  taik(x) +  0( t ) .
Finally, the functions a can be recovered from
r
aik{x) ■= ^2crij(x)akj(x) (4.39)
j= 1
where these are r Brownian motion; we can put r = 4, as from the equations in (4.26) we 
can see that there are four independent sources of randomness needed for both equations.
108
We have deaths and infectives leaving S, and we have infectives and latents entering I  and 
deaths leaving it. One source of randomness can be used for transfer between susceptibles 
and infectives, but we have to use different ones for deaths as the pattern of deaths may be 
different in each compartment. Hence, the stochastic differential equations are of the form
dX¡ = b \ ( X l , X 2) dt + an ( X ¡ , X 2) dWt(1) +  a l2( X ¡ ,X f )  dW ¡2) (4.40)
d x [ 2) = b2( X ¡ , X 2) dt +  a21( X ¡ , X 2t ) d w [ l) +  a23( X ¡ , X 2t ) dW t(3}
+ a24(X t1, X 2)d W t(4). (4.41)
where we assume that the randomness in the susceptible-infective transition is driven by the
Brownian motion dW  1, the removal from the susceptibles by dW 2, and from the infectives
by dW 4, while the random component of the transfer to latents is driven by dW?,.
Using (4.39) we have
4
an(*) =
i=1
=  cru ( )^2 +  <T\v(x)2 (4.42)
and is a similar way to that of the calculation of (4.42) we have
oi2 U ) =  <?n(x)2 +  cr2i(x)2,
« 2 1  ( x )  =  <yU { x )  . (T2 l ( x )  =  0 1 2 ( x ) ,
a2 2 (x) =  CT2l( x )2 +  (723 (x) 2 +  CT24 (x) 2
We can calculate a n ,  a22 from the second order moments
E[(X¡+ h - X ¡ ) 2\Ft] =  E[(Axi)2]
=  \ sx \ x 2h +  a x ih  +  o(h2). (4.43)
Thus
aii(z) =  lim j  E[(Xi(i +  h) -  x i ( t ) )2} (X i = (x1, x 2, x 3) 
/i-> o n
=  Xsxix2 +  j^otxi . (4.44)
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Similarly we can show that
«22 ( i )  =  A.,ari x 2 +  - jy  0 X 2  4- -jy a x 2 (4.45)
We need to calculate the cross product term
E[AxiA®2] = E  P[Aa:i =  pj, A i '2 =
We know that Ax\ = - 1 / N ,  and Ax2 =  1/N.  Hence (4.46) can be written as
11  A i '\
i =  ~N X2 =  ~N. • N 2 A x i  “  N ' Ax2  “  N i
+ pj^Aa;i j^ ,A x2 
+p[A xi = - - , A x2 = - ^ ] . j^
and we can write (4.47) as
E f A i j A ^ ]  =  aN At.5Nx2At-^ + aN A t  (aNx2At + 0Nx2At)j. — —
(4.46)
N>
(4.47)
+XsNxiX2At. -  -rpr + aN xi A t  (o(Ai)terms) + o((A t)2) (4.48) 
N z
Because removal and both outflows are independent we must have
A x  i =  pj, A x2 =  qj = p [Ax i = P j ] .  
=  A t .A t  
= °(A£)2).
P A x2 =  qj
(4.49)
But we assumed at the beginning of the section that terms of o((Ai)2) or higher, were 
sufficiently small enough to be ignored. Hence some of the terms in (4.48) can be ignored, 
which leaves us with
E [ A a : iA x 2 ]  =  —A$X\X2A t — (4.50)
Talking the limit of (4.50) as A i  -» 0, we have
« 1 2 (21) = lira -r-r E[—Asx-ix2 Ai^-] 
Aì-40 At. N
N X\X2
(4.51)
which is the desired result.
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Random terms associated with outflows from S  and I are independent (by hypothesis), so 
by considering (4.44), (4.45), we see that we must have
ou(x)2 = -jy <xrci
<722 fe)2 =  — (XXl •
Note that we can take either plus or minus, since — Wt is a standard Brownian motion 
whenever is a standard Brownian motion.
Returning to the transition probabilities mentioned in Table 4.1, we specifically concentrate
on the removal probability (ax2 A/.). Because the process of removal is independent of outflow 
(and also transition between I and S), we require another independent, source of randomness; 
this is why we introduce another Brownian motion W3 , independent of VV2. W4 . This means
<?23{x)2 =
where, as before, the sign of W3 does not matter. Finally, we introduced another independent
source, for the infection probability (Asx i3;2 Ai), WV Thus
<m(x) 2 -  j jK v iX i  
<722 (s ) 2 =  j f A s  X\ X2 .
0-21 (x) 2 =  ~ \ SX[X2 (4.52)
so that
o,tife)ff2 i(a) = - j j X sxiX2 (4.53)
and thus
f f l l t s )  =  v \ l j j  A,® 1*2
=  V - v "<721 ( x )  =  ~ V \  — \ sXlX2
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where v =  ±1.
Now that we know what all the a.ij terms are, we are able to find the corresponding a,jj 
terms, and combining these we can now write down the stochastic differential equations
dx i =  (a — Xsx \ x 2 — a x \)d t  — dW i — \ j a x \  dW 2 (4.54a)
dx2 ( \ sx iX 2 — a x i  + /3x2)dt + \ J ~  Xsx j x 2 dW \ -  \ j  — ¡3x\ dW 3
— \ j  —  a x2 dW 4 (4.54b)
where dW/ are the increments of the independent Wiener process Wi(t), i = 1 , . . .  ,4.
The equations in (4.54) are the stochastic version of the reduced S I L  model that we men­
tioned in Chapter 3. As can be seen from the calculations above, even the most basic 
stochastic model is very complicated. For instance, a number of independent sources of ran­
domness had to be introduced to account for the various interactions that take place between 
compartments. For example, the birth/death rate, a, used in the deterministic model, is 
replaced with three different rates in the equations above, i.e. a x xdt, ~ \ J j f  a x \ dW2, and
- y j j f  a x 2 dW 4.
Given the t ime restrictions it was decided to just concentrate on the deterministic model that 
was developed in Chapter 3. The stochastic model may be further extended to a stochastic 
delay differential equation model. Here X t  would have been replaced by X t-v ,  where u is the 
delay term mentioned in Section 3.5.3. This is different to the delay term that we mentioned 
in Chapter 3, as we have averaged our delay there whereas here we have not.
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C h a p t e r  5
Future Work /  Conclusions
I n  th is  c h a p t e r  w e  m a k e  o u r  c o n c lu d in g  c o m m e n ts  a b o u t  t h e  w o r k  d o n e  i n  t h e  p re v io u s  
c h a p te r s .  W e  a ls o  c o n s id e r  p o s s ib le  e x te n s io n s  a n d  im p r o v e m e n ts  to  o u r  m o d e l .  T h e r e  a re  a  
n u m b e r  o f  p o s s ib i l i t ie s  t h a t  c a n  b e  e x a m in e d .  W i t h  th e  p r o p o s e d  e r a d ic a t io n  p r o g r a m  d u e  
t o  c o m m e n c e  s h o r t ly ,  t h e  a u t h o r  fe e ls  t h a t  i t  w o u ld  b e  v e r y  b e n e f ic ia l  i f  s o m e  o f  th e s e  a re a s  
w e re  e x p lo r e d  in  m o r e  d e t a i l .
5.1 R ed u ce  P o p u la tio n  R e str ic tio n
F i r s t ly ,  w e  r e d u c e  th e  c o n s ta n t  p o p u la t io n  r e s t r ic t io n  t h a t  w e  h a d  i n  C h a p t e r  3 . S o  in s te a d  
o f  th e  b i r t h  r a t e  (a) a n d  th e  d e a t h  r a t e  ( / /  +  E ) b e in g  e q u a l ,  w e  w i l l  h a v e  tw o  s e p a ra te  
te r m s . H e n c e ,  w e  c a n  w r i t e  t h e  vaccinated m o d e l  i n  (3 .9 2 )  as
S'(t) = a — (/j, + E)S — kS  ( 5 .1 a )
I \ t )  =  Ay IP  -  ( / j  + E ) I -  rjl +  i L  ( 5 .1 b )
L'{t) =  - 7 L  +  rjl — {n +  E)L (5 .1 c )
P'(t) = kS -  {fi + E)P -  Ay I P .  ( 5 . I d )
F o r  c o m p u t a t io n a l  ease  w e  s e t fic = ¡1 + E. I n  a  s im i la r  m e t h o d  to  t h a t  u s e d  t o  c o m p u te  Rn 
a n d  Ry  w e  c a n  c a lc u la te  Rc,  w h ic h  is  t h e  r e p r o d u c t io n  r a t i o  fo r  t h e  non-vaccinated m o d e l
1 1 3
with the constant population restriction relaxed, to be
7? =  Xyanjuc + 'y) . .
C (Mc)2(/ic +  K)(^ + r? +  7 )' K ' }
T h e  e q u a t io n s  in  (5 .1 )  h a v e  tw o  e q u i l ib r iu m  p o in t s ,  t h e  D F E
(S*,I*,L*,P*) = ( - ^ - , 0 , 0 ,  -  a* -A (5 .3 )
 ^f^ C ft Me\f^ C ft) '
a n d  t h e  D P E
k )  <6-4>
w h e r e ,  kc =  ¿tc + k.
T h eo rem  5 . 1 . 1  TTie (5.3) always exists. (1) This equilibrium is asymptotically stable 
when R c  < 1 and unstable when R c  > 1■ (2) When the D PE (5-4) exists it is asymptotically 
stable when R c  > 1 and unstable when R c  < 1-
Proof:
T h e  p r o o f  o f  th is  th e o r e m  is v e r y  s im i la r  t o  t h a t  o f  T h e o r e m  3 .4 .1 .  T h e  m a in  d if fe re n c e  is  
t h a t  t h e  a  t e r m s  a re  r e p la c e d  by fi + E. T h e  c o m p u ta t io n s  a r e  m o r e  in te n s e , b u t  th e  d e s ire d  
r e s u lt  c a n  b e  o b t a in e d .  o
H o w e v e r ,  fa r m e r s  l ik e  t o  m a x im is e  t h e i r  o u t p u t ,  so a n im a ls  a r e  u s u a l ly  f u l l y  h o u s e d , i.e  
i f  o n e  a n im a l  d ie d  d u r in g  th e  f in is h in g  s ta g e , i t  w o u ld  b e  r e p la c e d  b y  a n o t h e r  a n im a l .  A s  
m e n t io n e d  in  C h a p t e r  2 , p ig s  a r e  f a r m e d  o n  a n  a l l  i n  -  a l l  o u t  b a s is , so o u r  c o n s ta n t  p o p u la t io n  
a s s u m p t io n  t h a t  a  = fj, + E  is  n o t  u n r e a l is t ic .  T h e  a u t h o r  fe e ls  t h a t  i t  w o u ld  b e  n o t  b e  in  
th e  b e s t  in te r e s ts  t o  p u r s u e  th is  a r e a  f u r t h e r ,  as t im e  c o u ld  b e  s p e n t  w o r k in g  o n  o n e  o f  th e  
fo l lo w in g  a re a s  t h a t  w e  a re  a b o u t  t o  d isc u s s .
5.2 E n v iron m en ta l C ap acity
I n  t h e  m o d e l  in  C h a p t e r  3 , w e  d e c id e d  t o  n e g le c t  th e  e n v i r o n m e n t a l  c a p a c i ty  o f  A D V ,  T h e r e  
a re  a  n u m b e r  o f  re a s o n s  w h y  t h is  w a s  d o n e . F i r s t ly ,  t h e  m a j o r i t y  o f  t h e  m o d e l l in g  w o r k
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done on ADV has also adopted this approach. However, some work on modelling with the 
environmental capacity has been done by [71], [72], but their stability analysis results are 
open to question.
Secondly, and most importantly, the main reason that this was not included in our model is 
the fact that the majority of Irish farms are intensive pig producing units. This means that 
no other animals are housed on the farms, and as such the transmission capacity of ADV 
to other animals is very much reduced. Another reason was that there are no wild boar in 
Ireland, and it has been shown that wild boar reduce the effectiveness of eradication [70], [87].
From an ADV point of view, such a model is important in a German context, where wild boar 
are a major problem [87], and also in Illinois, where raccoons arc carriers of AD [92], along 
with other wildlife [90]. Other diseases, such as tuberculosis in badgers [61] have encountered 
similar eradication difficulties. If we had incorporated the environmental capacity into our 
model, the vaccinated system in (3.92) would have become
S \ t ) =  a  — aS  — kS (5.5a)
I'(t ) =  A y / P -  (a + r) + ric) I +  'yL + a cEc (5.5b)
L'(t ) — — 7  L +  77/  — aL (5.5c)
P'(t) — k S  — aP — Ay IP (5.5d)
Ec'(t) — 1}c l  &C-Fc • (5.5e)
where we have the new parameters,
77c =  rate at which the local environment is contaminated 
ac =  instantaneous rate at which the virus is inactivated
Note:
l/i]c is the mean expected time virus particles persist in the local environment. After this 
period elapses the virus becomes inactive and presents no danger.
We have the new term
Ec = the number of infectives in the population that are shedding 
the virus and are contaminating the local environment.

5.3 Incomplete Immunity
In Section (3.4.5) we assumed that re-infected animals transmit the disease at reduced rates 
to that of first time infected animals. Looking at this assumption for a different perspective, 
we could create a new model that would have four new compartments; first time (Si) and 
subsequent time (S2) susceptibles, and first time (I 1 ) and subsequent time (I2) infecLives. 
Instead of having the models that we have developed in Chapter 3, we would have the 
following
and we define the new parameters,
Ai,A2 = the contact rate between first time and subsequent time individuals respectively 
a = the birth/death rate
61,62 — the rate of relapse for first time and subsequent time individuals respectively
(j> — the fraction of vaccinated individuals
7 1  = the reducing factor on subsequent infections.
Note that the </j term in (5.6) is related to the qv term that we mentioned in Section (3.5.2). 
Systems like (5.6) are very detailed and can be complicated to work with. It is only recently 
that systems of this type have been looked at with regards to eradication of various dis­
eases [24], [28]. As was done in Chapter 3, we could have calculated the reproduction ratio 
for (5.6) and looked at the stability analysis of the system. We may calculate Rn for this 
system using the next generation matrix, where JEq is the dominant eigenvalue [22], Indeed 
we can define Rq to be
h'(t) = S^h + Xil^ -ia + S^h
S2 '(t) = 0(f> — yiS 2{XiIi-\-X2I2) ^  6\S\ + 62I2 ~ 01S2 
h ' { t )  =  7i52(A1/ l +  A2/a) -  (a  +  í 2)/2
(5.6a)
(5.6b)
(5.6c)
(5.6d)
where
R q = (1 — <f>) R i  +  4> R 2
(5.7)
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Where R\ is the basic reproduction ratio for an S IS  epidemic model with no vaccination 
and i?2 is the basic reproduction ratio for an S IS  epidemic model that contains vaccination. 
If time had permitted, we would have looked at this system in much more detail as it seems 
to be the most useful and worthwhile of the three extensions that were considered. However, 
some corrections would have to be made before work could begin on a model of this type, as 
it does not take into account the latent period, and it is unlikely that animals will continue 
to become reinfected throughout their entire lifetime.
Mathematics aside, the way that animals are housed could also be looked at, as we have 
seen in Chapter 3 that the contact rate, A, is quite important. If animals could be housed in 
such a way that the comparments were better separated, the chances of meeting an infective 
would be lower, so ADV could be eradicated from the population much more quickly, as 
the infection would not have such a large base of susceptibles to infect. Other additional 
measures that could reduce Rq would include: the prevention of mixing of litters, an all-in 
all-out policy, and a central corridor between compartments.
Another modification that might have been considered would have been to take metapopula­
tions (population consists of a separate local population, by spatial or other characteristics) 
into account. Here we could have divided a farm up into separate compartments, e.g, breed­
ing, fattening etc. and considered each one as a separate metapopulation. We could also 
have looked at age-dependent models, e.g, older pigs more resistant to the disease, unvac­
cinated piglets more susceptible etc. A lot of modelling work of this type has been done 
on AIDS [57]. The only drawback to this kind of modelling work is that a considerable 
amount of information is needed, and as already mentioned in our case, this information is 
not readily available.
The area of disease modelling has become quite exciting in recent times. It was assumed that 
improvements in antibiotics and vaccination programmes would soon lead to the elimination 
of infectious diseases. However, infectious disease agents are adapting and evolving so that 
newer stronger infectious agents are emerging, which results in newer diseases emerging and 
the resurgence of some existing diseases. Indeed the discovery of new stronger infectious 
agents, known as prions, which are thought to be the main agent of BSE and CJD, has led 
to a renewal of interest in mathematical modelling [33].
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5 .4  C o n c lu s io n s
We began this thesis with the intention of creating various mathematical models for ADV 
in Ireland. The main objectives of our work were to look at something that has never been 
done in Ireland before, and to provide the reader with a more comprehensive picture of ADV 
worldwide. We also wanted to know what parameters were most important with regard to 
eradication of ADV. We showed that for all the models that were developed, Rq (in its 
various form, i.e R n ,R v  etc.) was the most important term. When Rq > 1, ADV will 
remain in the population, and will be very difficult to eradicate.
When Rq < 1, the disease is much easier to work with, and from the resulting theorems 
in Chapter 3, we learn that the disease can be eradicated when this happens. Similarly, 
the sign of a is very important, particularly in large herds, where the contact rate A would 
be large. Unfortunately, we do not have enough accurate data to see what happens to the 
models over various time periods. As a result we can only speculate as to what the outcome 
will be. If there is to be any further mathematical work done on AD, this data must be 
obtained, both on a national, regional (and breeding /  producing unit) scale.
We had hoped that the eradication programme would be implemented during the course of 
this work and we could have worked with the Department of Agriculture and the IFA in 
achieving this goal. If anything has been learned throughout this thesis, it is that AD can 
be eliminated from Irish herds, and can be done much more efficiently and economically 
than other European countries have, as we can learn from there mistakes. We hope that 
this work will inspire others to take an active interest in this area, and maybe someday, our 
initial goal of eradicating ADV in Ireland will be achieved.
The recent outbreak of various diseases in the UK (Classical Swine Fever, Foot and Mouth 
Disease (FMD)), previously thought to have been eradicated, farmers must now be even 
more vigilant if they are to survive in what is becoming an increasingly difficult industry. 
However, with the recent confirmation of FMD in Louth, the chances of the government 
giving due attention to ADV are very slim. Indeed, the author feels that it will be necessary 
for an ADV outbreak to occur before some official action will be taken against it.
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A p p e n d i x  A
Theorem s and Stability A nalysis
A . l  T h eorem s /  D efin itio n s
The author wishes that this thesis be self contained, and as a result the following definitions 
and theorems regarding stability are included.
Let x — £{i) be a solution of the differential equation
x  =  f ( x )  ( A . l )
Definition A .1.1 The solution x = £(t) of (A .l) is stable if every solution cj(t) of (A.l)
which starts sufficiently close to £(i) at t = 0  must remain close to £(/.) for all future time t.
The solution £(/,) is unstable if there exists at least one solution u>(t) of (A .l) which starts 
near £(t) at t — 0 but which does not remain close to £(£) for all future time. More precisely; 
the solution ({I) is stable if for every e > 0  there exists — r)s(e) such that each component
< e if |Wj(i) -£ j( i) | < 5s(e), j  = l , . . . , n
for every solution w(i) of (A.l).
The stability question can be resolved for each solution of the linear differential equation
x  =  Ax. (A.2)
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From this we have the following theorem.
Theorem  A .1 . 2  (1) Every solution x = £(i) of (A.2) is stable if all the eigenvalues of A 
have negative real part.
(2) Every solution x = £(£) of (A.2) is unstable if at least one eigenvalue of A has positive 
real part.
(3) Suppose all eigenvalues of A have real part < 0 and p\ =  ttji,■ ■ ■ ,pi = tut have zero 
real part. Lei pj — iOj have multiplicity kj. This means that the characteristic polynomial 
of A  can be factored into the form
h{p) = {p-i(T i)k' . . . { p -  LOi)k,g{p)
where all the roots of g(p) have negative real part. Then, every solution x =  £(/;) of (A. 1) is 
stable if A has kj linearly independent eigenvectors for each eigenvalue pj — iOj. Otherwise, 
every solution £(i) is unstable.
Proof: See [14] or [27]. o
In order for us to be able to use Theorem (A.1.2), we have to use the Hartman-Grobman 
theorem. This shows that near a hyperbolic equilibrium point xo, the nonlinear system
x = fi(x) (A.3)
has the same qualitative structure as the linear system in (A.2 ).
Theorem  A. 1.3 Let E be an open subset o /R " containing the origin, let fi G C ] (E) and
let £t be the flow of the nonlinear system (A.3). Suppose that f(0) = 0 and that the matrix A
has no eigenvalue with zero real part. Then there exists a homeomorphism. li  of an open set 
U containing the origin onto an open set V containing the origin such that for each xo € U, 
there is an open interval / j  C R  containing zero such that for all i q C R  and t C /o
U  o &  =  eA t n { x 0 );
i.e., 71 maps trajectories of (A.3) near the origin onto trajectories of (A.2) near the origin 
and preserves the parameterization.
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Proof: See [65]. o
Definition A .1.4 A solution x = £(i) of (A .l) is asymptotically stable if it is stable, arid, if 
every solution u(t) which starts sufficiently close to £(£) must approach £(i) as t approaches 
infinity. In particular, an equilibrium solution x(t) = x° of (A .l) is asymptotically stable if 
every solution x = w(i) of (A .l) which starts sufficiently close to x° for all future time, but 
ultimately approaches x° as t approaches infinity.
A .2 Non Vaccinated model
Here we calculate the reproduction ratio for the non-vaccinated model, i.e R ^ , using stability 
analysis as done in [72]
a -X I * S * -c x S *  = 0  (A.4a)
AI*S* - { a ± /3 ) I*  + 6L* = 0 <A.4b)
¡31* -5 L *  - a L *  =  0 (A.4c)
Prom (A.4c) we get
T* —
(a + <5)
next we put (A.5) into (A.4b) to give
61*L  = (A.5)
r *
Sim plifying (A .6) wc get
XI * S  * — (a + /?)/ * + 7 ^— -7T =  0. (A.6 )(a + oj
s , = o( °  + 0  +  <) ( A . 7 )
(a  +  <S)A
and putting (A.7) into (A.4a) we write
a _ I M a  + 0 + H _ ^  + 0  + i) _  0  (A8)(a + <5) (a; + d)A
Simplifying (A.8 ) we get
I* = j{RN- l). (A.9)
121

_  A (a +  J)
N  a ( a  +  13 +  6 ) '
IE the virus is to persist, in the non-vaccinated population, i.e I*  > 0, which occurs when 
R n > 1. It follows that disease eradication should occur when R ^  < 1.
where
A .3 V accin ated  m odel
Following on from the non-vaccinated model, we can calculate R v  for the vaccinated model 
in a similar way
a — (ck + k)5* =  0  (A.10a)
X y l 'P '  -  (a + T))r + ^L *  = 0 {A.10b)
—yL* +r]I* — aL* = 0 (A.10c)
kS* - a P *  -  XVI*P* = 0 . (A.IOd)
Prom (A. 10a) we get
a
5 • =  (o T ii)  (A U )
and from (A. 10c) we have
r,* — (a + 7)
Put (A. 1 2 ) into (A.10b) to give
L  =  , n I \  . (A.12)
\ v V P *  ~ { a  + r})I* +  7 , ^ x = 0. (A.13)( a +  7 )
Simplifying (A.13) we get
P* =  a ( a ,'t" '  + 7) (A.14)
Xv (a + j )
now, putting (A.11) and (A.14) into (A.IOd) we get
an a 2(a + ?} +  7 ) a (a  +  rj + 7) j*  _  0  
a  +  k A v ' f a  +  7 ) (qe H- 7 )
(A .15)
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Simplifying (A. 15) we get
where
_  A yn(a + 5)
V a (a  + K,)(a + f.3 + 5)
If the virus is to persist in the vaccinated population, i .e l*  > 0, which occurs when Ry  > 1. 
It follows that disease eradication will eventually occur when R y < 1. We also calculated 
R c  and R m  in a similar way, so it is unnecessary to include it hear. In terms of the models 
that we have developed in Chapter 3, when Rq  =  1 (i.e R n , R v , R m , R c )  only the DFE 
exists.
r  =  ^ ( i ? y - l )  (A.16)
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A p p e n d i x  B
Eradication Procedures
With (.lie possibility of a nationwide eradication program being implemented in the near 
future, work has begun on deciding how the scheme will be organised (Section 2.5.2). In 
order for us to obtain the necessary data for our model, it was decided that a questionnaire 
would be drawn up, with the intention of collecting the data and establishing the prevalence 
of AD in the National Herd, in a nationwide survey. The idea behind this questionnaire 
was based ori a survey carried out in the United States in 1995 [9]. The questionnaire was 
developed with the help of a number of people actively working in the Irish pig industry 
(Michael Martin and Brendan Lnych of Teagasc).
The plan was to distribute one to each pig producer in Ireland. As the number of producers 
has declined in recent year, this would not be as big a problem as originally expected (At 
the time of writing there are 550 highly specialised commercial units in the country). A 
pre-eradication survey, carried out at farm level in 1999, showed that 96% of respondents 
supported a Nationwide Eradication Programme while 96.7% were willing to participate in 
this programme [89]. From this information it is clear that the industry is fully behind an 
eradication programme, and we expected the questionnaire responses to be high.
The scale of this survey was large enough to warrant an acquisition of extra funding, which 
was to be provided by the Irish Farmer’s Association. With the EU announcement of an 
official deadline for an AD eradication programme to be in place, the full co-operation of 
the Department of Agriculture was also assured. However, subsequently the Irish Farmers
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Association were unwilling to commit to this work and, after initial preparations had begun, 
the survey had to be abandoned.
As mentioned in Section 2.5.2, meat juice could be used in the ELISA test. A draft eradi­
cation program was designed with the object of initially eliminating circulating virus from 
the National Herd [42]. The intention was to do this at a minimum cost, and subsequently 
achieving OADF status in accordance with EU regulations. An outline of the proposed 
eradication programme for breeding herds is shown in Figure Bl, and one for the finishing 
herds in Figure B2. Unfortunately, much like our survey, this draft proposal was overlooked 
by the Department of Agriculture.
More recent advances in the area of xenotransplantation (using animal organs as substitutes 
for failing human organs) have made the eradication of diseases like ADV even more impor­
tant. Because of the similar size of organs, and the widespread availability, the pig is one 
of the most commonly used animals in xenotransplantation [6 ]. Putting aside the ethical 
issues related to this area, it is clear that if scientists can establish that animal organs can 
be used as a long term solution, then the need for disease free animals will be great. The 
Irish pig industry is of superior health status compared to the rest of mainland Europe (see 
Table 2.1, Section 2.3.2). If ADV was to be eradicated, we would be ideally suited to breed 
animals to aid in the further develop of this important work.
Towards the end of this work we learned that the EU has set a deadline of October 1st, 
2001 for a Nationwide Eradication programme to be in place. Rather than acting on this, 
the Department of Agriculture immediately worked on obtaining an extension to this date, 
which was granted due to the Foot and Mouth crisis. The date has now been set as June 
1st, 2002. With the threat of future trade restrictions now very real it is finally time to take 
ADV seriously, otherwise the consequences for the Irish Pig Industry could be devastating.
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A U J E S Z K Y ’S D I S E A S E  S U R V E Y
Section 1: Company Details:
1(a) Name: ___________________________ Herd No.:
(Herd Owner)
1(b) Address: __________________________________________
1(c) Address of Pig Farm (if different from above): ___________________
2. Cattle herd number (if applicable)'. __________________
3. Name and telephone number of veterinary inspector / veterinary consultant
4. To which market do the majority of your pigs go (please tick as appropriate)?
Domestic □  European □  other _________  □
5. What type of pig farming do you specify in (please tick one)?
□
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6 . How many pigs do you have in your unit? 
(please be as specific as possible)
Number Sows Weaners B reeders F atteners
Less than 5,000
5,000 -  10,000
1 0 ,0 0 0  -  15000
15,000 -  2 0 , 0 0 0
20,000 -  30,000
More than 30,000
7. At any one time, how many pigs, in total, are kept, on the unit?
8 . From where do you purchase the majority of your animals?
8 (a). How close is your premises to the place where you purchase animals (please lick one)?
< one mile D 1 to 3 miles □  3 to 5 miles D more than five miles
8 (b). How close is the nearest slaughtering plant to your premises (please tick one)!
< one mile D 1 to 3 miles d  3 to 5 miles D more than five miles
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9. Do you have a perimeter fence that excludes wildlife? YES NO
10. Do domestic animals (dogs, cats etc.) have access to the production unit? YES NO
11. What disinfectant procedures do you undertake?
Disinfectant mat at entrance YES NO
Disinfecting of truck before loading YES NO
No unauthorized personnel entering farm YES NO
Other__________________  YES NO
12. Are visitors required to wear clothing supplied by the farm? YES NO
13. How are dead animals disposed of?
Burial YES NO
Incineration YES NO
Collected by dead animal collection service:
on the farm YES NO
at the perimeter of the farm YES NO
Other__________________  YES NO
14. How close is the nearest production unit to you (please tick one)?
< one mile □  1 to 3 miles D 3 to 5 miles □  more than five miles □
15. Where does your feed come from?
Section  2 B io s e c u ritv  D e ta ils :
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16. Which o f  the following diseases have been present in your herd (please tick as appropriate)
Disease YES/NO Last Outbreak
A c t in o b a c illu s  (H e m o p h ilu s )
E n z o o t ic  P n e u m o n ia
T ra n s m is s ib le  G a s tro e n te r it is  ( T G E )
P ro g re s s iv e  A tro p h ic  R h in it is
P R R S
S a lm o n e lla
S tre p to c o c c a l M e n in g it is
S w in e  D y s e n te ry
S w in e  In f lu e n z a
S w in e  V e s ic u la r  D is e a s e
1 7. W h o  c a rr ie s  o u t th e  m a jo r ity  o f  v a c c in a tio n s  o n  y o u r  p re m is e s ?
18. W h ic h  o f  th e  fo l lo w in g  d o  y o u  v a c c in a te  a g a in s t (please tick as appropriate)
Disease SowsWeanersBreders Fateners
A c t in o b a c il lu s  (H e m o p h ilu s )
E n z o o t ic  P n e u m o n ia
P R C V  /  T G E
P ro g re s s iv e  A tr o p h ic  R h in it is
P R R S
S a lm o n e lla
S tre p to c o c c a l M e n in g it is
S w in e  D y s e n te ry
S w in e  In f lu e n z a
S w in e  V e s ic u la r  D is e a s e
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Section  3 A u ie s z k v ’s D isease D e ta ils :
19. Have you ever had any clinical outbreaks of Aujeszky’s Disease? YES NO
(if YES, please tick which herds; if NO please go to question 22)
piglets □  sows □  weaners □  fatteners □
20. When did this outbreak occur (month / year)'? ______________
21. What percentage of your herd is infected with Aujeszky's Disease (please tick onep.
< 1 0 % □  between 1 0 % and 2 0 % □  more than 2 0 % □
22. Do you vaccinate against Aujeszky’s Disease? (if NO, go to question 29) YES NO
23. If yes, what type of vaccine do you use? __________________
24. What type of pigs do you vaccinate (please tick as appropriate)7
piglets □  sows □  weaners □  fatteners □
25. Are you happy with the vaccination procedures you have? YES NO
26. If NO, what other procedures would you implement? _____________
27. When purchasing new animals, which of the following would you do?
Vaccinate and quarantine for 30 days, then revaccinate YES NO
Vaccinate and introduce immediately YES NO
Introduce immediately YES NO
28. Do you purchase animals only from producers who vaccinate? YES NO
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29. Do the benefits o f  vaccination outweigh the costs? YES NO
3 0 . I f  y o u  a n s w e re d  N O  to  e ith e r  q u e s tio n s  19 o r  2 2 ,  d o  y o u  h a v e  a n y  fu tu re  p la n s  to
v a c c in a te  a g a in s t A u je s z k y ’ s D is ea se ?  Y E S  N O
3 1 . W o u ld  y o u  s u p p o rt g o v e rn m e n t re g u la t io n  in  th is  a rea ?  Y E S  N O
3 2 . W h a t  k in d  o f  re g u la t io n s  w o u ld  y o u  l ik e  to  see in  o p e ra tio n ?
S tr ic te r  c o n tro l o f  p ig  m o v e m e n t Y E S  N O
H e r d s ’ s tatus  le v e ls  used Y E S  N O
M o r e  a c c u ra te  re c o rd s  to  b e  k e p t Y E S  N O
V a c c in a t io n s  m a d e  c o m p u ls o ry  Y E S  N O
V a c c in a t io n  costs  b o rn e  b y  g o v e rn m e n t Y E S  N O
3 3 . W it h  th e  p o s s ib i l i ty  o f  e x p o r t  re s tr ic tio n s  b e in g  p la c e d  o n  Ir is h  h e rd s  in  th e  n e a r  fu tu re ,
w o u ld  y o u  b e  h a p p y  to  see a n a tio n w id e  e ra d ic a t io n  p ro g ra m  im p le m e n te d ?  Y E S  N O
3 4 . In  re la t io n  to  T a b le  3 o n  p a g e  7 , w h a t h e rd  s tatus  w o u ld  y o u  c o n s id e r  m o s t 
a p p ro p r ia te  fo r  y o u r  fa rm ?
3 5 . P lease  fe e l fre e  to  m a k e  a n y  fu r th e r  c o m m e n ts :
S ig n e d  __________________________________________ D a te
Please return to:
Glenn Finglelon
School of Mathematical Sciences 
Dublin City University 
Dublin 9
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Herd Status (1) Test Procedure (2) Vacination (3) Maintenance (4) Movement Control (5)
Officially 
Aujeszky’s 
Disease Free 
(OADF)
Full herd test 
with negative 
results
No vaccination 
for minimum of 2  
years
15% monitor of the 
breeding animals (or 25 
animals, whichever is 
greater) tested over the 
course of each year. Such 
testing shall be split into 
at least three 
approximately equal 
divisions each separated 
by at least two months
Purchase from 
OADF herds 
only with post 
movement test 
in isolation
Pending 
officially 
Aujeszky’s 
Disease Free 
(POADF)
Full herd test 
with negative 
results
No vaccination 
less that 2  years
15% monitor of the 
breeding animals (or 25 
animals, whichever is 
greater) tested over the 
course of each year. Such 
testing shall be split into 
at least three 
approximately equal 
divisions each separated 
by at least two months
Purchase from 
OADF herds 
only with post 
movement test 
in isolation
Aujeszky’s 
Disease Free 
(ADF)
Full herd test 
with negative 
results
Vaccination
practiced
15% monitor of the 
breeding animals (or 25 
animals, whichever is 
greater) tested over the 
course of each year. Such 
testing shall be split into 
at least three 
approximately equal 
divisions each separated 
by at least two months
Purchase from 
OADF or ADF 
herds with post 
movement test 
in isolation
Pending 
Aujeszky’s 
Disease Free 
(PADF)
Infected herds 
culling positive 
animals
Vaccination
practiced
Testing all sows post 
farrowing and culling 
positives
Purchase from 
OADF or ADF 
herds with post 
movement test 
in isolation
Infected 
Breeding Herd
Vaccination
compulsory
Monitoring at point of 
slaughter
Purchase from 
OADF or ADF 
herds with post 
movement test 
in isolation
Infected 
Breeding Herd
Vaccination
compulsory
Monitoring at point of 
slaughter
Unrestricted
Monitored
Herd
% of herd 
tested with 
negative results 
awaiting full 
herd test
Optional Awaiting full herd test Purchase from 
OADF or ADF 
herds
Non Status Untested Optional Awaiting test Unrestricted
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Figure B .l: Proposed Eradication program for B reeding Herds
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Tesi 25 finishing pigs by serology or meat juice 3 limes PA
Cat. 4
AD Senimftneat |ulce neg.
Test 23 senples 
3 PA
pmr+i««> xaro naoative weenars
CatS
> zero % AD Po*
Monitor supptiara
Purchase sera nag. waanere
Vaccinata all growera twica unii 23 
landom sirrpéoa negative on 2 
successive taits al approximatety 30 
day intwvais ihen mova lo categoiy A41
Figure B.2: Proposed Eradication program for Finishing Herds
The cost of testing, vaccination, veterinary visits and advice are influenced by the ability 
of the farm to eliminate ADV. This ability is greatly influenced by the Biosecurity of the 
farm. The cost of vaccination in a 500 sow unit increases from .£4000 in a CV- herd, to 
-Cl 1,000 in a CV+ herd [42]. It was estimated that the total cost of a nationwide eradication 
program was £  16,950,000, while the total cost of the proposed system is .£820,000, which 
as the reader can see, is in stark contrast to that of the full vaccinated costs.
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A p p e n d i x  C
Program s
A number of different programs were used for all of the various systems that we have con­
sidered in this thesis. As they are of a similar nature, it was decided that just the two main 
programs would be reproduced here. In all of the programs it was necessary to use Y  instead 
of /  as I is predefined as a complex number in Mathematica.
C .l  S ta b ility  A n a ly sis
(* This is 3 x 3 system when we do not vaccinate *)
(* The first thing we do is to calculate the equilibrium points of the system *)
Clear [A, A UA2, A,a, 5,0, S, Y, L]
eqonerhs =  — A * Y[t\ * S[f] + a  — a  * S[t]\
eqtworhs =  A * V[i] * S[i] — a  * Y[t] — 0 * Y[i] -(- 5 * L[t];
eqthrrhs =  /3 * Y[i] — 5 * L[t] — a * L[t]\
eqpts =  Solve[ eqonerhs = =  0, eqtworhs = =  0, eqthrrhs = =  0, S[t], Y[i], L[t]]
Simplify [eqpts]
{* next we find the linearised matrix of the above system and find its determinant *) 
linmatrix = D[eqonerhs, £'[/,]], D[eqonerhs, V[i]], D[eqonerhs, L[t]],
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D[eqtworhs, 5[i]], D[eqtworhs, V[i]], D[eqtworhs, L[i]], 
D[eqthrrhs, 5[i]], D[eqthrrhs, y[i]], D[eqthrrhs, L[t}\ ;
MatrixForm [linmatrix] 
eye =  1 ,0 ,0 , 0 ,1 ,0 , 0 ,0 , 1  
(* where eye is the identity matrix *)
MatrixForm[linmatrix - p*eye]
A =  Det[linmatrix - p*eye]
(* Then wc replace the S  and Y  terms with the equilibrium points we have calculated above, 
starting with the DFE. *)
ReplaceAll[A, 5[i] -> 1 , 1[t] —> 0]
A\ = Solve[[%] =  0 , p]\
Sim plify^]
(* Then we do the same thing with the DPE *)
RepiaceAll[A, S[t] -4 Y[t] f ( RN ~  1)]
Ai = Solvc[[%] —-  0, p]\
Simplify [^ 42 ]
(* What we have done in both A\ and A2, are calculate the characteristic equations that we 
first mentioned in Section 3.4.2. Then we look at both A\ and A2 with regard to stability 
analysis. The majority of this work was done by hand, so it was not necessary to use 
Matheiaatica, *)
C.2 Graphs
This is the general program that was used to draw the graphs in Chapter 3. Here we show the 
code for the non-vaccinaled system. As mentioned in Section 3.4.6, we used a combination 
of data from various sources.
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Clear [sol]
eqone = S ' [ t ]  == -0.25 * y[i] * S[t] + 0 .0 2  -  0.02S[i];
eqtwo =  Y'[t] == 0.25 * y[i] * S[t] -  0.02 * Y[t] -  0.1 * Y[L] +  0.002 * L[t]\
eqthr = L'[t) = =  0.1 * Y[t] -  0.02 * L[t) -  0.002 * L[t]\
sol =  NDSolve[eqone, eqtwo, eqthr,
S[0] = =  70, y  [0] = =  23, L[0] = =  7,
5[t],y[i],L[t], t, 0 , 31]
Plot[Evaluate[5[i],y[i],L[i] /. %], t, 0, 31,
PlotStyle —>
RGBColor[0.996109, 0, 0],
RGBColorfO, 0.996109, 0],
RGBColorfO, 0, 0.996109],
Frame -» False,
FrameStyle —> Automatic,
FrameTicks —> Automatic,
DisplayFunction —> $ Display Function,
AxesLabel —> time, N]
Here we define sols to use NDSolve to compute and then graph a numerical solution to the 
system.This works by:
• Defining the variables solt, S, Y  and t local to the functions sols.
• Defining eqone and eqtwo to be the equations above.
• Defining solt to be a numerical solution to the system above.
• Graphing solt for t in the range [0,30] (* usually *).
Finally, it plots S  and Y  on the one diagram in the range of t  specified.
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C . 3  V a c c in a t io n  L e v e l
Below is a table of the various values of Ay that we used in our vaccinated graphs. In the 
graphs we take a large range of values for Ay, ranging from the beginning of a vaccination 
program (Ay = 3.92) to the end (Ay = 0.02).
V A =  1 A = 0.02 A = 0.04 A = 0.06 A = 0.08 A = 0.1 A = 0.5
0 .0 1 3.921 0.0784 0.1568 0.2353 0.3134 0.3921 1.961
0 .1 3.297 0.0659 0.1319 0.1978 0.2637 0.3297 1.648
0.15 3.008 0.06 0.1203 0.1805 0.2406 0.3008 1.574
0 .2 2.753 0.0551 0 . 1 1 0 1 0.1652 0.2203 0.2753 1.378
0.25 2.528 0.0506 0 . 1 0 1 1 0.1517 0.2023 0.2523 1.264
0.3 2.329 0.0466 0.0932 0.1398 0.1863 0.2329 1.165
0.35 2.153 0.0431 0.0861 0.1292 0.1722 0.2153 1.076
0.4 1.995 0.0399 0.0798 0.1197 0.1596 0.1995 0.9976
0.45 1.855 0.0371 0.0742 0.1113 0.1485 0.1855 0.927
0.5 1.729 0.0346 0.0692 0.1038 0.1383 0.1729 0.865
0.55 1.617 0.0323 0.0647 0.097 0.1293 0.1617 0.8084
0 .6 1.515 0.0303 0.0606 0.0909 0 . 1 2 1 2 0.1515 0.7577
0.65 1.424 0.0285 0.057 0.0855 0.1139 0.1424 0.7121
0.7 1.342 0.0268 0.0537 0.0805 0.1073 0.1342 0.6708
0.75 1.267 0.0253 0.0507 0.0760 0.1014 0.1267 0.6335
0 .8 1.199 0.024 0.0478 0.0719 0.0959 0.1199 0.5995
0.85 1.137 0.0227 0.0455 0.0682 0.091 0.1137 0.5686
0.9 1.081 0.0216 0.0432 0.0648 0.0865 0.1081 0.5404
0.95 1.029 0.0206 0.0412 0.0617 0.0823 0.1029 0.5145
1 0.9817 0.0196 0.0393 0.0589 0.0785 0.0981 0.4908
Table C.l: Values taken for Ay
1 3 8
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